Effects of high vitamin K intake on bone and vascular health by Braam-Schreurs, L.A.J.L.M.
  
 
Effects of high vitamin K intake on bone and vascular
health
Citation for published version (APA):
Braam-Schreurs, L. A. J. L. M. (2002). Effects of high vitamin K intake on bone and vascular health.
Maastricht: Universiteit Maastricht.
Document status and date:
Published: 01/01/2002
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
  
 
 
 
EFFECTS OF HIGH VITAMIN K INTAKE ON 
BONE AND VASCULAR HEALTH 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Lavienja A.J.L.M. Braam, Maastricht 2002 
ISBN 90-5681-145-2 
 
Printed by: Unigraphic, Universiteit Maastricht 
Cover design by Roel van der Linden 
  
 
 
 
EFFECTS OF HIGH VITAMIN K INTAKE ON  
BONE AND VASCULAR HEALTH 
 
 
 
PROEFSCHRIFT 
 
ter verkrijging van de graad van doctor  
aan de Universiteit Maastricht, 
op gezag van de Rector Magnificus, Prof. Dr. A.C. Nieuwenhuijzen Kruseman 
volgens het besluit van het College van Decanen, 
in het openbaar te verdedigen op 
vrijdag 13 december 2002 om 12.00 uur 
 
 
door  
 
 
Lavienja Agnes Johannes Louise Maria Braam 
 
  
Promotor: 
Prof. Dr. J. Rosing 
 
Co-promotor: 
Dr. C. Vermeer 
 
Beoordelingscommissie: 
Prof. Dr. Ir. W.H.M. Saris (voorzitter) 
Prof. Dr. Ir. P.A. van den Brandt 
Prof. Dr. P.J.E.H.M. Kitslaar 
Prof. Dr. J.A. Knottnerus 
Dr. R. Landewé 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial support by the Netherlands Heart Foundation for the publication of this thesis is 
gratefully acknowledged. 
In addition the author thanks Novartis Consumer Health SA, Roche Vitamins Ltd, Pie Medical 
Benelux BV, Schering Nederland BV en VitaK BV for their financial support.  
  
 
Your living is determined not so much by what life brings to you 
as by the attitude you bring to life. 
Not so much by what happens to you  
as by the way your mind looks at what happens.  
 
Circumstances and situations do color life  
but you have been given the mind to choose what the color shall be.  
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1.1 GENERAL INTRODUCTION 
Discovery of vitamin K 
Vitamin K was discovered in 1935 as a necessary factor for normal haemostasis 1. Hendrik 
Dam described a bleeding disorder in chickens fed a cholesterol-depleted diet. The bleeding 
symptoms of these chickens were caused by the deficiency of a fat-soluble factor, which 
appeared to be essential for the maintenance of proper blood coagulation. After feeding the 
chickens with green plants such as clover and lettuce, the haemorrhages and spontaneous 
bleeding were stopped. A few years later, in 1939, two forms of vitamin K were isolated 
which were called vitamin K1 (phylloquinone) and vitamin K2 (menaquinone), respectively 2,3. 
In the same years, a natural occurring antagonist of the vitamin was discovered. The vitamin 
K antagonist was isolated and characterized as 3,3’-methylene-bis-(4-hydroxycoumarin) and 
called dicumarol 4,5. In the mid 1950’s four clotting factors were discovered and it was shown 
that they require vitamin K for their biological activity. Later on, in 1974, eventually the 
biochemical function of vitamin K and coumarin antagonists was elucidated 6. In the 50 years 
following its discovery, vitamin K was thought to be needed exclusively for the synthesis of 
blood clotting factors in the liver. In the last two decades the discovery of a diverse group of 
vitamin K-dependent proteins not related with blood coagulation has initiated renewed 
interest in vitamin K, notably the proteins involved in bone metabolism 7 and in vascular 
calcification 8 (Table 1).  
 
Table 1 
Tissue distribution and roles of vitamin K-dependent (Gla) proteins. 
Gla Protein Tissue Role 
Prothrombin (FII), Factors VII, IX, and X Liver (then plasma) Procoagulants 
Protein C, Z Liver (then plasma) Anticoagulants 
Protein S Liver (then plasma) Anticoagulant role as cofactor for protein C 
Osteocalcin (bone Gla-protein) Bone, dentin Regulator of orderly crystallization 
Matrix Gla Protein (MGP) Bone, cartilage, and most soft tissues Inhibitor of ectopic mineralization 
Gas-6 (growth arrest specific gene-6 protein) Most soft tissues Regulator of cell growth 
Proline rich Gla-protein (PRGP) Most soft tissues Unknown 
Transmembrane Gla-proteins (TMG) Most soft tissues Unknown 
   
 
Structure and function of vitamin K 
Vitamin K is a group name for several molecular forms that contain a common 2-methyl-1,4 
naphthoquinone ring but which differ in the structures of the aliphatic side chains attached at 
the 3-position (Figure 1). Phylloquinone (vitamin K1) is a single compound containing one 
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unsaturated and three saturated isoprenoid residues, and it is exclusively synthesized in 
green plants. Menaquinones (vitamin K2) comprise a spectrum of related forms generally 
designated as menaquinone-n (MK-n), where n stands for the number of isoprenyl groups 
which are all unsaturated. A number of bacteria synthesize the higher menaquinones with 
MK-7 through MK-10 as the most common forms. MK-4 is mainly found in animal products 
(meat, dairy) and originates from conversion of both K1 and K3 (menadione). Vitamin K3 is the 
synthetic water-soluble form of vitamin K, which is often added to animal food. K1 and MK-4 
are the two forms that are commercially available as synthetic products. It is generally 
accepted that the methylated naphtoquinone is the functional group, so the mechanism of 
action is similar for all K vitamins. Substantial differences may be expected, however, in 
intestinal absorption, transport, tissue distribution, and bioavailability. These differences are 
caused by the the various side chains and by the different food matrices in which they occur 
9-13.  
 
The only known function of vitamin K in mammals is that it serves as a cofactor for the 
endoplasmic enzyme gammaglutamyl carboxylase, where it promotes the posttranslational 
conversion of selective protein-bound glutamate residues into gammacarboxy glutamate 
(Gla) 14-16. The form of vitamin K required as the cofactor is not the stable quinone structure 
found in the diet, but the reduced quinol (or hydroquinone) structure (KH2). The subsequent 
Menadione;  Vitamin K3 
Phylloquinone;  Vitamin K1 
O
O
O
O
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n  
Menaquinone;  Vitamin K2 
Figure 1  
Chemical structures of menadione (vitamin K3), phylloquinone (vitamin K1), and 
menaquinone (vitamin K2). The (n) stands for number of isoprene residues.  
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oxidation of vitamin KH2 to vitamin K 2,3-epoxide provides the energy to drive the 
carboxylation reaction yielding the final Gla product. The resulting Gla-residues are found in 
a limited number of proteins and they confer calcium-binding properties. During vitamin K 
deficiency, the carboxylation reaction cannot proceed, so the Gla proteins are released in an 
undercarboxylated form. In all cases in which the function of the Gla protein is known, Gla is 
essential to the biological activity of these proteins. An important point to mention with 
respect to the vitamin K cycle is that vitamin K-epoxide (KO) can be reconverted into the 
active KH2 by the action of the enzyme KO-reductase. Via this pathway each molecule of 
vitamin K may be recycled several thousand fold (see Figure 2), which explains its very low 
daily requirement as compared to other vitamins and cofactors. Well-known vitamin K-
antagonists such as warfarin all block the KO-reductase, thus inducing an artificial vitamin K 
deficiency in all tissues. 
NAD(P)H + H+ NAD(P)+
K KH2 KO
K
dithiol-(SH)2
dithiol-S2
dithiol-S2
dithiol-(SH)2
g-glutamylcarboxylase
Glu Gla
CO2, O2 H2O
CH
CH2
CH2
COOH
CH
CH2
HC
COOH
O
C
H
N
O
C
H
N
COOH
5.
3.
4.
2.1.
 
Figure 2  
The vitamin K-cycle. Vitamin K-quinone (K) is first reduced to vitamin K-hydroquinone (KH2), 
and then oxidized to vitamin K-epoxide (KO). During the oxidation step glutamic acid (Glu) is 
reduced to g-carboxyglutamic acid (Gla). Finally KO is reduced to K. 1. = NAD (H)-
dependent reductase, 2. = g-glutamylcarboxylase enzyme, 3. extra introduced carboxy 
group, 4. = dithiol-dependent KO-reductase, 5. = dithiol-dependent K-reductase. 
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Occurrence and nutritional intake of K-vitamins 
By far the most abundant form of dietary vitamin K is phylloquinone (vitamin K1), which 
occurs in green vegetables such as kale, spinach, broccoli, and Brussels sprouts 17-19. Except 
some plant oils 20, other foods have far lower phylloquinone contents. Menaquinones have a 
more restricted distribution in the diet than phylloquinone, with nutritionally significant 
amounts of MK-4 only occurring in animal meat and liver, and higher menaquinones (MK-6 
through MK-9) in liver and some fermented products, such as cheese and curd cheese 19. 
Only in Japan the MK-7 intake is high because of the abundance of this vitamer in the typical 
Japanese food product natto, which consists of fermented soybeans. Also the intestinal flora 
in the colon produces menaquinones, but the colonic absorption of these highly lipophilic 
compounds is probably very poor, and will not form a major contribution to the human vitamin 
K status.  Several databases on vitamin K-content of food have been published at this time 
17,18,21, but most of them focus on K1. Recently the first detailed table for menaquinone 
content of various foods has been published 19. In Table 2 part of the data obtained in our 
own group have been summarized. Using this table the vitamin K intake by the Dutch elderly 
population (> 55 years old) has been calculated which ranged between 124 mg/day (lowest 
quartile of intake) and 375 mg/day (highest quartile) for K1 and between 10 and 45 mg/day for 
K2 21. Whereas for K2 intake only one population-based survey has been published, the 
obtained data for K1 intake are comparable with those reported for the Framingham cohort 
(ranging from 59 to 262 mg/day) 22. Other data have shown that K1 intake of adolescents and 
young adults is substantially lower than that of adults, and may be below the RDA value in 
the majority of this age group 23. When using these data it is important to realize that the 
efficacies of intestinal absorption of K1 and K2 are widely different. Whereas the poor 
extraction of K1 from green leafy vegetables results in the absorption of 5-15% of the total 
vitamin K ingested 19,24, K2 vitamins are taken up almost completely from their natural food 
matrix. It must be concluded, therefore, that although K1 comprises about 90% of our total 
vitamin K intake, both K1 and K2 may contribute equally to the human vitamin K status. 
 
Absorption and transport 
In the small intestine vitamin K is extracted from the food and incorporated into micelles 
consisting of bile salts, free fatty acids and monoglycerides. These micelles are subsequently 
taken up by the intestinal mucosa, from which the vitamin – bound to chylomicrons – is set 
free in the lymphatic system and the circulation 25-27. The intestinal absorption of dietary K-
vitamins requires concomitant fat intake and normal bile secretion, which facilitate the 
solubilization of vitamin K into the mixed micelles. This explains the positive correlation 
between phylloquinone concentration in plasma and plasma triglycerides 28,29 and also why a 
striking impairment of vitamin K absorption is observed in patients with biliary obstruction 
(obstructive jaundice) and fat malabsorption problems 26. In these patients intravenous or 
intramuscular injection of K1 is indicated.  
Chylomicrons are transported to the liver where they are taken up as chylomicron remnant 
particles. The genetically determined subtypes of apolipoprotein E within the chylomicrons, 
play a crucial role in the transport of chylomicrons and thus of vitamin K to the liver and other 
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target tissues 29,30. The hepatic clearance is highest in the E4 subtype, followed by E3 and 
E2 31. A high chylomicron clearance corresponds with low plasma vitamin K levels 29,32.  
 
Table 2  
Vitamin K content of various foods (µg/100g). 
Nutrient      K1 K2 
Meat 0.5 - 3 1 - 8 
Fish 0.1 - 1 0.1 - 1.6 
Milk 0.5 - 1 0.2 - 2 
Yoghurt 0.2 - 0.5 0.1 - 1 
Cheese (all types) 2.5 - 15 0.5 - 80  
Butter 9 - 20 10 - 20 
Margarines (from plant oil) 80 - 110 0   
Green vegetables 100 - 750 0   
Natto (fermented soybeans) 20 - 30 800 - 1,000 
Fruit 0.1 - 3 0   
Bread 0.5 - 1 0   
       
 
 
Tissue requirement 
Whereas at low vitamin K intake most of the absorbed vitamin is transported to the liver, 
many different types of tissue accumulate K-vitamins at higher levels of intake 33. Both in 
steady-state animal nutrition studies 33 as well as in single-dose experiments 34 it appeared 
that the ratio in which K1 and K2 accumulate is tissue-dependent, with relative high K2 
accumulation in the pancreas, the testis and the arterial vessel wall. In these studies it was 
also observed that in the latter three tissues K2 was high even after long-term intake of 
exclusively K1. The hypothesis that K1 is converted into MK-4 by the intestinal flora appeared 
to be incorrect: also in germ-free rats high concentrations of MK-4 were found upon nutrition 
with K1 35,36, and it was concluded that tissues which accumulate high amounts of MK-4 have 
the remarkable capacity to convert up to 90% of the available K1 into MK-4 in case MK-4 is 
lacking in their diet. Tissues characterized by preferential accumulation of K1 (liver, heart) do 
not show the ability to convert K1 into MK-4. Although the reason of the K1-MK-4 conversion 
is presently unknown, it seems that in these tissues either MK-4 is preferentially used by the 
gammaglutamate carboxylase system, or MK-4 has a second, yet undiscovered function. 
Present RDA values for vitamin K (1.5 mg/day/kg body weight) are solely based on the 
hepatic requirement for clotting factor synthesis. Various studies have demonstrated, 
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however, that the liver is extremely efficient in taking up vitamin K from the blood stream. 
Notably at low vitamin K intakes the liver was shown to be the principal target tissue for 
vitamin K, whereas at higher intakes other tissues (heart, pancreas, kidney, lung, aorta) 
accumulated vitamin K as well 33. It is likely, therefore, that intakes well above the RDA value 
are required for adequate carboxylation of extrahepatic Gla-proteins because this process 
requires higher vitamin K intakes than that required for normal haemostasis. Obviously, the 
fact that in the recent past carboxylase was detected in many extrahepatic tissues 37 implies 
that our vitamin K intake may be adequate for covering the needs of the liver, but to a varying 
degree insufficient for other tissues. This phenomenon, described as the concept of tissue-
dependent vitamin K-requirement, defines vitamin K-sufficiency as a state in which a certain 
tissue produces all its Gla-proteins in a fully carboxylated form. The required dietary vitamin 
K intake may depend on tissue-specific properties such as the blood flow and the apoE 
receptor density on the target cells. As a logical consequence, different RDA-values have to 
be defined for the maintenance of an optimal vitamin K-status in liver, bone, vessel wall, and 
other tissues. Another important point to realize is the large variety of K-vitamins present in 
our food. As was discussed above, K1 is preferentially accumulated in the liver, whereas K2 
vitamins seem to be of more importance in extrahepatic tissues. One of the mechanisms 
underlying this phenomenon is probably the distribution of K-vitamins over the lipoprotein 
fractions: after oral ingestion most of K1 is associated with the triglyceride fraction, whereas 
substantial amounts of K2 are recovered in LDL and HDL 38. Also, the hepatic clearance of 
higher menaquinones is much slower than that of K1, so that they remain available much 
longer for extrahepatic uptake. This was observed, for instance for MK-9 from cheese and 
curd cheese, and for MK-7 from natto 38. 
 
 
1.2 VITAMIN K AND BONE METABOLISM 
Vitamin K-dependent proteins regulate cartilage calcification and new bone formation 
The first indications for involvement of vitamin K-dependent proteins in bone metabolism 
were obtained in the mid-1970s, when serious bone malformations were observed in babies 
from women who had been treated with vitamin K-antagonists (oral anticoagulants) during 
the first trimester of pregnancy 39. The defect is known as chondrodysplasia punctata or fetal 
warfarin syndrome, and is characterized by hypoplasia of the nasal bridge and distal 
phalanges and by punctate calcifications in the growth plates and rapidly growing bone, 
which appear as stippling on X-ray photographs. The excessive calcifications lead to 
irregular local termination of further bone development, which is the cause of the bone 
malformations. There are two Gla-proteins associated with bone formation: osteocalcin and 
matrix Gla-protein (MGP) 40. Osteocalcin is a small protein (49 amino acid residues) 
containing 3 Gla-residues, and is exclusively synthesized by osteoblasts and odontoblasts in 
bone and dentin 41. Osteocalcin is one of the most abundant proteins in the human body, but 
it is concentrated almost exclusively in the bone tissue. A small part of the de novo 
synthesized osteocalcin, however, is set free in the blood stream where it is available for 
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testing 42. Circulating osteocalcin antigen is a well known marker for osteoblast activity and 
bone formation, but in the majority of the population it consists of both fully carboxylated as 
well as undercarboxylated species. In contrast to osteocalcin, MGP is synthesized in a wide 
variety of tissues; MGP mRNA has been found in various cells including chondrocytes 43, 
vascular smooth muscle cells 44 and epithelium 45. MGP is a 10 kD protein containing 5 Gla-
residues which is synthesized at low levels in most soft tissues. The function of both bone 
Gla-proteins became clear from transgenic mice in which either osteocalcin or MGP had 
been knocked out. Osteocalcin appeared to be a negative regulator of bone formation 46,47, 
whereas MGP is a strong inhibitor of soft tissue calcification 48. Since bone is the only tissue 
to be calcified physiologically, one might ask whether mineralization is an active function of 
bone, or whether inhibition of mineralization is a function of all soft tissues 47. The fact that 
MGP and other inhibitors of calcification such as fetuin 49 are constitutively expressed in a 
wide range of soft tissues is consistent with the view that prevention of calcification is an 
active function of soft tissues.  
Comparable symptoms as seen in the human fetal warfarin syndrome could be induced in 
young experimental animals such as rats 50,51 and lambs 52. The principle of the protocol was 
first described by Price et al. 50, and is based on the complete blockade of all KO-reductase 
by feeding the animals with excessive amounts of warfarin. To prevent their bleeding to 
death, the animals receive a balanced daily dose of vitamin K, which is used as an antidote 
for warfarin by the liver but not by extra hepatic tissues. In this way the clotting system 
remains operational, whereas severe vitamin K-deficiency is maintained in other tissues such 
as bone and vessel wall. As a result excessive tissue calcification is observed, notably of the 
epiphyses and other cartilage and arteries. These and other data have demonstrated that 
MGP is a strong inhibitor of calcification, chondrocyte mineralization, and ossification 43. 
Since both vitamin K-dependent proteins identified in bone have a regulatory function in bone 
development, the question remains whether in humans long term low vitamin K intake or the 
use of vitamin K-antagonists may lead to impaired bone quality.  
 
Effects of low vitamin K-status in humans 
The first results providing evidence for the hypothesis that vitamin K is associated with bone 
metabolism came in 1984. It was shown that 16 osteoporotic patients with femur neck 
fractures had circulating vitamin K1 levels which were less than 30% of those in 34 controls 
53. In subsequent studies, it was confirmed that in osteoporotic hip fractures and in spinal 
crush fractures the circulating vitamin K concentrations were less than 25% of those in 
matched controls 54,55. It remained to be proven, however, that the low circulating vitamin K 
concentrations were indicative of poor vitamin K-status in the bone tissue. It was shown that 
high levels of undercarboxylated osteocalcin were detectable in serum from postmenopausal 
women, and that osteocalcin carboxylation quickly improved upon vitamin K administration 
56. The data, which strongly suggest that a mild vitamin K-deficiency is common in elderly 
women, were confirmed by others, and it turned out that circulating undercarboxylated 
osteocalcin is inversely correlated with bone mass 57,58 and that it is a strong risk factor for 
hip fracture 59,60. Osteocalcin was isolated from the femoral heads removed during hip 
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replacement surgery in elderly subjects suffering from osteoporotic fractures or degenerative 
joint disease, and it turned out that there is a widespread under-carboxylation of osteocalcin 
in humans, a defect that may reflect inadequate levels of vitamin K in bone cells 61. In a first 
population-based prospective study among over 72,000 elderly women it was demonstrated 
that subjects with nutritional vitamin K intake below 109 µg/day had a significantly higher 
age-adjusted relative risk of hip fracture than those with a higher intake 62. A comparable 
study was carried out among both men and women of the Framingham Heart Study, and 
again an association was found between low vitamin K intakes and hip fracture risk 22. Since 
the mean vitamin K intake in the American population is about 150 µg/day 63 we must 
conclude that the vitamin K status in a substantial fraction of the population is sub-optimal. 
Furthermore, in a recent meta-analysis Caraballo et al. concluded that regular intake of 
vitamin K-antagonists was associated with low bone mass 64. In Japan postmenopausal 
osteoporosis is successfully treated with very high doses of MK-4 65,66. An answer to the 
question of what levels of vitamin K intake and which form of vitamin K is required for optimal 
bone maintenance will come from a number of clinical trials from our group and others, two 
of which are presented in this thesis.  
 
 
1.3 VITAMIN K AND ARTERIAL CALCIFICATION 
Vitamin K-dependent proteins regulate arterial calcification 
Although the MGP null mutants were developed to study the effect of MGP-deficiency on 
bone metabolism, the most important and unexpected information from this transgenic model 
was the rapid calcification of a number of soft tissues including the large arteries, bronchi, 
and trachea. The profound impact of MGP-deficiency appeared from the fact that null 
mutants were all healthy at birth, but developed massive calcifications of the large vessels 
within the first weeks of life leading to death by rupture of the thoracic and abdominal aorta 
within 8 weeks after birth 48,67. Re-evaluation of the model based on coumarin / vitamin K 
treatment showed similar calcifications, typically starting at the elastic lamellae of the arterial 
media, with subsequent proliferation extension of calcifications at longer periods of treatment 
68,69. In humans, vascular calcification may occur in two distinct forms. Calcification of the 
tunica media (also known as Mönckeberg's sclerosis) often occurs in the absence of overt 
vascular disease and is frequently seen in patients with diabetes mellitus and in those with 
dialysis-dependent renal failure. Intima calcification, on the other hand, is widely associated 
with atherosclerosis. For many years it has been thought that vascular calcification is a 
passive process in which high local calcium concentrations were the result of dying cells 
within necrotic vascular lesions. Recent studies have shown, however, that the calcifying 
vessel wall shares many similarities with bone 8,70. On one hand vascular smooth muscle 
cells seem to be able to differentiate to cells with osteogenetic / osteoblastic protein 
expression type 71, on the other hand many proteins generally regarded as characteristic for 
bone and cartilage (osteocalcin, MGP, osteopontin, osteonectin, bone morphogenetic 
proteins, bone sialoprotein) have been identified in the calcifying vessel wall 72,73. It seems 
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therefore, that calcification of the vessel wall is a process regulated by similar proteins and 
processes as those known from bone metabolism. Among the proteins identified, the two 
vitamin K-dependent ones (osteocalcin and MGP) are known as potent mineralization 
inhibitors. Hence local vitamin K-deficiency in the vessel wall might lead to 
undercarboxylated (i.e. non-functional) forms of osteocalcin and MGP and thus to increased 
calcium deposition. In a population-based study Jie and colleagues observed an inverse 
correlation between dietary intake of vitamin K1 and mineralization of the abdominal aorta 74. 
Recently, a much stronger inverse correlation was found between vitamin K2 intake and 
artery calcification, with a 50% risk reduction for myocardial infarction and total cardiac death 
in the highest tertile of K2 intake 75. These data are consistent with a recent publication from 
Kawashima et al., who used hypercholesterolemic rabbits to demonstrate that high 
menaquinone intake suppresses the progression of atherosclerotic plaques, intimal 
thickening and pulmonary atherosclerosis, and that it significantly suppressed circulating 
cholesterol levels, cholesterol-ester deposition in the aorta, and plasma lipid peroxidation 76. 
In situ hybridisation studies demonstrated that the vitamin K-dependent MGP is particularly 
expressed around atherosclerotic lesions, and in vascular smooth muscle cells located in the 
tunica media 8. From subsequent immunohistochemical data with antibodies directed against 
human MGP it appeared that MGP accumulates in vascular areas prone to calcification such 
as the tissue surrounding the growing plaque and the elastin fibres in the tunica media 77. 
The current hypothesis is that this strong increase of MGP expression is a defence 
mechanism triggered by the increased local calcium concentration, but that precipitation of 
calcium salts is not inhibited because the vascular vitamin K status is insufficient to support 
the carboxylation of all MGP. Unless vitamin K-containing supplements are taken, most of 
the MGP will be synthesized in an undercarboxylated (i.e. inactive) form. Hence patients and 
subjects at risk for cardiovascular disease are not optimally protected against arterial 
calcification because of a dietary inadequacy of vitamin K. 
Recently, it was shown that high local calcium concentrations or precipitated calcium salts 
strongly induce MGP synthesis, probably in an attempt to minimize calcification and tissue 
damage 78. However, since the local vitamin K supply is insufficient, merely 
undercarboxylated and hence inactive MGP is produced. An answer to the question whether 
vitamin K supplements may contribute to optimal vessel wall condition comes from a clinical 
trial from our group, which is described in this thesis.  
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1.4 THE OBJECTIVE OF THIS THESIS 
The main objective of the work presented in this thesis was to study the effects of high 
vitamin K intake on bone and vascular health. In part I, two intervention studies on the effects 
of vitamin K1 supplementation on bone mineral density are described. Although many 
observational studies have shown an association between vitamin K-status and bone mineral 
density, no randomised intervention study has been published until now. Postmenopausal 
women form a high risk group for bone loss, due to the reduction in oestrogen production 
right at the onset of the menopause. The same is true for female athletes who often suffer 
from amenorrhoea due to extreme training intensity. In both high risk groups for bone loss, 
the effects of vitamin K supplementation were studied. In 181 postmenopausal women the 
effect of 1 mg vitamin K1 per day, co-administered with minerals and vitamin D, was 
investigated on bone mineral density during a follow-up period of three years (chapter 2). In 
115 female athletes with high training intensity, the rate of bone loss was quantified as a 
function of menstrual status and the potential effects of vitamin K1 (10 mg/per day) 
supplementation was investigated during a follow-up period of two years (chapter 3). 
In part II of this thesis, investigations are described on different aspects of the association 
between vitamin K and vascular health. To investigate the association between vitamin K 
and intermediary markers of cardiovascular disease, the data of the well-known 
epidemiological study, the Framingham offspring cohort, were analysed (chapter 4).  In a 
follow-up study the process of ageing (chapter 5) and the effects of vitamins D + K on vessel 
wall characteristics were investigated (chapter 6). The results of these studies contribute to a 
better understanding in the mechanisms underlying the association between vitamin K and 
vascular biology. Finally, in chapter 7, an assay for measuring the vitamin K-dependent 
protein matrix-gla protein (MGP) in serum is described. With this assay it is possible to study 
the potential utility of MGP as a serum marker for cardiovascular disease.  
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ABSTRACT 
Although several observational studies have demonstrated an association between vitamin K 
status and bone mineral density (BMD) in postmenopausal women, no placebo-controlled 
intervention trials on the effect of vitamin K1 supplementation on bone loss have been 
reported thus far. In the trial presented here we have investigated the potential 
complementary effect of vitamin K1 and a mineral + vitamin D supplement on 
postmenopausal bone loss. In total 181 healthy postmenopausal women between 50 and 60 
years old were recruited for this randomised double-blind placebo-controlled intervention 
study; 155 of whom completed the study. During the 3-year treatment period participants 
received a daily supplement containing either placebo, or calcium, magnesium, zinc and 
vitamin D, or the same formulation with additional vitamin K1. The main outcome measure 
was the change in BMD of the femoral neck and lumbar spine after three years, as measured 
by DEXA. The group receiving the supplement containing additional vitamin K1 showed 
reduced bone loss of the femoral neck; the differences in decrease of BMD (relative to 
baseline) with both the placebo (1.7%) (95% CI: 0.35 to 3.44) and the mineral + D group 
(1.3%) (95% CI: 0.10 to 3.41) were statistically significant. No significant differences were 
observed between the three groups with respect to change of BMD at the site of the lumbar 
spine. If co-administered with minerals and vitamin D, vitamin K1 may substantially contribute 
to reducing postmenopausal bone loss at the site of the femoral neck.  
  
  Chapter 2: Bone Loss in Postmenopausal Women 
  29 
INTRODUCTION 
The role of calcium and vitamin D in the maintenance of skeletal health has long been 
recognized. Supplements containing vitamin D and calcium were reported to be effective in 
the prevention of hip fractures in women with a low dietary vitamin D and calcium intake 1,2. 
However, vitamin D supplements did not decrease hip fracture rate in women with normal 
calcium intakes 3. 
Accumulating evidence suggests that poor vitamin K status may be an independent risk 
factor for postmenopausal bone loss. The two most important forms of vitamin K are vitamin 
K1 (phylloquinone) and the group of K2 vitamins (menaquinones). Green vegetables such as 
broccoli and spinach, as well as some plant oils are the major sources of phylloquinone in 
the human diet 4-7. Menaquinones are primarily found in meat (menaquinone-4) and 
fermented foods like cheese and curds (menaquinone-6-9) 7. The mean dietary vitamin K 
intake by the Dutch elderly population (> 55 years) ranges between 124 µg/day (lowest 
quartile of intake) and 375 µg/day (highest quartile) for phylloquinone and between 10 and 45 
µg/day for the combined menaquinones. Vitamin K functions as a cofactor in the 
posttranslational carboxylation of several bone proteins, the most abundant one of which is 
osteocalcin. Vitamin K-deficiency of bone tissue results in the synthesis of undercarboxylated 
osteocalcin (ucOC), and the concentration of circulating ucOC is generally accepted as a 
sensitive marker for vitamin K status 8-10. Several authors have demonstrated that low serum 
concentrations of either vitamin K1 11,12 or ucOC 13-15 are associated with low bone mineral 
density (BMD) and an increased risk for osteoporotic hip fractures. Also, a number of clinical 
studies have demonstrated that the use of vitamin K antagonists (oral anticoagulants) is 
associated with low BMD and increased hip fracture risk 16-18. Such association was not 
found in all studies, however 19-21. The first intervention study with vitamin K showed that 
supplementation with 1 mg vitamin K1 per day for 2 weeks induced a decrease of urine 
markers for bone resorption and an increase of serum markers for bone formation 10. So far, 
there has been no intervention trial on the effects of vitamin K1 on BMD. A number of 
Japanese studies, however, have shown significant reduction of osteoporotic bone loss after 
supplementing patients with high doses (45 mg/day) of vitamin K2 (menatetrenone) 22.  
In the present study, we have investigated the effect of minerals + vitamin D supplementation 
on postmenopausal bone loss, and the potential additive effect of vitamin K1 on this 
treatment. It is the first intervention trial in which the potential prevention of bone loss by 
vitamin K1 supplementation has been monitored. 
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METHODS 
Protocol 
Participants were recruited by local newspaper calls. Inclusion criteria were: apparently 
healthy women, Caucasian race, between 50 and 60 years old and at least two years 
postmenopausal. Exclusion criteria were: bone fractures during the preceding year, 
metabolic bone disease, use or recent use (£ one year) of oral anticoagulants, hormone 
replacement therapy, bisphosphonates, vitamin concentrates or food supplements, drugs 
known to interfere with calcium metabolism (such as corticosteroids), and alcohol 
consumption of > 2 glasses/day. In total 188 women met the criteria for participation, and 
were randomized into our study. The enrollment of participants took place between 
November 1997 and March 1998. Follow-up measurements were performed until March 
2001. The primary outcome measures of the study were the BMD of the femoral neck and 
lumbar spine both measured with a dual-energy x-ray absorptiometer (DEXA; Lunar, 
Madison, WI). Scans of the lumbar spine (L2-L4) and femoral neck were performed at 
baseline and after one, two and three years of treatment. To measure the effect of seasonal 
influences on BMD we performed also a measurement after 1.5 years; these data are 
beyond the scope of this paper and will be published elsewhere. Measurements were 
performed by the same two experienced in-hospital technicians throughout the whole study-
period. The mean coefficient of variation of repeated measurements was 1.4% for the 
femoral neck and 1.0% for the lumbar spine. Together with BMD, height and weight were 
measured each year with standardized equipment. Fasting blood and 2-h morning urine 
samples were collected at t = 0, 3, 12, and 36 months to measure biochemical markers for 
bone metabolism. Participants were asked to refrain from taking the supplement on the day 
preceding blood and urine sampling. Markers tested in serum were: undercarboxylated 
osteocalcin (ucOC, Takara, Japan) and total osteocalcin (Cis Bio International, France) for 
compliance and bone vitamin K status, 25OH-vitamin D3 (Incstar, USA) for vitamin D status, 
and bone alkaline phosphatase (Hybritech, Belgium) for bone formation. In urine we 
measured deoxypyridinoline (Metra Biosystems, USA) for bone resorption, as well as 
calcium, measured by an atomic absorption spectrophotometer. For both urinary markers, a 
correction was made for creatinine excretion. Between measurement points the same 
investigator visited the participants at home to check their compliance at regular intervals. All 
participants gave written informed consent and the trial was approved by the University 
Hospital medical ethics committee. 
 
Assignment  
Participants were randomized into three groups, the first one (n=60) receiving a placebo 
(maltodextrine), the second one (n=58) receiving a supplement containing 500 mg calcium 
(natural calcium complex derived from milk), 10 mg zinc, 150 mg magnesium and 8 mg 
vitamin D3 (minerals + vitamin D = MD-group), whereas subjects in the third group (n=63) 
received a supplement containing the same constituents as the MD-group but with additional 
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1 mg vitamin K1 (minerals + vitamins D+K = MDK-group). The participants were allowed to 
choose between a supplement in the form of either a tasteless powder (to be mixed with 
water before intake) or chocolate-coated tablets with a crunchy malt core. The percentage of 
subjects using the powder or tablets was equally distributed across the three groups. 
Participants were instructed to take one sachet with powder or three tablets per day during 
evening hours, preferably after the meal. Also, they were advised to maintain their usual 
diets and to avoid taking supplements containing either calcium, vitamin D, or vitamin K 
throughout the study. After randomization, the women received their first batch of 
supplements and were supplied with subsequent portions every six months. Novartis 
Consumer Health SA (Nyon, Switzerland) prepared and provided all supplements.  
 
Masking 
Randomization was performed according to a computer-generated randomization list and the 
randomization codes were kept apart from the study site during the trial. The participant 
randomization codes were allocated sequentially in the order in which the participants were 
enrolled. One investigator who supervised the whole study was responsible for the 
enrollment and assignment of participants to the respective groups. Because the three 
different types of supplements were similar in appearance and taste, neither participants nor 
investigators were aware of group assignment.  
 
Statistical Analysis 
The sample size was calculated on the assumption that the desired minimal detectable effect 
was a 15% decrease of bone loss in one of the treatment groups compared to placebo with a 
90% power and a 0.05 level of significance. With the assumption of a dropout rate of 10% 
per year we calculated that 180 subjects had to be included. Statistical analysis was 
performed using the Statistical Package SPSS (SPSS Corp, Chicago, IL). Only the results on 
women who had more than one measurement were included in the analysis. Results are 
presented as means ± SD, unless indicated otherwise. For each subject separately, all 
follow-up measurements were related to the corresponding baseline-value by expressing 
changes as % from baseline. Values of bone loss for each participant were adjusted for the 
exact time she had been in the trial. At all time-points changes in BMD from baseline were 
compared between treatment groups and placebo and between both treatment groups using 
linear regression analysis. In these analyses, the change in BMD from baseline was used as 
the dependent variable and the initial BMD value, the treatment groups, and other covariates 
were used as explanatory variables. Age, BMI, and years since menopause were chosen as 
covariates, because their influence on the rate of bone loss or response to supplementation 
could not be excluded. Data were analysed according to the intention-to-treat principle. 
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RESULTS 
Participant flow and follow-up  
Figure 1 shows the flow of participants through each stage for the separate groups. After the 
first bone densitometry, seven subjects (1 in the placebo group, 3 in the MD-group, 3 in the 
MDK-group) were removed from the study and referred for treatment because their BMD was 
> 2.5 SD below the reference population. From the remaining 181 subjects who entered the 
study, 31 subjects discontinued their participation, reasons given for discontinuation were: 
personal reasons (n=13: 2 in the placebo group, 8 in the MD-group, 3 in the MDK-group), 
illness (n=6: 2 in the MD-group, 4 in the MDK-group), glucocorticosteroid (1 in the placebo 
group) or estrogen therapy (n=3: 1 in the placebo group, 2 in the MD-group) or multivitamin 
supplements (1 in the MDK-group), whereas seven participants withdrew because of 
complaints of mild constipation (4 in the MD-group, 3 in the MDK-group). No other adverse 
events were reported during the study. The majority of the subjects who discontinued 
treatment did so during the first year (n=19), so no follow-up data could be collected on these 
subjects. Drop-out rates in both treatment groups were higher than in the placebo. Given the 
specific reasons for drop-out as mentioned in the results it is unlikely that the treatment 
Assessed for eligibility
(n=200)
Randomized (n=188)
Excluded (n=12)
Not meeting inclusion criteria (n=2)
Refused to participa te (n=9)
Other reasons (n=1)
Allocated to placebo (n=61)
Received allocated treatment (n=60)
Did not receive allocated intervention (n=1);
referred for treatment outside study
Allocated to  MD (n=61)
Received allocate d treatment (n=58)
D id not receive allocated intervention (n=3);
referred for treatm ent outside study
Allocated to MDK (n=66)
Received allocated treatment (n=63)
Did not receive allocated intervention (n=3);
referred for treatment outside study
Lost to follow-up (n=0)
Discontinued intervention (n=4)
Analyzed (n=56)
Lost to follow-up (n=12)
Discontinued intervention (n=4)
Lost to follow-up (n =7)
Discontinued intervention (n=4)
Analyzed (n=60) Analyzed (n=46)
Complet ed three years (n=56 ) Completed three  years (n=42) Completed three years (n=52)
 
 
Figure 1 
Flow diagram of participants through the different stages of the study. 
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assignment is responsible for the higher drop-out rate. The subjects who discontinued 
treatment during the second and third year (n=12) were included in the analysis. There were 
no significant differences between the three groups in baseline characteristics and the initial 
mean values for BMD at both sites measured were similar in the three groups (Table 1). 
Omission of the drop-outs from the analyses did not change these baseline data. 
 
Table 1 
Baseline characteristics (mean ± standard deviation) in the three treatment groups. 
Baseline-characteristics Placebo Mineral + vitamin D Mineral + vitamin D+K 
 (n=60) (n=46) (n=56) 
       
Age (yr)  54.6 ± 2.8 55.7 ± 2.9 55.3 ± 2.8 
Weight (kg) 69.5 ± 11.4 69.4 ± 10.3 67.4 ± 11.4 
Height (m) 1.63 ± 0.05 1.65 ± 0.07 1.64 ± 0.06 
BMI (kg/m2) 26.1 ± 4.3 25.5 ± 3.9 25.1 ± 25.1 
Postmenopausal age (yr) 5.0 ± 3.5 7.0 ± 5.2 6.0 ± 5.2 
Non-smokers (%) 75.0  73.9  85.0  
L2-L4 BMD (g/cm2) 1.16 ± 0.15 1.10 ± 0.14 1.13 ± 0.16 
Neck BMD (g/cm2) 0.95 ± 0.14 0.93 ± 0.10 0.96 ± 0.14 
Abbreviations used: body mass index (BMI) and bone mineral density (BMD). 
 
Bone mineral density 
The changes in femoral neck BMD during the study are shown in Figure 2. In the placebo 
group the BMD decreased regularly, as was to be expected. During the first year of the study 
the BMD of the femoral neck had remained constant in both treatment groups. At two and 
three years after the start, the femoral neck BMD had also declined significantly in both 
treatment groups, although the rate of bone loss was lower in the MDK-group than in either 
the placebo or the MD-group. The differences in % BMD loss from baseline between the 
MDK-group and placebo (1.7%) (95% CI: 0.35 to 3.44) and between the MDK- and the MD-
group (1.3%) (95% CI: 0.10 to 3.41) were statistically significant after three years (p<0.05) 
after adjustment for baseline BMD, age, BMI, and years since menopause. After three years, 
there was no significant difference in the % change from baseline in femoral neck BMD 
between the MD-group and placebo (mean difference: 0.4%, 95% CI: -1.51 to 1.79). 
During the first year of the study we found no significant decrease in the lumbar spine BMD 
of the MD-group, whereas in both other groups the BMD decreased significantly. The 
difference in % bone loss from baseline after three years between the MD-group and placebo 
was 1.3% (95% CI: -0.28 to 2.69) and between the MD- and MDK-group the difference was 
0.9% (95% CI: -0.70 to 2.23) after adjustment for baseline BMD, age, BMI, and years since 
menopause. Although the bone loss in the MD-group seems to be less than in both other 
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groups, the differences in % bone loss between the three groups were not statistically 
significant. Hence a positive effect of the mineral + D supplement at the level of lumbar spine 
cannot be concluded. Neither a beneficial effect of vitamin K could be demonstrated at this 
site (difference with placebo: 0.5%, 95% CI: -0.95 to 1.82). 
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Figure 2 
Mean percent change from baseline (± standard error of the mean) in femoral neck bone 
mineral density. Explanation of symbols: placebo (n=60) (p), group MD (n=46) (¢), group 
MDK (n=56) (). *: p < 0.05, significantly different from placebo and MD-group.  
 
 
 
Biochemical markers for bone metabolism 
The data on biochemical markers are summarized in Table 2. As was to be expected, ucOC 
strongly declined in the MDK group, but not in both other ones, thus showing the compliance 
to treatment as well as the increase in vitamin K status in this group. In both treatment 
groups serum vitamin D increased during the first year, thus confirming compliance to 
treatment and the increase was statistically significant both as compared to baseline as well 
as to placebo. The elevated vitamin D levels were maintained throughout the study, although 
at T=36 months significance was lost in the MDK-group. During the first year all markers for 
bone metabolism showed a trend for decrease in both treatment groups, but not in all cases 
this trend did reach the level of statistical significance. In the MDK-group the decline in bone 
metabolism seems to be (at least partly) maintained at this time, although the effects are 
weak and may not be clinically relevant.  
 
* 
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Table 2 
Bone markers (mean ± standard deviation) in the three treatment groups at all  
timepoints. 
Marker Group  T=0 T=3 months T=12 months T=36 months 
ucOC (ng/mL) Placebo 2.77 ± 0.90 n.m.  2.77 ± 1.12 2.84 ± 1.07 
 MD-group 2.58 ± 0.78 n.m.  2.18 ± 1.15 2.49 ± 0.93 
 MDK-group 3.01 ± 0.95 n.m.  0.78 ± 0.48*# 0.54 ± 0.27 *# 
25OH-vit D3 (ng/mL) Placebo 20.4 ± 5.6 19.4 ± 5.5 22.3 ± 5.1* 19.8 ± 4.9 
 MD-group 22.5 ± 5.8 24.8 ± 5.2*# 25 ± 4.6* 24.5 ± 5.4*# 
 MDK-group 22.9 ± 7.4 27.5 ± 4.5*# 25 ± 5.9* 23.7 ± 5.8 
OC (ng/mL) Placebo 23.8 ± 6.1 24.2 ± 6.5 21 ± 6.1* 23.3 ± 7.6 
 MD-group 24.6 ± 7.3 23.7 ± 7.1 21.2 ± 7.6* 23.3 ± 7.9 
 MDK-group 25.5 ± 6.4 23 ± 4.9*# 19.1 ± 4.7*# 23.8 ± 8.6 
BAP (ng/mL) Placebo 14.5 ± 5.8 14.3 ± 4.7 13.9  ± 4.6 15.8 ± 4.5 
 MD-group 14.8 ± 4.7 14 ± 5.5* 12.1 ± 3.8* 15 ± 5.0 
 MDK-group 15 ± 5.8 14.5 ± 6.0* 13.3 ± 5.3* 14.9 ± 5.6 
DPD/creat (µmol/mol) Placebo 7.4 ± 3.2 7.3 ± 2.6 6.7 ± 2.5 7.2 ± 3.2 
 MD-group 7.6 ± 4.6 6.5 ± 1.8 6.4 ± 1.6 7.4 ± 3.7 
 MDK-group 7.1 ± 3.4 7.5 ± 2.8 6.5 ± 2.1 6.9 ± 3.1 
Ca/creat (mol/mol) Placebo 0.3 ± 0.17 0.27 ± 0.13 0.28 ± 0.14 0.3 ± 0.16 
 MD-group 0.36 ± 0.22 0.3 ± 0.19*# 0.35 ± 0.19 0.36 ± 0.25 
 MDK-group 0.32 ± 0.18 0.33 ± 0.16 0.32 ± 0.15 0.36 ± 0.20 
*significant difference compared to baseline (p<0.05)  
#significant difference compared to placebo (p<0.05)  
Abbreviations used: not measured (n.m.), undercarboxylated osteocalcin (ucOC), 
osteocalcin (OC), bone alkaline phosphatase (BAP), deoxypyridinoline (DPD), creatinine 
(creat) and calcium (Ca).   
 
 
DISCUSSION 
The efficacy of calcium and vitamin D in retarding postmenopausal bone loss is presently not 
clear. A general tendency in many (although not in all) studies published thus far, is that most 
clear effects were observed in cohorts with a low baseline calcium and vitamin D intake 1,2. 
Also, short-term (1-2 years) studies often show a positive effect of treatment 23, whereas 
potential benefits are less obvious during longer treatment periods 24,25. From our study it 
appeared that also a more complex mineral supplement containing calcium, magnesium, and 
zinc as well as vitamin D3 resulted in a transient, but no long-term retardation of bone loss at 
the site of the femoral neck. Addition of vitamin K1 to this supplement, however, showed 
complete protection during the first year and a partial but persisting protective effect 
thereafter, leading to a 35% reduction of bone loss (as compared to placebo) after three 
years. From the fact that - after a transient delay - bone loss also in the MDK group 
continued (though at a lower pace), we conclude that the bone balance had remained 
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negative. This phenomenon has also been described for other inhibitors of postmenopausal 
bone loss 26. The bone densitometry data are consistent with the biochemical markers for 
bone metabolism, showing a trend towards a decreased bone turnover for both treatment 
groups during the first year of the study, which returned to baseline values after 3 years. 
However, the differences with baseline are small and not in all cases statistically significant. 
Osteocalcin has a vitamin D-responsive element in its promotor gene, and the fact that the 
vitamin D-containing supplement did not increase circulating osteocalcin levels suggests that 
all subjects were adequate in vitamin D at baseline. The circulating ucOC, and its sharp 
decrease after vitamin K treatment demonstrates that the participants were sub-optimal in 
vitamin K. Some Gla-proteins (such as rat prothrombin) exhibit a strongly decreased cellular 
secretion in their undercarboxylated form. From the fact that the improved osteocalcin 
carboxylation did not result in an increase in circulating osteocalcin total antigen, we 
conclude that both carboxylated and undercarboxylated species of human osteocalcin are 
secreted by the osteoblast comparably well. 
Our study is the first intervention trial showing a retardation of postmenopausal bone loss by 
increased vitamin K1 intake, and is consistent with a number of observational studies in 
which an association between vitamin K status and either femoral neck BMD or fractures 
were demonstrated 11-15,27. Comparable intervention trials among the Japanese population 
indicated that vitamin K2 has a more complete effect on bone loss both at the site of the 
lumbar spine and the femoral neck. The doses used in these studies were extremely high, 
however 22. No clear functional differences between vitamin K1 and K2 are known, although 
several recent observations suggest that the liver is the main target tissue for vitamin K1, 
whereas vitamin K2 is accumulated and used preferentially in extra-hepatic tissues 28. This 
might explain why vitamin K2 could have a more profound effect on bone than vitamin K1. 
In our study we did not find an effect of treatment on the rate of bone loss at the site of the 
lumbar spine. Although it seems remarkable that an effect of vitamin K1 was only seen on the 
femoral neck and not the lumbar spine, it must be kept in mind that several factors interfere 
with DEXA measurement of the vertebrae. Other calcifications, such as osteoarthritis with 
occurrence of osteophytes, or extensive aortic calcification may hamper the correct reading 
of true vertebral BMD. Therefore, these data have to be interpreted with caution. The 
mechanism underlying the protective effect of vitamin K1 on bone loss of the femoral neck is 
probably related with the higher carboxylation degree of vitamin K-dependent proteins in 
bone. This needs not remain restricted to osteocalcin (which was only used as a marker 
protein in this study), since several other Gla-proteins have been identified in bone 29,30. The 
data presented here do not warrant any speculation regarding the molecular mechanism 
underlying the observed effects. 
In conclusion, we have demonstrated that a supplement containing minerals and vitamins D 
and K has a long-term preventive effect on bone loss in healthy postmenopausal women, 
although a complete halt of bone loss was not achieved. If the observed effect sustains 
during longer periods of intake, it may result in postponement of osteoporosis to later ages. 
The nutritional supplement does not replace classical anti-osteoporotic therapy, and this 
study does not allow to draw any conclusions concerning fractures. 
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ABSTRACT 
Low bone mass leading to stress fractures is a well known and as yet unsolved problem in 
female elite athletes. In a prospective study among healthy athletes we have quantified the 
rate of bone loss, and we have investigated the potential effects of oestrogen 
supplementation, vitamin K supplementation, as well as other factors such as dietary calcium 
intake. In total 115 female endurance athletes (between 15 and 50 years old) were selected 
and classified into amenorrheic, eumenorrheic, or oestrogen-supplemented women and 
randomised to receive either placebo or vitamin K1 (10 mg/day) for two years. Primary 
outcome measure was the change in bone mineral density (BMD) of the femoral neck and 
lumbar spine after two years, as measured by DEXA. The results showed that the femoral 
neck BMD had decreased significantly after two years in all three subgroups. The decrease 
was higher in amenorrheic (-6.5 ± 4.0%) than in eumenorrheic (-3.2 ± 4.1%, p< 0.01) and 
oestrogen-supplemented athletes (-3.9 ± 3.1%, p=0.07). In all three subgroups the lumbar 
spine BMD remained constant. Amenorrhea was the only significant predictor found for bone 
loss in this study (ß-coefficient: 3.2%, 95% CI: -5.7 to –0.612). Supplementation with vitamin 
K did not affect the rate of bone loss. In conclusion, the rate of bone loss in female 
endurance athletes was unexpectedly high. Oestrogen supplementation may retard, but not 
prevent the bone loss. High training intensity maintained over several years must be 
regarded as a significant risk factor for osteoporosis, and protocols for optimal treatment 
should be developed.  
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INTRODUCTION 
Normal physical activity positively contributes to peak bone mass and may decrease the rate 
of bone loss in postmenopausal women 1,2,3. Also, a less active lifestyle has been associated 
with an increased risk for osteoporotic fractures 4. Hence moderate exercise is generally 
recommended to decrease the rate of bone loss after menopause 5. On the other hand, high 
training loads may have a detrimental effect on bone both in men and women. It was 
reported, for instance, that lumbar spine bone mineral density (BMD) was significantly lower 
in young male runners than in an age-matched group of non-runners 6. It was hypothesised 
that the high weekly mileage of runners may result in low testosterone and high cortisol 
levels, resulting in a catabolic effect on bone. Thus, a hormonal mechanism may be 
responsible for reduced BMD in endurance athletes engaged in a high training load 7,8. The 
different effects of normal and high exercise intensity on BMD may be explained by 
assuming that until a threshold level of exercise bone formation is stimulated, but that at 
higher training intensity the beneficial effect is lost and – in extreme cases – may even result 
in actual bone loss 9. Bone loss in early life is especially of concern for women, since their 
peak bone mass is lower than that of men, and because they experience higher bone loss 
after menopause. Female endurance athletes possess a number of risk factors for bone loss 
that are intimately related, such as: large training volumes with a high intensity affecting the 
oestrogen status, high incidence of amenorrhea, low body mass index (BMI), low body fat 
content, and relatively low energy and calcium intake 8,10-14. In these women there is a high 
incidence of skeletal problems related to osteopenia such as stress fractures 15, and little is 
known about their bone development at later ages. It is assumed that the combination of 
oestrogen deficiency with any of the above factors increases the risk of bone loss 16,17. Thus 
far, the problem of bone loss in female elite athletes has mainly been addressed in cross-
sectional studies, whereas longitudinal studies – especially in relation to treatment – have 
been rare. Oestrogen supplementation is a common treatment for amenorrheic athletes, but 
whether this prevents further bone loss is not completely clear.  
During recent years it has been shown that vitamin K is involved in bone metabolism. Vitamin 
K functions as a cofactor in the synthesis of a group of calcium-binding proteins generally 
known as the ‘Gla-proteins’, where Gla stands for the unusual amino acid g-carboxy glutamic 
acid 18. The bone Gla-protein osteocalcin is involved in the regulation of calcium deposition in 
bone and biochemical vitamin K deficiency of bone tissue is common in large parts of the 
population 19,20. Osteoporotic hip and vertebral fractures where shown to be associated with 
depressed levels of circulating vitamin K 21-23, high concentrations of Gla-deficient osteocalcin 
24,25 and low dietary intakes of vitamin K 26. A number of Japanese studies 27,28 as well as a 
placebo-controlled clinical trial from our group (Braam et al., unpublished data) have shown 
beneficial effects of vitamin K supplementation on BMD to postmenopausal women and renal 
dialysis patients. Moreover, data from a small pilot study suggest that high vitamin K intake 
may lead to an improved bone balance in female athletes 29. 
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In this paper we report a 2-year follow-up study in which we have monitored the BMD change 
in female athletes as a function of their menstrual status and oestrogen supplementation. To 
find additional ways for protection against further bone loss, the potential effects of vitamin K 
supplementation were also investigated.  
 
 
METHODS 
Subjects 
Female endurance athletes from the Netherlands, Belgium and Germany between 15 and 50 
years of age were selected in collaboration with sports physicians of the Royal Dutch and 
Belgian Athletics Union and the German Athletics Union. All participants completed a 
questionnaire providing information on their training schedules, menstrual status, dietary 
habits and use of medication and food supplements. Inclusion criteria were: apparently 
healthy, performance on an international/national top or medium level (training intensity of at 
least 7 hours per week). Exclusion criteria were: recent (< 1 year ago) bone fractures, use of 
oral anticoagulants, use of medication known to influence calcium metabolism. In total 115 
women were enrolled in the study between October 1998 and September 1999. The study 
protocol was approved by the University Hospital Medical Ethics Committee, and written 
informed consent was obtained from all participants.  
 
Study Design  
On basis of the information obtained from the questionnaires the study cohort was 
subdivided into the following three groups: amenorrheic/oligomenorrheic  athletes (in this 
paper further described as amenorrheic athletes): those who experienced absence of 
menstruation or who had fewer than 6 menstrual cycles in the last 12 months, in all athletes 
the amenorrhea was secondary (n=29); eumenorrheic athletes: those who had 10-13 
menstrual cycles in the previous year and not using oral contraceptives (n=49); oestrogen-
supplemented athletes: those who were using oral contraception, the duration of 
supplementation ranging from 1-17 year (n=37). Subjects in each of these subgroups were 
randomised for treatment with either vitamin K1 (10 mg/day, n=59) or placebo (corn starch 
gran, n=56). Randomisation was performed using a computer-generated randomisation list 
and the randomisation codes, which were kept apart from the study site during the trial, were 
allocated sequentially in the order in which the participants were enrolled. One investigator 
who supervised the whole study was responsible for the enrollment and assignment of 
participants to the respective groups. Capsules with vitamin K and placebo were kindly 
supplied by Roche Vitamins Ltd (Basel, Switzerland). Because the two different types of 
supplements were similar in appearance and taste, participants and investigators were not 
aware of group assignment. The subjects were instructed to take one capsule per day during 
evening hours, preferably after the meal. After randomisation and baseline measurements, 
the women received supplements for the first year, and after one year they were supplied 
with a new batch for the second year.  
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Measurements 
The BMD of the lumbar spine (L2-L4) and femoral neck were measured using a dual energy  
X-ray absorptiometer (DEXA, Lunar Co, Wisconsin, USA). Scans of the lumbar spine (L2-L4)  
and femoral neck were performed at baseline and after two years of treatment. The same 
two experienced in-hospital technicians performed the measurements throughout the whole 
study-period. The mean coefficient of variation of repeated measurements was 1.4% for the 
femoral neck and 1.0% for the lumbar spine. Blood samples were drawn at baseline and 
after two years. The participants were not allowed to perform any kind of exercise in the 
morning before blood sampling. Serum was prepared by leaving the samples for 2h at room 
temperature, followed by centrifugation for 15 min at 2000 x g. Urine was collected during the 
last two hours of a 16-hour fasting period to exclude dietary influences. All samples were 
immediately frozen and kept at –80 ºC until use. In serum, total osteocalcin (Cis Bio 
International, France) and bone alkaline phosphatase (Hybritech, Belgium) were measured 
as markers of bone formation by radio immunoassay. In urine, total calcium (atomic 
absorptiometry) and deoxypyridinoline (competitive immunoassay from Metra Biosystems, 
USA) were used as markers for bone resorption; correction for creatinine excretion was not 
justified in this case because of the association between creatinine excretion and training 
intensity. The habitual dietary calcium intake of our subjects was measured with a validated 
food frequency questionnaire (FFQ), as described elsewhere 30. Height and weight were 
measured using standardized equipment, body mass index (BMI) was calculated as weight 
(kg) / height2 (m2). In the two years between baseline and end-point measurement, the 
responsible investigator contacted the participants every 6 months to check their motivation 
and compliance.  
 
Statistical Analysis 
The sample size was calculated on basis of the assumption that the desired minimal 
detectable effect of vitamin K treatment would be a 30% decrease of bone loss in the 
treatment group compared to the placebo group with a 90% power and a 0.05 level of 
significance. With the assumption of a dropout rate of 15% per year we calculated that 115 
subjects had to be included. Statistical analysis was performed using the Statistical Package 
SPSS (SPSS Corp, Chicago, IL). Results are presented as means ± SD, unless indicated 
otherwise. The baseline characteristics and changes in bone mineral density and bone 
markers after two years between the three subgroups were compared by analysis of 
variance (ANOVA). The follow-up measurement of each subject was related to the 
corresponding baseline-value by expressing change as % from baseline. The total cohort 
was analysed to study the effect of treatment. Changes in BMD from baseline between the 
vitamin K group and placebo were compared using a student T-test. Linear regression 
analysis was used to study the effects of treatment after adjustments for potential 
confounders and to assess significant predictors of bone loss. Change of BMD after two 
years was used as the dependent variable and age, BMI, calcium-intake, stress fractures 
(yes/no), age of menarche and of start training, amenorrhea (yes/no), use of oral 
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contraceptives (yes/no) and vitamin K treatment (yes/no) were used as independent 
variables. 
 
 
 
 
 
 
 
 
 
 
Table 1 
Baseline characteristics in three groups of female athletes classified according to 
menstrual status. 
Variables Amenorrhea Eumenorrhea Oestrogen users 
 Mean ± SD (n=17) Mean ± SD (n=36) Mean ± SD (n=26) 
age (yr)  22.2 ± 8.4 31.8 ± 10.9* 28.7 ± 9.8 
BMI (kg/m2) 19.3 ± 1.1 20.5 ± 2.0 20.4 ± 1.8 
age menarche (yr) 14.5 ± 1.5 13.6 ± 1.2 14.2 ± 1.6 
age of start training (yr) 14.8 ± 9.3 19.2 ± 10.3 18.1 ± 8.8 
training intensity (hours/week) 9 ± 2 10 ± 2.5 9 ± 1.5 
calcium intake (mg/day) 781 ± 363 753 ± 453 864 ± 579 
lumbar spine BMD (g/cm2) 1.2 ± 0.1 1.3 ± 0.2 1.2 ± 0.1 
femur neck BMD (g/cm2) 1.1 ± 0.1 1.1 ± 0.2 1.1 ± 0.2 
serum BAP (ng/ml)1 17.6 ± 8.2  15.2 ± 10.3 11.3 ± 4.1* 
serum osteocalcin (ng/ml)2 30 ± 12.5 23 ± 11.8 23 ± 8.4 
urinary DPD (mmol/2h)3 5.7 ± 3.4 5.4 ± 2.3 6.1 ± 2.6 
urinary calcium (mmol/2h) 0.2 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 
% vitamin K treatment 58%  40%  50%  
* significant difference with group A (p<0.05) 
Abbreviations used: body mass index (BMI), bone alkaline phosphatase (BAP), deoxypyridinoline 
(DPD) and bone mineral density (BMD). 
1 mean value in premenopausal females: 8.7 ± 2.9 (ng/ml) (Hybritech, Belgium) 
2 mean value in premenopausal females: 17.1± 3.5 (ng/ml) (Cis Bio International, France) 
3 mean value in premenopausal females: 4.5 ± 1.4 (mmol/2h) (Metra Biosystems, USA) 
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RESULTS 
After inclusion, 36 of the 115 participants discontinued the study prematurely; reasons for 
drop out were: lack of motivation, sudden ending of athletics career, and non-specified 
personal reasons. The number of dropouts was equally distributed across the three 
subgroups and both treatment groups. In Table 1 the baseline characteristics of the 79 
participants who completed the study are shown. There were no significant differences in 
baseline values between the 79 participants who completed the study and the group of 36 
subjects who discontinued treatment. The main form of training of our participants consisted 
of endurance running for about 9 hours per week (i.e. except the regular competitions). The 
three subgroups were comparable in all variables measured except age, which was 22 years 
in the amenorrheic group, and 29 and 32 years in the oestrogen-users and eumenorrheic 
group, respectively. Also, bone alkaline phosphatase in the oestrogen-users was slightly 
lower than in the amenorrheic group, but other markers for bone metabolism were similar in 
all three groups. In all three groups the bone markers were well above the normal range for 
this age group, indicating a high bone turnover (see Table 1).  
Table 2 shows the relative change of the variables monitored after two years. It appeared 
that the BMD decreased in all three groups. At the site of the lumber spine the decrease was 
not statistically significant, but a very high rate of bone loss was found in the femoral neck. At 
this site the difference from baseline was statistically significant in all three subgroups 
(p<0.000), whereas the decrease in the amenorrheic group was substantially higher than in 
both other groups. There was a tendency for all bone markers to increase during the study 
period, although this increase reached the level of significance only for bone alkaline 
phosphatase in the oestrogen-supplemented group and for urinary calcium in the 
eumenorrheic athletes.  
We have also analysed the total cohort for the effect of vitamin K treatment. Effects of 
vitamin K treatment did not differ by menstrual status (data not shown); hence, the results of 
vitamin K treatment within each group of menstrual status were pooled. There were no 
significant differences in baseline characteristics between the vitamin K and the placebo 
group (data not shown), and we did not found an effect of vitamin K on the rate of bone loss 
(Table 3). Also in this analysis we observed a general tendency for bone markers to 
increase, with an exception for serum osteocalcin which decreased as a result of vitamin K 
treatment. 
In a subsequent multiple regression analysis we have tested the independent contribution of 
a number of variables on the observed bone loss including vitamin K supplementation to 
study also the effect of treatment after adjustment for potential confounders (Table 4). It 
turned out that the variable amenorrhea was the only significant predictor of bone loss in our 
study population. Other variables such as BMI, calcium-intake, and age at menarche showed 
to be no significant predictors of bone loss in our study.  
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Table 2 
Relative change in BMD and bone markers after two years of follow-up in three groups of 
female athletes classified according to menstrual status. 
% change Amenorrhea 
Mean ± SD (n=17) 
Eumenorrhea 
Mean ± SD (n=36) 
Oestrogen users 
Mean ± SD (n=26) 
lumbar spine BMD  -0.6 ± 4.4 -0.5 ± 2.8 -0.2 ± 2.6 
femur neck BMD   -6.5 ± 4.0#   -3.2 ± 4.1*#  -3.9 ± 3.1# 
BMI               +2.4 ± 6.0              +1.0 ± 5.2        +1.3 ± 4.1 
serum BAP            +23.2 ± 25.2            +16.0 ± 26.5 +30.8 ± 36.8# 
serum osteocalcin +3.0 ± 39.9 +7.7 ± 32.6 +5.0 ± 38.6 
urinary DPD            +27.2 ± 72.6 +8.6 ± 50.2     +17.0 ± 72.5 
urinary calcium  +40.7 ± 101.1 +52.9 ± 96.8 #     +51.5 ± 117.0 
*significant difference with group A (p<0.05) 
#significant change from baseline (p<0.05) 
Abbreviations used: body mass index (BMI), bone alkaline phosphatase (BAP), 
deoxypyridinoline (DPD) and bone mineral density (BMD). 
 
 
Table 3 
Relative change in BMD and bone markers after two years follow-up in two groups of 
female athletes classified according to vitamin K intake. 
% change Placebo Group 
Mean ± SD (n=42) 
Vitamin K Group 
Mean ± SD (n=37) 
lumbar spine BMD  -0.37 ± 3.6  -0.49 ± 2.5 
femur neck BMD    -3.5 ± 4.6#     -4.8 ± 2.8# 
BMI  +1.3 ± 6.1   +1.5 ± 3.5 
serum BAP +16.4 ± 32.8    +29.9 ± 25.5# 
serum osteocalcin +14.9 ± 39.9        -5.6 ± 27.1*# 
urinary DPD +29.6 ± 68.2      -2.0 ± 50.9* 
urinary calcium   +49.3 ± 104.1  +49.2 ± 97.8 
% amenorrheic 17% 27% 
% eumenorrheic 52% 38% 
% oestrogen-users 31% 35% 
* significant difference with placebo group (p<0.05) 
# significant change from baseline (p<0.05) 
Abbreviations used: body mass index (BMI), bone alkaline phosphatase (BAP), 
deoxypyridinoline (DPD) and bone mineral density (BMD). 
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Table 4 
Regression coefficients (95% confidence intervals) for the effect of possible predictors of 
femoral neck bone loss in the total study population. 
Independent variables ß -coefficient p-value 95% CI 
 
age (yr) -0.040 ± 0.074 0.587 -0.189 to 0.108 
BMI (kg/m2) -0.170 ± 0.261 0.517 -0.692 to 0.351 
calcium-intake (mg/day)  0.002 ± 0.001 0.891 -0.002 to 0.003 
age of start training (yr)      0.070 ± 0.08 0.501 -0.001 to 0.002 
age menarche (yr)  0.001 ± 0.003 0.406 -0.092 to 0.224 
amenorrhea (yes/no) -3.180 ± 1.300 0.010  -5.740 to -0.612 
use oral contraceptives (yes/no) -0.776 ± 1.050 0.463 -2.870 to 1.320 
vitamin K treatment (yes/no) -1.200 ± 0.889 0.182 -2.970 to 0.573 
previous stress fractures (yes/no)  0.929 ± 0.976 0.345 -1.018 to 2.880 
Abbreviations used: body mass index (BMI). The level of significance (p-value) was used 
to test which independent variables are significant predictors of femoral neck bone loss 
and to test the hypothesis that vitamin K treatment significantly influences bone loss after 
adjustments for potential confounders. 
 
DISCUSSION 
To our knowledge this is the largest prospective study in which bone loss among female elite 
athletes is monitored. A first observation is that there were no significant differences in 
baseline lumbar spine and femoral neck BMD between the three subgroups stratified for 
menstrual status. These findings are in contrast to results of previous cross-sectional studies 
in which a significantly decreased lumbar spine BMD was found in amenorrheic as compared 
to eumenorrheic athletes 7,8,11,31. Only a few studies showed also reduced BMD at the site of 
the femoral neck 32-34. A possible explanation for the discrepancy between these findings and 
our study is the significantly younger age of the amenorrheic group: the total period of high 
training intensity (and thus the period of potential bone loss) was 3.2 – 5.2 years shorter than 
in the other groups. At the observed rate of bone loss extrapolation to the ages in both other 
groups would lead to substantial lower bone mass in the amenorrheic athletes. Although we 
did not observe baseline differences, the rate of bone loss at the site of the femoral neck was 
significantly higher in the amenorrheic athletes than in the eumenorrheic athletes. The 
lumbar spine BMD remained constant in all three subgroups. Whereas there are many cross-
sectional studies in female athletes, not many follow-up studies are available for comparison 
of our findings. Taaffe 35 also found a greater decrease in femoral neck BMD (-1.2%) than 
lumbar spine BMD (-0.2%) in female runners after a follow-up period of 8 months. In a 12-
month longitudinal study of Bennel 36, small increases in BMD were found in endurance 
athletes. For a long time, it has been thought that only trabecular and not cortical bone would 
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be affected by loss of menses, because it would be more susceptible to hormonal stimuli that 
lead to demineralization. These assumptions were based on studies showing no significant 
differences in radius BMD between different groups of menstrual status. However, the radius 
is not a weight-bearing bone and in long distance runners only the weight-bearing bones are 
subjected to repeated mechanical stresses. An explanation for the difference between the 
two skeletal sites found in our study could be a relative higher pressure on the lower 
extremities rather than on the spine in runners. However, more follow-up studies in female 
athletes are needed to unravel the mechanism underlying the differential effect of physical 
activity and oestrogen on cortical and trabecular bone.  
With 3.3% per year the rate of femoral bone loss was unexpectedly high in the group of 
amenorrheic athletes, this value being about twice that found in the first years after 
menopause of non-sporting women. Remarkably, also in both the eumenorrheic athletes and 
the oestrogen-supplemented group we observed considerable bone loss, amounting 1.6 and 
2.0% per year, respectively. These rates of bone loss in amenorrheic and eumenorrheic 
athletes are higher than those found by others 35-37. Earlier studies have shown that 
especially calcium intake may influence bone changes in association with exercise 31,38. In an 
earlier study 7 it was concluded that the calcium requirement for amenorrheic women should 
approximate that described for postmenopausal women, namely 1500 mg per day. In this 
perspective, the mean intake (792 mg) of our athletes must be regarded as well below the 
recommended levels. Furthermore, our reported intakes are also below the observed 
calcium-intakes (1100 mg/day) in a large population-based study in the Netherlands among 
20921 non-athletic men and women 39. The fact that calcium intake was not a significant 
predictor of the observed bone loss, is maybe partly due to the low number of subjects in our 
study. 
It should be pointed out that in the group of oestrogen-users most athletes received 
oestrogen because they had been amenorrheic previously. Thus, although supplementation 
of amenorrheic athletes with oestrogen may decrease the rate of bone loss, additional 
treatment will have to be found in order to completely solve the problem. Several other 
studies have addressed the question whether oestrogen therapy has beneficial effects on 
bone mineral density. It was shown that the bone mineral density in female athletes 
increased after therapy, but not to levels found in normally menstruating healthy young 
women. Until now, no consensus has been reached on the potential benefits of oestrogen 
therapy for athletes 40.  
Another observation in our study is that amenorrheic athletes had started their training at 
much younger age than eumenorrheic ones. This means that girls starting endurance 
athletics at young age not only may have a longer athletics career, but that they are also at 
risk for higher bone loss than those starting at later ages. Accordingly, an early start of 
extensive endurance training at high intensity is questionable and measures to limit these 
effects should be defined. The high bone loss was consistent with the high bone turnover (a 
well-known risk factor for bone loss) at baseline. High bone turnover reflected by high bone 
formation and resorption markers has been demonstrated before in male runners 41. 
However, other studies have shown a reduced bone turnover among female athletes 42.  
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In the same cohort we have analysed also the effect of vitamin K administration. Since 
effects of vitamin K treatment did not differ by menstrual status, the results of vitamin K 
treatment within each group of menstrual status were pooled. Vitamin K treatment had no 
effect on the rate of bone loss. This seems to be in contrast with an earlier study from our 
group, in which we found a 35% decrease of bone loss in post-menopausal women during a 
3-year supplementation period (Braam et al., unpublished data). In the latter study, however, 
calcium, magnesium, zinc, and vitamin D were co-administered with vitamin K. One possible 
reason for the different outcome of both studies is, therefore, a synergistic effect of minerals, 
and vitamins D and K with a much lower effect of each of the components separately. 
Another reason for the different outcomes of both trials may be the very different 
characteristics of the respective study populations. The female athletes described in this 
study differed from postmenopausal women in that they had a low BMI and low calcium 
intake, in combination with an extreme training intensity. These factors have been identified 
as risk factors for developing early osteoporosis in female athletes 34,40. Together with their 
relatively low oestrogen production, these conditions probably all contribute to the high rate 
of bone loss observed, and – like oestrogen supplementation – also increased vitamin K 
intake may not be sufficient to overcome these negative effects. The poor effect of vitamin K 
on bone maintenance was reflected in the markers for bone turnover, which were high at 
baseline and which (except osteocalcin) had a tendency to even increase. Only osteocalcin 
decreased as a result of vitamin K treatment, but this may be related to more complete 
gammacarboxylation, resulting in an increased affinity for the hydroxyapatite matrix in bone 
rather than to decreased bone turnover. One limitation of this study is a high drop-out rate of 
our participants. As a consequence a considerable amount of follow-up data was missing 
which could potentially introduce bias. The reasons for drop-out were not related to the 
menstrual status or treatment assignment of our participants and the number of drop-outs 
was equally distributed across the subgroups and treatment groups. Furthermore, there were 
no significant differences in baseline values between the drop-outs and the subjects who 
completed the study. Therefore we expect the potential bias to have minimal effect on the 
results.  
By multiple regression analysis it was shown that the variable amenorrhea was the only 
significant predictor of bone loss in our study population. Oestrogen supplementation to 
amenorrheic athletes should be encouraged, therefore. This does not explain, however, why 
also in the eumenorrheic and oestrogen-supplemented groups considerable bone loss took 
place. In other studies it was demonstrated that besides amenorrhea, also body weight and 
age of menarche were important predictors of bone loss in athletes 33,34. Although in our 
study we have not made a direct comparison with non-sporting women, the mean age at 
menarche of the athletes was relatively high. This is consistent with comparative studies by 
others 31,32,43. Delayed puberty could be associated with a lower rate of bone mineral 
accretion during adolescence leading to a lower peak bone mass. Endurance athletes are 
known to continue their high training intensity longer than in many other sports, sometimes 
for 20 years or more. Extrapolation of our data would mean that at the end of their sport 
career a substantial part of these athletes will be osteopenic. Since it is not known whether 
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bone will quickly recover from many years of bone loss, it seems that these subjects are at 
disadvantage when entering the menopause. It is regrettable, therefore, that the mineral 
intake by athletes from all three participating countries was low. A low calcium intake has 
also been demonstrated in the USA where inadequate calcium intakes below 900 mg/day 
were found in sporting girls between 12 and 19 years 44. It seems likely that dietary 
recommendations are primarily focussed on optimal performance. Our study demonstrates 
that medical supervision, dietary recommendations and hormonal substitution should 
consider optimal skeletal development with high priority. High training intensity maintained 
over several years must be regarded as a significant risk factor for osteoporosis, and 
protocols for optimal treatment should be developed.  
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ABSTRACT 
The objective of this study was to determine associations between reported dietary intakes of 
two forms of vitamin K (phylloquinone and menaquinones) and intermediary markers of CVD 
risk in a population-based cohort of men and women. Dietary phylloquinone- and 
menaquinone-intakes were assessed by food frequency questionnaire in 1338 men and 
1603 women. All subjects were free-living participants in the Framingham Offspring Study.  
Lifestyle characteristics and lipid profiles, including total-, LDL- and HDL-cholesterol and 
triacylglycerol concentrations, were measured. Cross-sectional associations were estimated 
across increasing quintiles of reported phylloquinone and menaquinone intakes. Participants 
in the highest quintile of reported phylloquinone intake were older (P<0.001), had lower BMI 
(P=0.04), smoked less (P<0.001), and consumed more fruit, vegetables and dietary 
supplements (P<0.001) and less meat and total fat (P<0.001) compared to participants in the 
lowest quintile. Consistent with this overall heart healthy lifestyle, higher phylloquinone 
intakes were associated with lower triacylglycerol concentrations and higher HDL-cholesterol 
concentrations. Participants in the highest quintile of reported menaquinone intake were 
younger (P<0.001), had higher BMI (P<0.001), and consumed less fruit and fiber (P<0.001) 
and more meat and total fat (P<0.001), yet were associated with lower LDL-cholesterol 
concentrations (P=0.005) and higher HDL-cholesterol concentrations (P=0.03). In this study 
it was demonstrated that high phylloquinone intakes were associated with an overall heart 
healthy lifestyle, whereas high menaquinone intakes were not. However, reported dietary 
intakes of both forms of vitamin K were associated with a more favorable lipid profile.  
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INTRODUCTION 
The vitamin K-dependent step in the synthesis of vitamin K-dependent proteins is the 
posttranslational carboxylation reaction in which specific glutamate residues are converted 
into gamma-carboxyglutamate (Gla) residues 1. The Gla-residues form the calcium-binding 
groups in vitamin K-dependent proteins, and are thought to be required for functionality. 
Vitamin K-dependent carboxylase, the endoplasmic enzyme involved in the synthesis of Gla 
residues, has been identified in various organs, including liver and vessel wall 2.    
Vitamin K-dependent proteins produced by the vessel wall include protein S, growth-arrest-
specific gene 6 protein (Gas6) and matrix Gla protein (MGP). Protein S is associated with 
local inhibition of thrombosis 3, whereas Gas6 is thought to stimulate normal cell growth and 
to prevent apoptosis in growth-arrested cells 4. MGP is a potent inhibitor of calcium 
precipitation, as was demonstrated in MGP-null mice, which died by eight weeks of life from 
massive arterial calcification and rupture of the thoracic or abdominal aorta 5. Aorta 
mineralization was also observed in rats after 4 to 6 weeks of treatment with warfarin, a 
vitamin K antagonist, suggesting that vitamin K is essential for the function of MGP 6. 
Collectively these observations are suggestive of a role for vitamin K in atherosclerosis and 
cardiovascular disease (CVD).    
Two natural forms of vitamin K are found in the human diet: phylloquinone (vitamin K1), which 
occurs in leafy green vegetables and in some plant oils 7, and menaquinones (K2 vitamins), 
which occur in meats (menaquinone-4; MK-4) and fermented foods like cheese and curds 
(menaquinone-6-9; MK-6 to MK-9) 8-10. To date, only dietary phylloquinone intakes have 
been assessed in different populations 7. An inverse relationship between reported dietary 
phylloquinone intakes and risk for age-related chronic diseases, such as atherosclerotic 
calcification 11 and hip fracture risk 12,13 has been reported in population-based studies. 
These findings should be interpreted with some degree of caution because dietary 
phylloquinone may be a marker for an overall healthy lifestyle, given that it is concentrated in 
green, leafy vegetables 14,15. In contrast, it is less probable that any association between 
reported menaquinone intakes and risk for age-related chronic diseases is confounded by 
diets that reflect an overall healthy lifestyle because menaquinones are concentrated in 
animal products, such as meats and cheeses.  
In this study, we examined the associations among reported dietary phylloquinone and 
menaquinone intakes and lifestyle characteristics, including dietary patterns that are 
indicative of an overall heart healthy lifestyle, in men and women participating in the 
Framingham Offspring Study. Furthermore, we examined the associations among reported 
dietary intakes of these two forms of vitamin K and plasma lipid and lipoprotein profiles, 
which are related to CVD risk. 
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METHODS 
Subjects 
The Framingham Offspring Study is a longitudinal community-based study of cardiovascular 
disease among the children, and their spouses, of the original participants in the 
Framingham Heart Study Cohort 16. In 1971, 5135 participants were enrolled into the 
Offspring Study and have returned every 3-4 years for an extensive physical examination, 
comprehensive questionnaires, anthropometric measurements, blood chemistries and 
assessment of cardiovascular and other risk factors by trained clinical personnel 17.  Between 
1991 and 1995, there were 3799 participants in the 5th examination cycle of the Framingham 
Offspring Study. Valid food frequency questionnaire (FFQ) data were available for 3418 
participants. Of these, participants were excluded from the analysis of the current study if 
they were using medication to control blood glucose (insulin n=36; oral hypoglycemic n=90), 
or if they were taking cholesterol-lowering medication (n=214). Participants with missing 
covariate information were also removed, reducing the final sample to 2941 (1338 men and 
1603 women). The Institutional Review Board for Human Research at Boston University and 
the Human Investigation Research Committee of New England Medical Center approved the 
protocol. 
 
Dietary Assessment 
Usual dietary intakes for the previous 12 months were assessed at the 5th examination using 
a 126-item semiquantitative FFQ, as described elsewhere 18. This FFQ has been validated 
for numerous nutrients 18, including phylloquinone 13, but not for menaquinones. 
Questionnaires were mailed to the subjects prior to the exam and once completed, were 
returned to the examination site. Questionnaires with reported energy intakes below 2.51 
MJ/d and above 16.74 MJ/d (600 and 4000 kcal, respectively), or with more than 12 food 
items left blank were considered invalid and excluded from further analysis. Vitamin and 
mineral supplement use and specific type of breakfast cereal most commonly consumed 
were used in the estimate of total micronutrient intakes. Daily phylloquinone intake was 
calculated by multiplying the phylloquinone content per serving of each food 19,20 by the 
reported frequency of consumption, and summing over all foods. Phylloquinone intakes as 
reported here do not include intake from multivitamin and mineral preparations, or other 
nutrient supplements. The menaquinone intake was a compilation of MK-4 and MK-5-10 
using the menaquinone contents of different food items 8,10. All values found in the literature 
were converted to µg per 100 g of food. When multiple published values were reported for 
the same food item, the median value was used for the menaquinone content of that food. 
Daily menaquinone intakes were calculated by multiplying the menaquinone contents per 
serving of each food by the reported frequency of consumption, and summing over all foods, 
similar to that of phylloquinone. Initially, MK-4 and MK-5-10 intakes were analyzed 
separately, in addition to analysis of total menaquinone intake.  However, as the results were 
consistent across intakes of individual menaquinones, only the total menaquinone intakes 
are reported here.  
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Serum Lipids 
Fasting blood samples were drawn after an overnight fast for measuring lipid concentrations. 
Serum lipid measurements included enzymatic measurement of total cholesterol and 
triacylglycerol concentrations 21.  The HDL fraction (HDL-C) was measured after precipitation 
of LDL and VLDL with dextran sulfate magnesium 22. LDL-cholesterol concentrations (LDL-C) 
were calculated using Friedewald equation 23 for only those individuals with triacylglycerol 
concentrations less then 400 mg/dl (n=2879).  
 
Covariate Information  
Height and weight were measured with the subject standing. Body mass index (BMI) was 
calculated as the weight in kilograms divided by the square of the height in meters (kg/m2). 
Subjects were classified as hypertensive if both of the two measurements for diastolic blood 
pressure and systolic blood pressure was > 90 mm Hg or > 140 mm Hg, respectively, or if 
use of antihypertensive medications was reported (Joint National Committee on Detection) 
24. Current smokers were defined as those who reported smoking at least one cigarette per 
day during the previous year. Physical activity was assessed as a weighted sum of the 
proportion of a typical day spent sleeping and performing sedentary, slight, moderate, or 
heavy physical activities 25. Estrogen replacement therapy among postmenopausal women 
was classified as current or no use at the time of the physical examination.  Alcohol 
consumption was estimated in grams per day from the FFQ.  Multivitamin use was classified 
as current or no use at the time of the physical examination. 
 
Statistical Analysis 
SAS statistical software (release 8.0, SAS institute, Cary NC) was used for all statistical 
analysis. Dependent variables were total-C, LDL-C, the ratio of LDL-C to HDL-C and the 
natural logarithms of HDL-C, triacylglycerol concentrations and the ratio of total-C to HDL-C. 
To express transformed variables to their natural scale, geometric means were computed by 
exponentiation of adjusted least squares means. There were no systematic interactions by 
sex between vitamin K (phylloquinone and menaquinone) intakes and lipid concentrations.  
All analyses between the lipid concentrations and phylloquinone or menaquinone intake were 
adjusted for the following variables: sex, age (years), body mass index (BMI), energy intake 
(kcal/d), multivitamin supplementation use (Y/N), alcohol intake (g/d), blood pressure 
medication (Y/N), current cigarette smoking (Y/N), physical activity score (continuous), 
current estrogen replacement therapy among women (Y/N) and saturated fatty acid (SFA) 
intake (percentage of total energy intake, continuous). Dietary fiber intake was adjusted for 
associations with phylloquinone intakes because the predominant sources of phylloquinone 
are green leafy vegetables, which are fiber-rich foods.  Statistical significance of trends 
across quintiles of phylloquinone or menaquinones intake was assessed with linear 
regression models (for continuous outcome variables) or Mantel-Haenszel test of trend (for 
categorical variables). Associations were considered to be statistically significant at P<0.05. 
All P-values were 2-sided. The data were presented as means ± SD, unless stated 
otherwise. 
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RESULTS 
The mean ± SD reported daily intakes of phylloquinone and total menaquinones were 162 ± 
114 µg and 16 ± 11 µg, respectively. Of the menaquinones, there was a mean ± SD intake of 
7.5 ± 3.8 µg/d of MK-4, and 7.3 ± 9.5 µg/d of MK-5-10. There were no significant differences 
in reported phylloquinone or menaquinone intakes between men and women after 
adjustment for energy intake. Consistent with other studies using this FFQ 12,13 reported 
phylloquinone intakes were higher than the current adequate intake of 90-120 µg/d of 
phylloquinone (Institute of Medicine) 26. The food items on the FFQ that contributed the most 
to phylloquinone were broccoli (17%), iceberg lettuce (17%), spinach (14%), romaine lettuce 
(7%), and cabbage/coleslaw (5%). The highest contributors to the total dietary MK-4 were 
chicken (38.1%), red meat (26.5%) and eggs (11.5%); for the higher menaquinones, dietary 
intake was almost exclusively derived from cheese (97.2% of total MK-5-10 intake).   
The age, sex and energy-adjusted descriptive characteristics of the study population across 
quintiles of phylloquinone- and menaquinone-intake are shown in Tables 1 and 2, 
respectively. When compared to the lowest quintile of intake (median: 63 µg/d), participants 
in the highest quintile of phylloquinone intake (median: 282 µg/d) were older and had lifestyle 
characteristics and dietary patterns consistent with an overall heart healthy lifestyle, such as 
lower BMI, less smoking, greater estrogen use among women, higher intakes of fruit, 
vegetable, fish, folate, vitamin E and dietary fiber and lower intakes of meat. In contrast, 
participants in the highest quintile of menaquinone intake (median: 28 µg/d) were younger, 
had a higher BMI, a lower intake of carbohydrate, dietary fiber, folate and fruit, and a higher 
intake of monounsaturated and saturated fatty acids, cholesterol and animal products when 
compared to those in the lowest quintile of menaquinone intake (median: 7 µg/d). There was 
no significant association between reported phylloquinone and menaquinone intakes in this 
study group. These contrasting dietary and lifestyle patterns between high phylloquinone and 
high menaquinone intakes are not unexpected given the unique dietary sources of each form 
of vitamin K. 
The lipid concentrations compared across quintiles of reported phylloquinone intake are 
shown in Table 3. When compared from the lowest to the highest quintile of phylloquinone 
intake, HDL-C was significantly higher (P=0.003), triacylglycerol was significantly lower 
(P<0.001), and the ratios of LDL-C to HDL-C and total cholesterol to HDL-C were 
significantly lower (more favorable).  No trends were observed for LDL-C or total cholesterol 
concentrations. The lipid concentrations compared across quintiles of reported menaquinone 
intakes are shown in Table 4. When compared from the lowest to the highest quintile of 
reported menaquinone intake, HDL-C was significantly higher (P=0.031), whereas LDL-C, 
the ratio of LDL-C to HDL-C and total cholesterol to HDL-C were all significantly lower 
(P<0.01).  There was a non-significant trend across quintiles of menaquinone intake for total 
cholesterol, but not for triacylglycerol concentrations. 
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Table 1 
Characteristics of Framingham Offspring participants (n=2941; 1,338 men and 1,603 
women) by quintiles (Q1-Q5) of phylloquinone intake in examination 5 (1991-1995)1. 
Phylloquinone intake Q1 Q2 Q3 Q4 Q5 P for trend2 
µg/d 63 103 139 185 282  
N 588 588 589 588 588  
Age (years) 52.5 54.1 53.7 54.9 55.1 <0.0001 
BMI (kg/m2) 27.1 26.9 27.0 26.8 26.5 0.04 
Current smoker (%) 27.9 21.8 16.6 14.3 16.2 <0.0001 
Estrogen use3 (%) 6.3 6.1 7.5 12.1 13.8 <0.0001 
Multivitamin user (%) 24.7 23.1 29.4 35.0 35.5 <0.0001 
Hypertension (%) 18.2 19.6 20.0 17.9 18.9 0.94 
PA score  34.8 34.5 34.9 35.2 35.2 0.10 
Carbohydrate (% of E) 47.4 47.1 47.6 47.6 49.1 <0.0001 
Protein (% of E) 15.6 16.4 16.9 17.4 17.9 <0.0001 
Total fat (% of E): 28.4 28.6 27.8 27.1 25.4 <0.001 
     SFA  11.6 11.1 10.7 10.3 9.3 <0.0001 
     MUFA  11.8 11.8 11.4 11.0 10.2 <0.0001 
     PUFA  5.0 5.7 5.7 5.8 5.9 <0.0001 
Cholesterol (mg/day) 204 207 211 210 202 0.47 
Dietary fiber (g/day) 12.8 15.3 17.6 18.9 22.4 <0.0001 
Alcohol (g/day) 4.5 4.9 5.2 5.8 6.1 <0.0001 
Vitamin E (mg/d) 4.5 5.5 5.9 6.2 7.0 <0.0001 
Vitamin E, incl. supplements (mg/d) 46.2 44.2 44.4 54.3 63.9 0.01 
Folate (mg/d) 217 258 285 306 366 <0.0001 
Fruit (servings/wk) 5.8 6.9 8.6 9.6 12.7 <0.0001 
Vegetables (servings/wk) 8.1 12.1 16.0 20.5 32.9 <0.0001 
Meat (servings/wk) 6.2 6.1 5.7 5.1 4.0 <0.0001 
Fish (servings/wk) 1.6 1.9 2.2 2.5 3.1 <0.0001 
1 All analyses were adjusted for sex, age and total energy 
2 P for linear trend  
3 Estrogen use among postmenopausal women  
Abbreviations used: body mass index (BMI), physical activity (PA), total energy (E), 
saturated fat (SFA), monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids 
(PUFA). 
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Table 2 
Characteristics of Framingham Offspring participants (n=2941; 1,338 men and 1,603 
women) by quintiles (Q1-Q5) of total menaquinone intake1 in examination 5 (1991-1995)2. 
Menaquinone intake Q1 Q2 Q3 Q4 Q5 P for trend3 
mg/d 7 10 15 19 28  
N 588 588 589 588 588  
Age (years) 55.7 54.3 53.8 53.6 52.8 <0.0001 
BMI (kg/m2) 26.3 26.4 27.1 27.0 27.6 <0.0001 
Current smoker (%) 20.8 17.2 19.9 19.7 19.2 0.94 
Estrogen use4 (%) 11.6 9.0 8.2 8.7 8.3 0.11 
Multivitamin user (%) 26.9 34.4 27.0 28.2 31.3 0.55 
Hypertension (%) 22.8 16.7 20.5 16.8 17.7 0.08 
PA score  35.1 35.0 34.9 35.1 34.6 0.23 
Carbohydrate (% of E) 53.1 49.8 47.4 45.8 42.6 <0.0001 
Protein (% of E) 15.0 16.4 16.8 17.4 18.5 <0.0001 
Total Fat (% of E): 23.8 26.2 27.5 29.0 31.1 <0.0001 
SFA  8.5 10.0 10.6 11.4 12.8 <0.0001 
MUFA  9.9 10.8 11.3 11.8 12.5 <0.0001 
PUFA  5.4 5.4 5.6 5.8 5.8 <0.0001 
Cholesterol (mg/day) 149 195 213 237 259 <.0001 
Dietary fiber (g/day) 17.5 17.8 17.1 16.9 16.0 <.0001 
Alcohol (g/day) 4.9 4.8 5.9 5.4 5.2 0.40 
Vitamin E (mg/d) 5.6 5.7 5.8 5.9 5.8 0.14 
Vitamin E incl.supplements (mg/d) 48.7 54.0 51.3 42.8 55.5 0.75 
Folate (ug/d) 279 292 284 283 269 0.009 
Fruit (servings/wk) 9.7 9.3 8.5 8.5 7.5 <.0001 
Vegetables (servings/wk) 17.7 17.8 17.8 17.3 18.0 0.85 
Meat (servings/wk) 4.2 4.8 5.2 6.0 7 <.0001 
Fish (servings/wk) 2.2 2.2 2.3 2.3 2.3 0.48 
Phylloquinone (mg/d) 165 160 162 154 159 0.43 
1    Total menaquinone intake is the sum of MK-4 and MK-5-10 intakes 
2   All analyses were adjusted for sex, age and total energy 
3    P for linear trend 
4   Estrogen use among postmenopausal women  
Abbreviations used: body mass index (BMI), physical activity (PA), total energy (E), 
saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) and polyunsaturated 
fatty acids (PUFA). 
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Table 3 
Lipid concentrations of Framingham Offspring participants (n=2941; 1,338 men and 1,603 
women) by quintiles of phylloquinone intake in examination 5 (1991-1995)1. 
Phylloquinone intake Q1 Q2 Q3 Q4 Q5 P for trend2 
mg/d 63 103 139 185 282  
N3 588 588 589 588 588  
HDL-C (mmol/l) 1.22 1.22 1.24 1.24 1.27 0.003 
Triacylglycerol (mmol/l) 1.73 1.60 1.58 1.56 1.50 <.0001 
Total cholesterol (mmol/l) 5.25 5.22 5.28 5.20 5.20 0.33 
LDL-C (mmol/l) 3.13 3.13 3.15 3.08 3.10 0.49 
LDL : HDL-C  2.7 2.7 2.7 2.6 2.6 0.04 
Total : HDL-C 4.3 4.3 4.2 4.1 4.1 <.0001 
1 All analyses were adjusted for sex, age, total energy, saturated fat (% of total energy), 
BMI, physical activity, alcohol intake (g/d), smoking, estrogen use, treatment for blood 
pressure and multivitamin use 
2 P for linear trend 
3 There were 576 participants per quintile for LDL-C and the ratio of LDL to HDL-C. 
 
Table 4 
Lipid concentrations of Framingham Offspring participants (n=2941; 1,338 men and 1,603 
women) by quintiles of total menaquinone intake1 in examination 5 (1991-1995)2. 
Menaquinone intake Q1 Q2 Q3 Q4 Q5 P for trend3 
mg/d 7 10 15 19 28  
N4 588 588 589 588 588  
HDL-C (mmol/l) 1.22 1.20 1.25 1.25 1.25 0.03 
Triacylglycerol (mmol/l) 1.62 1.61 1.57 1.56 1.59 0.47 
Total cholesterol (mmol/l) 5.29 5.22 5.21 5.21 5.19 0.15 
LDL-C (mmol/l) 3.20 3.17 3.09 3.09 3.05 0.005 
LDL : HDL-C  2.8 2.8 2.6 2.6 2.6 0.005 
Total : HDL-C 4.3 4.3 4.1 4.1 4.1 0.009 
1 Total menaquinone intake is the sum of MK-4 and MK-5-10 intakes 
2 All analyses were adjusted for sex, age, total energy, saturated fat (% of total energy), 
BMI, physical activity, alcohol intake (g/d), smoking, estrogen use, treatment for blood 
pressure and multivitamin use 
3 P for linear trend 
4 There were 576 participants per quintile for LDL-C and the ratio of LDL to HDL-C. 
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DISCUSSION 
In the present study, we examined associations among reported dietary intakes of vitamin K, 
lifestyle characteristics and serum lipid concentrations in a population-based cohort. Of the 
two forms of vitamin K analyzed, participants with a reported high phylloquinone intake 
appeared to have characteristics and dietary patterns consistent with an overall heart healthy 
lifestyle. The mean reported phylloquinone intake of 162 µg/d is similar to those reported in 
the Framingham Study original cohort (mean age: 72 y) 12 and the Nurses’ Health Study 13 
using the same FFQ.  While this FFQ overestimates phylloquinone intakes when compared 
to diet records 13, it is suitable for the purpose of ranking individuals according to reported 
intake. Green, leafy vegetables were the predominant sources of phylloquinone, which is 
consistent with other studies 12,13.  Furthermore, higher reported phylloquinone intakes were 
associated with a lipoprotein profile indicative of decreased risk of developing cardiovascular 
disease (higher HDL-C, lower LDL-C, and lower ratio of total cholesterol to HDL-C). 
Participants with a higher phylloquinone intake tended to smoke less, have a higher intake of 
fruits, vegetables and fish, had lower meat intakes, and were more likely to take multivitamin 
supplements.  There was also more estrogen use among the post-menopausal women with 
higher phylloquinone intakes. Most of these characteristics have also been associated with 
reduced CVD risk 27-36.  The strong overlap among chronic disease risk factors complicates 
the interpretation of studies with inverse associations between reported dietary phylloquinone 
intakes and chronic disease risk.  However, phylloquinone intakes may be a suitable 
surrogate marker of a heart healthy lifestyle in a population-based cohort where more 
detailed data are impractical to collect or are unavailable. 
In contrast to phylloquinone, reported dietary menaquinone intakes were associated with an 
overall less heart healthy lifestyle pattern, including higher BMI, higher intakes of total fat, 
SFA, cholesterol and meat, and lower intakes of dietary fruit and fiber. There were no 
significant associations between menaquinone intakes and multivitamin or vitamin E 
supplement use. This was an expected finding given that dietary menaquinones are primarily 
found in meats and cheeses in the U.S. diet, but may not be a global phenomenon because 
there are populations with a high consumption of fermented foods such as natto in Japan 37.   
There are several major caveats in the interpretation of the reported menaquinone intakes in 
the current study.  In the absence of menaquinone food composition data for the U.S. food 
supply, we used data from Europe 10 and Asia 8. The current food composition data for 
menaquinones are very limited, and geographical variation in content has not yet been 
examined. Secondly, the low endogenous concentrations of menaquinones in circulation 
preclude validation of this FFQ with a biological marker. Finally, there is a tendency to 
underreport meats and dairy products using this FFQ, especially among men 38. However, 
this underreporting may attenuate our ability to detect associations between reported dietary 
menaquinone intakes and lifestyle patterns. It is plausible that use of additional food 
composition data and other methods of dietary assessment may result in a stronger 
association than reported here. 
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Dietary phylloquinone intakes were inversely associated with triacylglycerol concentrations in 
the current study.  Unfortunately, the absence of plasma phylloquinone concentrations in the 
current study precludes comparison with those that have a reported positive association 
between plasma phylloquinone and triacylglycerol concentrations 39,40. Although plasma 
phylloquinone concentrations are associated with recent dietary intakes 7, few data exist on 
the vitamin K diet-plasma association relative to lipid and lipoprotein concentrations in a 
population-based cohort.   Surprisingly, reported menaquinone intakes in the current study 
were also associated with more favorable lipid concentrations, despite an overall less heart 
healthy lifestyle.  Pharmacologic doses of menaquinone-4 have been reported to lower total 
cholesterol concentrations in patients on peritoneal dialysis 41. While suggestive, these 
effects were associated with menaquinones doses that were approximately 2,000 times 
greater that the dietary intakes reported in the current study. Until a common biological 
mechanism is identified to explain these associations, the existing data are difficult to 
interpret. In conclusion, reported dietary phylloquinone intakes are positively associated with 
heart healthy lifestyle characteristics in a population-based cohort.  Assessment of 
phylloquinone intakes may have potential as a marker for CVD risk on a population-wide 
basis. 
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ABSTRACT 
Many cross-sectional studies have shown in healthy subjects that the elastic properties of 
major arteries decrease with increasing age, but prospective studies on this have been rare. 
In the present paper we describe the effects of ageing on vascular characteristics of the 
common carotid artery in a group of 60 postmenopausal women who were followed for three 
years. At baseline and after three years, compliance, distensibility, and intima-media 
thickness were measured with an ultrasound technique, and the changes in these variables 
over three years were evaluated. It was shown that the distensibility coefficient and 
compliance coefficient decreased with 10% (mean decrease: 1.8 Mpa-1, 95% CI: 0.73 to 2.9) 
and 6% (mean decrease: 0.05 mm2/kPa, 95% CI: 0.02-0.09), respectively, and the intima-
media thickness (IMT) increased with 9% (mean increase: 0.05 mm, 95% CI: 0.02 to 0.07). 
In postmenopausal women ageing causes a decrease in the elastic properties and an 
increase in the wall thickness of the common carotid artery. These results are in line with 
previously reported cross-sectional studies. 
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INTRODUCTION 
Changes in the elastic properties of the main arteries have major implications for the 
development of vascular disease. Arteries, especially the larger elastic arteries such as the 
common carotid artery, become stiffer during ageing 1.  Arterial stiffness was shown to be 
associated with cardiovascular disease and this association is corroborated by an increased 
pulse pressure following increased arterial stiffness and arteriosclerosis 2. In cross-sectional 
studies it has been shown that the distensibility and compliance of the elastic common 
carotid artery decreased linearly with age, but that the reduction in compliance is less 
pronounced than the reduction in distensibility 3,4. 
Women tend to catch up with men after menopause with respect to the risk of cardiovascular 
disease 5. The disappearance of the risk difference between men and women has been 
attributed to the decrease of female sex hormones, notably estrogen, after menopause 6-8. 
Therefore, also postmenopausal women are regarded nowadays as a high-risk group for 
developing cardiovascular disease. The decrease in arterial stiffness with increasing age is 
suggested to be more marked in women between 45 and 60 years than in men of the same 
age, and changes in vessel wall properties may probably be detected faster in these women 
4.  
An increasing amount of research is focused on the evaluation of arterial properties, 
facilitated by the recent availability of accurate non-invasive methods to measure arterial 
stiffness 9,10. However, until now there has been no extensive prospective study to 
investigate the effect of ageing on compliance and distensibility. It was the aim of the present 
investigation to monitor changes of the distensibility coefficient (DC) and the compliance 
coefficient (CC) in a group of healthy postmenopausal women, during a 3-year study period. 
With the same technique, also the intima-media thickness (IMT) of the artery wall can be 
measured 11. IMT is assumed to represent the endothelial adaptive response to physiological 
and pathophysiological processes 12-14 and IMT has been used as an indicator of 
arteriosclerosis in various studies 15,16. Several population-based studies have investigated 
changes in IMT over time 17, however this has never been investigated in coherence with DC 
and CC.  The Young’s Modulus (E) expresses the elasticity of tissue independent of its 
volume 18. The present study also included the effects of ageing on changes in IMT and E.   
 
 
METHODS 
Subjects 
The study was performed in 60 healthy female volunteers between 50 and 60 years who 
were at least 2 years postmenopausal. Information on cardiovascular risk factors, current 
health status, medical history, drug use and smoking behavior was obtained before the start 
of the study. No history of important systemic disease was reported and none of the 
volunteers were using or had recently used hormonal replacement therapy. Baseline 
measurements were performed between November 1997 and March 1998, whereas the 
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follow-up examination took place between December 2000 and March 2001. All participants 
gave written informed consent and the trial was approved by the University Hospital Medical 
Ethics Committee.  
 
Study Design  
The participants were enrolled in a 3-year double-blind placebo-controlled clinical trial in 
which the effects of certain supplements were investigated on bone mineral density and 
vessel wall characteristics. The participants were selected based on strict in- and exclusion 
criteria, which were defined for the specific purposes of this clinical trial. Because participants 
were enrolled in a three-year controlled study, they were monitored frequently and therefore 
regular check-ups on health status and medication use took place. The vascular examination 
took place at baseline and at the end of the study after 3 years. Here we report the change of 
vessel wall characteristics in the placebo group of the study, thus elucidating the effects of 
ageing on the vessel wall characteristics.  
 
Measurements 
The ultrasonic vessel wall tracking system (WTS) to determine arterial wall properties has 
been described in detail before 9,19. This ultrasound system provides estimates of the arterial 
end-diastolic adventitia-adventitia diameter (d) and the change in diameter from diastole to 
systole (Dd) normalized for the end-diastolic diameter (Dd/d) for each captured heartbeat. 
Simultaneously with measuring diameter changes, arterial blood pressure measurements 
were obtained at the level of the brachial artery by means of a semiautomated oscillometric 
device (DINAMAP). Pulse pressure (PP), defined as systolic minus diastolic blood pressure, 
was determined by averaging the three measurements nearest to the distension 
measurements. From d, Dd and Dp (PP), vessel wall properties were calculated according to 
the following equations: 
 
DC= (2dDd + Dd2)/(d2Dp) 
CC= p(2dDd  + Dd2)/4Dp 
 
The intima-media thickness was measured simultaneously at the same location (2-3 cm 
proximal to the bifurcation) where the end-diastolic diameter and diameter changes were 
measured. Only the IMT of the posterior wall was assessed, because here the reflections 
from the blood-intima and media-adventitia transition are distinctly visible, whereas, at the 
anterior wall, the trailing edge of the adventitia reflections may obscure the media and intima 
signal. At the end of the session, recorded IMT-files were processed employing the wall 
thickness program. The threshold for the derivative was maintained at 0.025 11. Each heart 
beat within a recording resulted in an estimate of wall thickness; the median of the estimates 
per recording was used for further evaluation. The end-diastolic diameter, DC and IMT were 
also used to calculate the ratio of the end-diastolic diameter to IMT (D/IMT) and E 
((D/IMT)/DC). 
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To save time we have investigated only the right common carotid artery. To our knowledge 
no different ageing effects have been reported in the wall properties of the right and the left 
common carotid artery. The same investigator performed all examinations at the start and 
the end of the study and for each participant several repeated measurements (5-7) were 
made during one session. Reproducibility was evaluated for the assessed common carotid 
artery distension and diameter. Before the vascular examination, height and weight were 
measured with standardized equipment to estimate the body mass index (weight/height2). 
 
Statistical Analysis 
Statistical analysis was performed using the Statistical Package SPSS (SPSS Corp, 
Chicago, IL). For every participant, the percentage change from baseline in all parameters 
was calculated and results were presented as means ± standard deviation (SD), unless 
indicated otherwise. Only participants who had completed the study were included in the 
analysis. Furthermore, participants who during the study had started to use medication, 
known to have a direct effect on the vessel wall, were excluded from analysis.  Also, 
participants with atherosclerotic plaques in the common carotid artery and a high variability in 
their results (arterial translation of > 2 mm and beat-to-beat variation in distension of > 20%) 
were excluded. A paired t-test was used to evaluate the change in the vessel wall 
characteristics over the three years within the group. We considered a level of p<0.05 to be 
statistically significant.  
 
Table 1 
Baseline characteristics study population (mean ± SD).  
Baseline-characteristics         Mean ± SD (n=40) 
Age (yr)  54.1 ± 2.97 
Weight (kg) 69.5 ± 11.9 
Height (m) 1.65 ± 0.05 
BMI (kg/m2) 25.6 ± 4.27 
Years postmenopausal 4.6 ± 3.7 
% non-smokers 97.5% 
Abbreviations used: body mass index (BMI) 
 
 
RESULTS 
Subjects 
Baseline characteristics of the participants are presented in Table 1. From the 60 control 
subjects who entered the study, 4 subjects discontinued their participation and were not 
available for the follow-up measurement. Of the 56 subjects who completed the study, we 
excluded 16 subjects from the analysis: 2 subjects started to use medication, known to have 
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direct effects on the vessel wall, in 3 subjects we found atherosclerotic plaques in the 
common carotid artery and 11 subjects had arterial translations of more than 2 mm or beat-
to-beat variations in distension of more than 20%. Analysis was performed on 40 participants 
who completed the study and who did not have any of the above mentioned interfering 
factors. 
 
 
Table 2 
Change in vessel wall characteristics (mean ± SD) in study population after 3 years. 
N=40 T= 0 T= 3 yr Difference 
(T=3)-(T=0) 
(paired t-test) 
Diameter (mm)       7162 ± 562       7358 ± 594   196  (p<0.001) 
Distension (mm) 372 ± 118         351 ± 107    -21  (p<0.05) 
Pulse Pressure (mmHg)        51.9 ± 11        54.6 ± 13    2.7  (p=0.093) 
Distensibility  (MPa-1) 15.8 ± 5.24        14.0 ± 4.8   -1.8  (p<0.01) 
Compliance (mm2/kPa) 0.64 ± 0.23 0.59 ± 0.19 -0.05  (p<0.01) 
Intima-media thickness (mm) 0.62 ± 0.11 0.67 ± 0.10  0.05  (p<0.001) 
Heart rate (beats/min)        60.8 ± 9.2 63.9 ± 10.1  3.04  (p<0.01) 
Diameter / IMT        11.7 ± 1.9        11.1 ± 1.6   -0.6  (p<0.05) 
E (kPa)         811 ± 296         885 ± 333   +74  (p=0.115) 
    
 
 
 
Follow-up results 
Figures 1 and 2 represent scatter plots of the individual values of DC and CC at baseline and 
after three years. These figures allow comparison of the individual changes of the 
participants. Table 2 summarizes the mean values and paired-levels of significance of all 
vascular parameters at the start and the end of the study. As compared to baseline, the DC 
had decreased by 10% (mean decrease: 1.8 Mpa-1, 95% CI: 0.73 to 2.9, p<0.01) and the CC 
by 6% (mean decrease: 0.05 mm2/kPa, 95% CI: 0.02-0.09, p<0.01). On the other hand, the 
arterial diameter had increased by 2% (mean increase: 196 mm, 95% CI: 102 to 291, 
p<0.001) and also the heart rate (beats/minute) had increased with 5% (mean increase: 3.0, 
95% CI: 0.8 to 5.3, p<0.01). The pulse pressure increased by 5%, but this increase was not 
significant (mean increase: 2.7 mmHg, 95% CI: -0.48 to 5.9, p<0.10). Figure 3 shows the 
individual values of IMT at baseline and after three years of follow-up in the participants. The 
intima-media thickness (IMT) had increased by 9% relative to baseline (mean increase: 0.05 
mm, 95% CI: 0.02 to 0.07, p<0.001), the D/IMT ratio decreased by 3.8% (mean decrease: 
0.56, 95% CI: 0.06 to 1.06) and the E also increased by 13% relative to baseline (mean 
increase: 74 kPa, 95% CI: -19 to 167).   
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Figure 1 
Scatter plot of individual values of distensibility 
coefficient at baseline (DC1 at x-axis) and after three 
years (DC2 at y-axis) in a group of healthy 
postmenopausal women (n=40).  
 
Figure 2 
Scatter plot of individual values of compliance 
coefficient at baseline (CC1 at x-axis) and after 
three years (CC2 at y-axis) in a group of 
healthy postmenopausal women (n=40).  
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Figure 3 
Scatter plot of individual values of intima-media 
thickness at baseline (IMT1 at x-axis) and after three 
years (IMT2 at y-axis) in a group of healthy 
postmenopausal women (n=40).  
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DISCUSSION 
In this prospective study on effects of ageing on vascular characteristics in healthy 
volunteers, we observed a significant decrease in the distensibility and compliance of the 
common carotid artery after a 3-year follow-up period in postmenopausal women. The 
decrease in compliance was smaller than the decrease in distensibility. In parallel with the 
decrease in DC and CC we observed a significant increase in the arterial diameter and the 
intima-media thickness; the increase in E did not reach the level of significance. The less 
pronounced decrease in compliance can be explained by the concomitant increase in arterial 
diameter of the common carotid artery. Our results show that ageing causes a decrease in 
the elastic properties and an increase in the wall thickness of the common carotid artery (and 
possibly in other arteries as well), which may result in an increased risk of development of 
vascular diseases. 
Although several cross-sectional studies have already shown the effects of ageing on the 
elastic properties of major arteries and a few prospective studies have shown the effects of 
ageing on IMT, to our knowledge no prospective studies have been reported showing the 
concomitant effects of ageing on DC, CC and IMT in the same group of healthy subjects. In a 
cross-sectional study by Reneman et al. 3 it was found that in healthy subjects between 50 
and 60 years the DC decreased with 2.2% / year, which is slightly lower than our findings (-
3.3% / year) and the CC was reported to decrease with 1.3% / year, which is also slightly 
lower than the 2% / year decrease found in our study. In a comparable study 4 in which the 
pressure strain elastic modulus (Ep) was used as an inverse estimate of distensibility, the 
distensibility decreased with 2.7% / year in women between their 45th and 60th year of age. 
The figures from these cross-sectional studies are fairly consistent with the data obtained 
using the follow-up design in our trial. In a recent longitudinal study 20, Barenbrock et al. 
evaluated the vessel wall properties in a group of 24 normotensive and 24 hypertensive renal 
transplant patients. Within two years the DC decreased by 6.3% (3.2 % / year). Although the 
results from the latter study are similar with our data, it must be kept in mind that the renal 
transplant patients form a specific and inhomogeneous population, which is not comparable 
with our study population. In the mentioned cross-sectional studies, linear extrapolation is 
used to estimate changes in the vessel wall properties over years while in longitudinal 
studies changes are detected in the same group of subjects. To find out if there might be a 
faster non-linear decrease in DC and CC in women in the early postmenopausal period, as is 
suggested by the study of Hansen 4, a longitudinal study with more subjects and longer 
duration is needed. Changes in IMT over time have been investigated in a few prospective 
studies; a two-year follow-up study in 100 Finnish men 12 showed a mean increase of 0.03 
mm / year in subjects without atherosclerotic lesions, which is comparable to the increase in 
IMT in our study. Furthermore, our results are also in line with the results of the highest age-
group (56-60 years) in a 6-year follow-up study of 472 men and women showing a mean 
increase in IMT of 0.03 mm / year 21.  Our results on E are comparable with the results of an 
earlier study 10, but differ from that of a recent cross-sectional study 22 in which a 20% lower 
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E was found, mainly due to a higher IMT and distension. This discrepancy might be 
explained by differences in recording techniques.   
Reliable assessment of distensibility and compliance requires the determination of pulse 
pressure at the site of the measurement of the end-diastolic diameter and distension. The 
brachial pulse pressure tends to deviate from the pulse pressure in the common carotid 
artery 23. One should realize, however, that errors due to differences in location of blood 
pressure measurement and artery wall property assessment will be methodological in nature 
and of the same order of magnitude at the various moments of determination, because intra-
subject variation was determined in time. Therefore, the absolute error made in the 
determination of pulse pressure has not significantly influenced the outcome of our study.   
In summary, in this study we have found that during three years in healthy postmenopausal  
women the elastic properties of the common carotid artery significantly decreased, whereas  
the intima-media thickness significantly increased.  
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ABSTRACT 
Matrix-Gla Protein (MGP) is a strong inhibitor of vascular calcification, the expression of 
which is vitamin D dependent. MGP contains five g-carboxyglutamic acid (Gla)-residues 
which are formed in a vitamin K-dependent carboxylation step and which are essential for its 
function. Hence vascular vitamin K-deficiency will result in undercarboxylated, inactive MGP 
which is a potential risk factor for calcification. In the present study we describe the effects of 
vitamin K1 and D supplementation on vascular properties in postmenopausal women. In a 
randomized placebo-controlled intervention study 181 postmenopausal women were given 
either a placebo or a supplement containing minerals and vitamin D (MD-group), or the same 
supplement with vitamin K1 (MDK-group). At baseline and after three years, vessel wall 
characteristics including compliance coefficient (CC), distensibility coefficient (DC), intima-
media thickness (IMT) and the Young’s Modulus (E) were measured to assess the effect of 
the supplements on the change of these parameters. The results showed that the elastic 
properties of the common carotid artery in the MDK-group remained unchanged over the 
three-year period, but decreased in the MD- and placebo-group. Comparing the MDK- and 
placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC 
(8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01). There were no 
significant differences between the MD-group and placebo. No significant differences were 
observed in the change of IMT between the three groups. It is concluded that a supplement 
containing vitamin K1 and D has a beneficial effect on the elastic properties of the arterial 
vessel wall.  
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INTRODUCTION 
Vitamin K is a cofactor in the post-translational carboxylation of selective protein-bound 
glutamate residues which are converted into gamma-carboxy glutamate (Gla) 1. Presently 
only a dozen mammalian Gla-containing proteins (shortly: Gla-proteins) have been identified. 
Vitamin K deficiency results in the synthesis of under-carboxylated, biologically inactive Gla-
proteins. Examples of Gla-proteins are several blood coagulation factors (all synthesized in 
the liver), osteocalcin (synthesised in bone) and matrix Gla-protein (MGP), which is 
synthesized in a number of non-hepatic tissues, notably cartilage and the arterial vessel wall. 
Today MGP is regarded as a major inhibitor of soft tissue calcification 2. 
Vascular calcification is an important factor that contributes to considerable morbidity and 
mortality, notably in diabetics and in hemodialysis and atherosclerotic patients 3. Calcification 
may occur either in the tunica intima in association with atherosclerosis or in the tunica 
media where it is known as Mönckeberg’s sclerosis 4. Medial vascular smooth muscle cells 
(VSMCs) synthesize most of the MGP in the vessel wall 5. It was found that the overall 
arterial expression of MGP was decreased in Mönckeberg’s sclerosis suggesting that low 
levels of MGP may predispose to calcification 6. However, in VSMCs adjacent to the calcium 
salt deposits, MGP mRNA expression was substantially elevated which may represent a 
response to the locally increased calcium concentration in order to enhance calcium 
clearance 5. Using monoclonal antibodies against MGP, Schurgers et al 7 demonstrated that 
MGP also accumulates around the calcified areas. 
Although the precise sequence of events in the association between MGP-expression and 
calcification still needs to be elucidated, a number of animal studies have established 
unequivocally that MGP is a potent inhibitor of calcification. The vascular phenotype of the 
transgenic MGP null mouse showed massive calcification of the large arteries within 4 weeks 
after birth 8. The fact that comparable results were obtained in normal rats after treatment 
with the vitamin K-antagonist warfarin demonstrated that Gla-residues are essential to the 
calcification inhibitor function of MGP 2.  
Whereas vitamin K is involved in the posttranslational processing of MGP, vitamin D has a 
role in the regulation of MGP gene expression. Fraser et al have shown that the MGP 
promotor contains a vitamin D response element that is responsible for a 2-3 fold 
enhancement of MGP expression after vitamin D binding 9. To our knowledge, a direct 
association between vitamin D deficiency and arterial media calcification has not yet been 
demonstrated, however. With respect to vitamin K, it was shown in postmenopausal women 
that low vitamin K1 intake is a risk factor for aortic calcification 10. In an independent 
population-based study among 4500 elderly subjects an inverse correlation was 
demonstrated between vitamin K2 intake and aortic calcification, myocardial infarction and 
sudden cardiovascular death 11. Based on these findings, it is suggested that in a substantial 
part of the population the vitamin K status of the arterial vessel wall is inadequate to support 
full MGP carboxylation 7. We wish to put forward the hypothesis that local vitamin K 
deficiency forms a risk factor for vascular hardening, increasing stiffness, and loss of elastic 
properties.  
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The present study forms part of a large intervention trial, in which we investigated the effects 
of minerals (calcium, magnesium, and zinc) and vitamins D and K on bone mineral density 
and vascular properties. Here we report the effects of minerals + vitamin D, and minerals + 
vitamins D and K supplementation on the vascular properties during a three-year follow-up 
period. Measures of functional vascular properties are distensibility and compliance as they 
characterize the arterial stiffness of the vessel wall, which may be modified by medial 
calcification. The intima-media thickness (IMT) is assumed to represent an endothelial 
adaptive response to physiological and pathophysiological processes 12-14 and is regarded as 
an indicator of atherosclerosis 15,16. The ratio of diameter to IMT corrects the functional 
parameter DC for the tissue volume involved, resulting in a parameter for the structural 
elasticity, known as the Young’s Modulus (E) 17. The present study also included the effects 
of vitamin K1 and D on changes in IMT and E. We selected a group of healthy 
postmenopausal women to assess the effects of vitamin K1 and D supplementation on 
changes in vessel wall characteristics, because it has been suggested that changes in vessel 
wall properties occur faster in postmenopausal women between 45 and 60 years than in men 
of the same age 18. 
 
 
METHODS 
Subjects 
The participants were enrolled in a 3-year double-blind placebo-controlled clinical trial in 
which the effects of minerals, vitamins D and K were investigated on bone mineral density 
and vessel wall characteristics. The participants of this trial were recruited by newspaper 
advertisements. Inclusion criteria were: apparently healthy women, Caucasian race, between 
50 and 60 years old and at least 2 years postmenopausal. Exclusion criteria were: use or 
recent use (< 1 year) of oral anticoagulants, corticosteroids, hormone replacement therapy, 
vitamin concentrates or food supplements, and alcohol consumption of > 2 glasses/day. In 
total 188 women met the criteria for participation, and were randomized into our study. 
Information on cardiovascular risk factors, current health status, medical history, drug use 
and smoking behavior was collected before the start of the study. No medical history of 
important systemic diseases was reported. Within this trial participants were seen every 3 
months to check for compliance and physical health; on a number of these occasions bone 
densitometry (DXA) and blood sampling were performed. The vascular examination only took 
place at baseline and at the end of the study after 3 years. Baseline measurements were 
performed between November 1997 and March 1998, and the follow-up examination took 
place between December 2000 and March 2001. All participants gave written informed 
consent and the trial was approved by the University Hospital medical ethics committee. 
 
Study Design  
The subjects were randomized into three groups. In the first group (n=60) participants 
received a placebo (maltodextrine, i.e. placebo group), in the second group (n=58) 
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participants received a supplement containing 500 mg calcium (natural calcium complex 
derived from milk), 10 mg zinc, 150 mg magnesium and 8 µg vitamin D3 (minerals + vitamin 
D = MD-group), and in the third group (n=63) participants received a supplement containing 
the same constituents as the MD-group but with additional 1 mg vitamin K1 (minerals + 
vitamins D+K = MDK-group). In the present study, we compared the changes of vessel wall 
characteristics between treatment groups and placebo to elucidate the effects of vitamins K 
and D on the vessel wall characteristics. 
The randomization of the participants to the three groups was performed according to a 
computer-generated randomization list and the randomization codes were kept apart from 
the study site during the trial. The participant randomization codes were allocated 
sequentially in the order in which the participants were enrolled. One investigator who 
supervised the whole study was responsible for the enrollment and assignment of 
participants to the respective groups. Because the three different types of supplements were 
similar in appearance and taste, participants and investigators were not aware of group 
assignment. Participants were allowed to choose between a supplement in the form of a 
tasteless powder (to be mixed with water before intake) or in the form of chocolate-coated 
tablets with a crunchy malt core. The percentage of subjects who used the powder or tablets 
was equally distributed across the three groups. Participants were instructed to take one 
sachet with powder or three tablets per day during evening hours, preferably after the meal. 
Also, they were advised to maintain their usual diets and to avoid taking supplements 
containing either calcium, vitamin D, or K two months before and throughout the study. 
Novartis Consumer Health SA (Nyon, Switzerland) prepared and provided all supplements. 
After randomization, the women received the first batch of supplements and were supplied 
with a new batch of supplements every six months.  
 
Measurements 
The primary outcome measures for the purpose of this study were the vessel wall 
characteristics of the common carotid artery measured with ultrasound (7.5 MHZ, ATL Mark 
V). The ultrasonic vessel wall tracking system (WTS) to determine arterial wall properties has 
been described in detail previously 19,20. It provides estimates of the arterial end-diastolic 
adventitia-adventitia diameter (d) and the change in diameter (distension) from diastole to 
systole (Dd) normalized for the end-diastolic diameter (Dd/d) for each captured heart beat. In 
parallel with diameter change measurements, arterial blood pressure was recorded at the 
level of the brachial artery by means of a semiautomated oscillometric device (DINAMAP). 
Pulse pressure (PP), defined as systolic minus diastolic blood pressure, was determined by 
averaging the three measurements nearest to the distension measurements. From d, Dd and 
Dp(PP), vascular distensibility coefficient (DC) and compliance coefficient (CC) were 
calculated according to the following equations: 
 
DC= (2dDd + Dd2)/(d2Dp) 
CC= p(2dDd  + Dd2)/4Dp  
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The intima-media thickness (IMT) was measured simultaneously at the same location (2-3 
cm proximal to the bifurcation) of the common carotid artery where the diameter and 
diameter changes were measured. Only the IMT of the posterior wall was assessed, 
because here the reflections from the blood-intima and media-adventitia transition are 
distinctly visible, whereas, at the anterior wall, the trailing edge of the adventitial reflections 
may obscure the medial and intimal signal. At the end of the session, recorded IMT-files 
were processed employing the wall thickness program. The threshold for the derivative was 
maintained at 0.025 21. Each heart beat within a recording resulted in an estimate of wall 
thickness; the median of the estimates per recording was used for further evaluation. The E 
follows from the ratio of the end-diastolic diameter to IMT (d/IMT), normalized with respect to 
the DC (d/IMT)/DC). 
To save time we have investigated only the right common carotid artery. To our knowledge 
no significant differences between the wall properties of the right and the left common carotid 
artery have ever been reported. The same investigator performed all examinations at the 
start and the end of the study and for each participant several repeated measurements (5-7) 
were made during one session. Reproducibility was evaluated for the assessed common 
carotid artery distension and diameter. Before the vascular examination, height and weight of 
each participant were measured with standardized equipment to estimate the body mass 
index (weight/height2). 
 
Statistical Analysis 
The sample size was calculated on the assumption that the desired minimal detectable effect 
was a 15% reduced decrease in distensibility of the MDK-group compared to the placebo 
group with a 90% power and a 0.05 level of significance. With the assumption of a dropout 
rate of 10% per year we calculated that 180 subjects had to be included. Statistical analysis 
was performed using the Statistical Package SPSS (SPSS Corp, Chicago, IL). Results are 
presented as means ± standard deviation (SD), unless indicated otherwise. Only participants 
who had completed the study were included in the primary outcome analysis. Furthermore, 
participants who during the study had started to use medication, that directly affects the 
vessel wall, were excluded from analysis. Also, participants with atherosclerotic plaques in 
the common carotid artery and a high variability in their results (arterial translation of > 2 mm 
and beat-to-beat variation in distension of > 20%) were excluded. The primary outcome 
analyses were repeated to exclude the possibility of bias by drop-outs and excluded 
subjects. In these repeat analyses, the missing values of drop-outs and excluded subjects 
were replaced by mean values of outcome variables of the total population of 108 
participants. A paired t-test was used to evaluate the change in the vessel wall 
characteristics over the three years within each group. We considered a level of p<0.05 to be 
statistically significant. For every participant, the percentage change from baseline in all 
parameters was calculated and the mean change from baseline was calculated per group. 
Primary outcome analysis consisted of comparison of the change in DC, CC, PP, IMT, d/IMT 
and E between the MD-group and placebo and between the MDK-group and placebo using 
linear regression analysis. In this analysis, the change in vascular parameters relative to 
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baseline was used as dependent variable and the treatment groups and several covariates 
were used as explanatory variables. Baseline values of age, weight, smoking (yes or no), 
heart rate and mean arterial pressure were chosen as covariates, because their influence on 
the change in vascular properties or response to the supplementation could not be excluded.  
 
 
Table 1 
Baseline characteristics (mean ± standard deviation) in the three treatment groups. 
Baseline-characteristics Placebo (n=40) MD-group (n=30) MDK-group  (n=38) 
Age (yr)  54.1 ± 3 55.9 ± 2.8* 55.4 ± 2.8 
Weight (kg) 69.5 ± 11.9 70.6 ± 11.1 66.3 ± 9.5 
Height (m) 1.65 ± 0.05 1.65 ± 0.07 1.63 ± 0.06 
BMI (kg/m2) 25.6 ± 4.3 26 ± 4.4 25.1 ± 3.1 
Postmenopausal age (yr) 4.6 ± 3.7 7.6 ± 5.1** 5.1 ± 4.3 
Non-smokers (%) 75   73.9   85   
Diameter (µm) 7162 ± 562 7314 ± 582 7173 ± 411 
Distension (µm) 372 ± 118 353 ± 83 332 ± 83 
Pulse Pressure (mmHg) 51.9 ± 11.1 52.9 ± 10.1 53.7 ± 14.3 
Diastolic Blood Pressure (mmHg) 73.5 ± 7 73.9 ± 8.7 73.3 ± 8.6 
Heart Rate (beats/min) 60.8 ± 9.2 63.1 ± 8.9 60.6 ± 6.6 
CC (mm2/kPa) 0.64 ± 0.23 0.61 ± 0.2 0.56 ± 0.17 
DC (MPa-1) 15.8 ± 5.2 14.5 ± 4 14 ± 4 
IMT (mm) 0.63 ± 0.11 0.64 ± 0.1 0.61 ± 0.08 
Diameter / IMT  11.7 ± 1.9 11.6 ± 1.8 12 ± 1.7 
E (kPa) 822 ± 300 852 ± 266 941 ± 298 
* significant different from placebo (p<0.05) 
** significant different from placebo and MDK-group (p<0.05) 
Abbreviations used: body mass index (BMI), compliance coefficient (CC), distensibility 
coefficient (DC) and intima-media thickness (IMT). 
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Assessed for eligibility
(n=200)
Randomized (n=188)
Excluded (n=12)
Not meeting inclusion criteria (n=2)
Refused to participa te (n=9)
Other reasons (n=1)
Allocated to placebo (n=61)
Received allocated treatment (n=60)
Did not receive allocated intervention (n=1);
referred for treatment outside study
Allocated to  MD (n=61)
Received allocate d treatment (n=58)
D id not receive allocated intervention (n=3);
referred for treatm ent outside study
Allocated to MDK (n=66)
Received allocated treatment (n=63)
Did not receive allocated intervention (n=3);
referred for treatment outside study
Lost to follow-up (n=0)
Discontinued intervention (n=4)
Lost to follow-up (n=12)
Discontinued intervention (n=4)
Lost to follow-up (n =7)
Discontinued intervention (n=4)
Analyzed (n=40)
Exclude d from analysis (n=1 6)
M edication (n=2)
High variability in results (n=11)
Atherosclerotic plaques (n=3)
Complet ed three years (n=56 ) Completed three  years (n=42) Completed three years (n=52)
Analyzed (n=30)
Excluded from analysis (n=12)
Medication (n=1)
High variability in results (n=9)
Atherosclerotic plaques (n=2)
Analyzed (n=38)
Excluded from analysis (n=14)
Medication (n=1)
High variability in results (n=7)
Atherosclerotic plaques (n=6)  
 
Figure 1 
Flow diagram of participants through the different stages of the study. 
 
 
RESULTS 
Baseline characteristics  
Baseline characteristics of the selected participants are presented in Table 1. The MD group 
differed slightly but significantly from the placebo and the MDK group with respect to age and 
the number of years since menopause. No significant differences were observed in the 
baseline values of the vessel wall characteristics. Figure 1 shows for the separate groups the 
flow of participants through each stage. From the 181 subjects who entered the study, 31 
discontinued their participation during the course of the study, and were not available for the 
follow-up measurement. Of the remaining 150 participants who completed the study, we 
excluded 42 subjects from the analysis: 4 women started to use medication, known to have 
direct effects on the vessel wall (ACE-inhibitors, b-blockers or Calcium-antagonists), in 11 
subjects atherosclerotic plaques in the common carotid artery were clearly visible and they 
were referred for treatment outside the study, and 27 subjects had a high variability in their 
repeated measurements (arterial translation of > 2 mm and beat-to-beat variation in 
distension of > 20%). Analysis was performed on 108 participants who completed the study 
and who did not have any of the above mentioned interfering factors. There were no 
significant differences in baseline values of the vessel wall characteristics between the 108 
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selected participants and those who discontinued treatment or were exluded (n=73). The 
only side-effect of the allocated intervention reported to the investigator were complaints of 
mild constipation in a few participants of the MD-group (n=4) and the MDK-group (n=3). No 
further adverse events occurred during the study. 
 
Vascular parameters of elasticity  
Table 2 summarizes per group the differences between the mean values at baseline and the 
end of the study for all vascular parameters with their paired-levels of significance. The DC 
and CC in the placebo group decreased significantly with 10% and 6%, respectively. The PP, 
on the other hand increased by 7%, but the increase did not reach the level of significance. 
In the MD-group, DC decreased significantly with 7% and CC decreased with 4%, while the 
PP increased with 6%, however these latter two changes did not reach the level of 
significance. In the MDK-group, the DC, CC and PP remained constant over the three years 
period, with even a tendency for the CC to increase (+3%). Figure 2 illustrates the change in 
DC and CC of the three groups. After adjustment for baseline heart rate, mean arterial 
pressure, age, weight and smoking, there were significant differences between the MDK- 
group and the placebo with respect to DC (8.8%; 95% CI: 1.9 to 21.4),  CC (8.6%; 95% CI: 
1.8 to 20.3), and PP (-6.3%; 95% CI: -17.1 to –0.7). In the same analysis no differences were 
found between the MD- and placebo-group with respect to DC (2.5%; 95% CI: -6.3 to 14.8), 
CC (2.2%; 95% CI: -6.3 to 13.8), and PP (-0.11%; 95% CI: -12.1 to 5.6). The repeat analyses 
in which mean values were allocated to drop-outs and excluded subjects, showed the same 
trends as those described above; as to be expected the differences between the MDK-group 
and placebo in change of DC, CC and PP were smaller, but they remained statistically 
significant. 
 
Table 2 
Change in vessel wall characteristics (mean ± SD) in study population after 3 years. 
Change between T=0  Placebo (n=40) MD-group (n=30) MDK-group (n=38) 
and T=3 years (paired t-test)          
Diameter (µm) 196 ± 295 (p<0.01) 154 ± 179 (p<0.01) 131 ± 226 (p<0.01) 
Distension (µm) -21 ± 61 (p<0.05) -12.6 ± 47 (p=0.15) -3.9 ± 49 (p=0.63) 
Pulse Pressure (mmHg) 2.7 ± 9.9 (p=0.09) 2.8 ± 10.1 (p=0.14) -0.2 ± 7.6 (p=0.89)* 
DC  (MPa-1) -1.8 ± 3.4 (p<0.01) -1.4 ± 3.0 (p<0.05) -0.4 ± 3.0 (p=0.43)* 
CC (mm2/kPa) -0.05 ± 0.1 (p<0.01)  -0.04 ± 0.1 (p=0.10) 0.01 ± 0.11 (p=0.75)* 
IMT (mm) 0.05 ± 0.08 (p<0.01) 0.02 ± 0.09 (p=0.32) 0.06 ± 0.06 (p<0.01) 
Diameter / IMT  -0.56 ± 1.5 (p<0.05) -0.14 ± 1.5 (p=0.63) -0.85 ± 1.1 (p<0.01) 
E (kPa) 74 ± 279 (p=0.12)  68 ± 254 (p=0.17) -27 ± 236 (p=0.50)* 
* significant different from placebo (p<0.05) 
Abbreviations used: compliance coefficient (CC), distensibility coefficient (DC) and  
isntima-media thickness (IMT). 
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Intima-media thickness 
Changes of the intima-media thickness relative to baseline are also given in Table 2. In all 
three groups the IMT increased: 9% in the placebo (p<0.01), 10% in the MDK-group 
(p<0.01), but only 4% in the MD-group (p=0.32). The d/IMT ratio decreased significantly in 
the placebo and MDK-group with 3.8% and 6.5% respectively, while in the MD-group the 
ratio remained constant. The Young’s Modulus (E) increased in the placebo and MD-group 
by 13.2% and 13.7% respectively, however these changes did not reach the level of 
significance. In the MDK-group E remained constant. Figure 2 illustrates the change in IMT 
and E of the three groups. In the multivariate analysis with adjustments for baseline heart 
rate, mean arterial pressure, age, weight, and smoking, the difference in increase of IMT 
between the MDK-group and placebo was 1.3% (95% CI: -3.2 to 9.2) and between the MD-
group and placebo the difference was -4.5% (95% CI: -8.9 to 4.2). Hence neither for the MD- 
nor for the MDK-supplement a significant beneficial effect on the age-related increase of the 
IMT could be demonstrated. However, there was a significant difference in the change of E 
between the MDK-group and placebo (-13.2%; 95% CI: -35.8 to -5.3), while no significant 
difference was observed between the MD-group and placebo (0.46%; 95% CI: -23.2 to 9.4) 
and neither significant differences were observed between the groups in change of the d/IMT 
ratio.  
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Figure 2 
Mean percent change (± standard error of the mean) from baseline (0%) in distensibility 
coefficient, compliance coefficient, intima-media thickness and the Young’s Modulus (E) 
of the common carotid artery in the placebo (n=40), group MD (n=30) and group MDK 
(n=38) after three years of treatment. *: p < 0.05, significantly different from placebo. 
 
 
* 
* 
* 
  Chapter 6: Vitamin K and Arterial Elastic Properties 
  95 
DISCUSSION 
In the present investigation, we have demonstrated a long-term beneficial effect of a 
supplement containing vitamin K1 and D on the elastic properties of the carotid artery. In 
contrast, no effect was found on the IMT. Vitamin D alone did not influence these variables. 
To our knowledge, this is the first study which shows a longitudinal beneficial effect of 
vitamins K1 + D supplementation on vascular properties. 
During recent years the classical role of vitamin K in blood coagulation has been extended to 
widely different functions in extra-hepatic tissues, such as bone and the vessel wall. Since 
the first observation of the association of poor vitamin K1 status and age-related osteoporosis 
22, population-based studies on correlations between low dietary vitamin K1-intakes and 
undercarboxylated osteocalcin on one hand and fracture risk and low bone mineral density 
on the other hand have been accumulating 23-26. The occurrence of vitamin K-dependent 
proteins in the arterial vessel wall was discovered more recently, and only limited data are 
available on a possible relation between vitamin K intake and vessel wall properties. In 
animals it was found that pharmacological doses of vitamin K2 prevent the progression of 
atherosclerosis by supression of plaque formation, intima-thickening and pulmonary 
atherosclerosis 27. One of the few studies in humans showed an inverse correlation between 
dietary vitamin K1 intake and aortic calcification in postmenopausal women 10. In a recent 
population-based study an inverse correlation was found between vitamin K2 intake and 
aortic calcification, myocardial infarction and sudden cardiovascular death 11. The latter study 
suggests that vitamin K2 may be a more powerful inhibitor of arterial calcification than vitamin 
K1. Furthermore, vitamin K2 was shown to decrease the total circulating cholesterol 
concentration 28. Most of the studies published thus far have focused on effects of vitamin K2 
and not of vitamin K1.  
When hypothesizing about the mechanism underlying our observations, we would like to 
focus on the vitamin K-dependent protein MGP. It is synthesized by the vascular smooth 
muscle cells 5, and accumulates in or around the elastic fibres in the tunica media 7. In this 
respect it is noteworthy to mention that transgenic MGP-deficient mice developed arterial 
calcifications starting in the media, but even at later stages there was no neo-intima 
formation or atherosclerosis. Rather, the type of calcification was similar to that found in 
Mönckeberg’s sclerosis of the media such as is often seen in diabetics and hemodialysis 
patients. In these patients calcification starts from the elastic lamellae of the media and 
occurs without inflammation. DC and CC are related to the functions of elastin and collagen 
in the vascular media as they represent the elastic properties of the vessel wall. IMT, on the 
other hand, is regarded as endothelial response to pathophysiological processes as in 
atherosclerosis. While DC and CC represent functional characteristics of the vessel wall, the 
Young’s Modulus (E) expresses the structural characteristics of the tissue. In this study it 
was shown that supplementation with vitamin D+K exerted beneficial effects on both 
structural and functional characteristics of the vessel wall. There was no age-related change 
in structural characteristics (Young’s Modulus) in contrast to the age-related change in the 
functional characteristics as shown in the placebo group. 
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In many papers it has been suggested that the vitamin K requirement of extra-hepatic tissues 
is substantially higher than that of the liver. Although these conclusions are mainly based on 
the bone Gla-protein osteocalcin, which was found to be undercarboxylated in the majority of 
the population (notably elderly) 29, also for MGP substantial undercarboxylation has been 
reported 30. Assuming that at baseline also in our study population part of the MGP was 
synthesized in an undercarboxylated (i.e.: inactive) form, this must be expected to form a risk 
factor for media sclerosis and vascular stiffening, but not for atherosclerosis. In this view it is 
conceivable that increased vitamin K intake will increase the vascular vitamin K status and 
hence the production of active MGP, thus contributing to the inhibition of calcification and 
protection against arterial stiffening. Although this is precisely the effect observed in our 
study, it cannot be excluded that other vitamin K-dependent proteins are involved in 
maintaining vascular elasticity.  
Since the MGP promotor contains a vitamin D-responsive element, it is theoretically possible 
that a low vitamin D status also affects the level of MGP expression. To make certain that the 
participants were sufficient in vitamin D, the treatment included supplementation with vitamin 
D (1 x RDA) together with the vitamin K1 (8 x RDA). In a third arm of the study it was 
demonstrated that vitamin D alone had no effect on any of the vessel wall characteristics 
measured. No significant differences were observed in longitudinal changes between the 
placebo and the vitamin D group.  
To which extent vessel wall characteristics of the carotid artery represent a measure for risk 
on cardiovascular disease remains to be investigated. In various studies increased IMT of 
the carotid artery was shown to be a risk factor for atherosclerosis, especially if the IMT is > 1 
mm. Since in our study population the IMT in all three groups remained between 0.6 – 0.7 
mm, it cannot be excluded that under different conditions (e.g. in older age groups, or after 
prolonged treatment) also an effect of vitamin K on IMT will be seen. This may especially 
occur at later stages of atherosclerosis in which calcification of the lesions forms an end 
stage process. Less information is available on the correlation of distensibility and 
compliance with cardiovascular disease, although in previous studies also arterial stiffness 
was shown to be associated with myocardial infarction and coronary artery disease 31,32. In a 
recent study of 110 end-stage renal disease patients, a strong correlation was found 
between calcification score and arterial stiffness, especially with E, but also with DC, CC and 
IMT 33. It has been suggested in this study that measurement of arterial parameters, 
exploring both structural and functional properties, could be helpful in the assessment of risk 
on cardiovascular disease and in the evaluation of risk reduction by treatment. However, 
extrapolation of these results to other groups may not be justified because of the particular 
characteristics of these patients. The fact that our data suggest a more pronounced effect of 
vitamin K1 supplements on (medial) calcification than on IMT thickening warrants further 
studies in other populations, for instance diabetics or patients with severe atherosclerosis.   
One limitation of our study is the fact that we observed a higher drop-out rate in the treatment 
groups than in the placebo group. Given the specific reasons for drop-out as mentioned in 
the results, it is unlikely that the treatment assignment was responsible for the higher drop-
out rate. However, it cannot be excluded that the higher drop-out rate was due to minor 
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differences in taste of the different supplements. Another limitation of this study was the 
exclusion of part of our randomized population. Extensive analysis of the collected 
ultrasound data lead to necessary exclusions because of technical difficulties in measuring 
diameter changes within regular heart cycles, as exhibited by example arterial translations of 
> 2 mm and beat-to-beat variations in distension of > 20%. Additional analyses were 
performed to exclude the possibility that the high drop-out rate and exclusion of subjects had 
seriously biased our results. This turned out not to be the case. The study presented in this 
paper is a first step to corroborate the role of vitamin K in vascular tissue. Clinical trials 
measuring other endpoints and progression of calcification are needed to provide further 
evidence that vitamin K contributes to the prevention of cardiovascular disease.  
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ABSTRACT 
Matrix Gla-protein (MGP) is synthesized in a vitamin K-dependent way in smooth muscle 
cells of the healthy vessel wall and its mRNA transcription is substantially upregulated in 
atherosclerotic lesions. Here we report the preparation of a monoclonal antibody against 
human MGP and its use in an enzyme-linked immuno sorbent assay. The intra- and inter-
assay variations in serum samples were 5.4 and 12.6%, respectively, and the lower detection 
limit was 8.5% of the normal serum value. Individual within-day variations were below 11%, 
and did not show a distinct circadian pattern. Day-to-day variations in fasting morning 
samples were below 8%. In a first explorative survey, serum MGP concentrations were found 
to be significantly increased in patients with severe atherosclerosis, whereas they were 
normal in those with low bone mass and osteoporosis. This is consistent with the high MGP 
mRNA-expression observed in atherosclerotic vessels and plaques. Furthermore, in this 
study it was shown that the serum MGP levels were significantly correlated to one of the 
MGP-polymorphisms. More elaborate studies are required to assess the potential clinical 
utility of the newly developed assay. 
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INTRODUCTION 
Vitamin K is a cofactor in the posttranslational conversion of glutamate residues into g-
carboxyglutamate (Gla). At this time 10 mammalian Gla-containing proteins have been 
described in detail, and the number of Gla-residues per molecule varies from 3 (osteocalcin) 
to 13 (protein Z). In all cases in which their function was known, the activity of the various 
Gla-proteins was strictly dependent on the presence of the Gla-residues 1. One of the Gla-
proteins is Matrix Gla-Protein (MGP); it is synthesized by chondrocytes and vascular smooth 
muscle cells 2,3. Small amounts of MGP mRNA have also been detected in various other 
tissues 4, but this may reflect - at least in part - synthesis in small vessels and capillaries. 
Although its mode of action on a molecular level has remained obscure until now, recent data 
in rodents strongly suggest that MGP plays a key role in the inhibition of tissue calcification. 
MGP-deficient mice were generated by Luo et al. 2, who observed excessive cartilage and 
growth plate mineralization resulting impaired growth of the long bones. An even more 
prominent phenomenon, however, was that all animals showed massive calcification of the 
main arteries and died within eight weeks after birth due to rupture of the thoracic or 
abdominal aorta. The importance of Gla-residues for MGP to exert its mineralization-
inhibitory function was demonstrated in rats in which extrahepatic protein carboxylation had 
been blocked by treatment with warfarin 5. After 3-4 weeks of treatment these animals 
developed arterial calcifications starting around the elastic lamellae of the media in a similar 
way as was reported for MGP-deficient mice. Whether this effect was due to poor cellular 
excretion of undercarboxylated MGP or because of its lack of functionality has remained 
unclear in this experiment. It is generally assumed, however, that - like in other Gla-proteins - 
also in MGP the Gla-residues are important for its function. Taken together, the available 
data in rodents demonstrate that MGP is a potent inhibitor of tissue calcification, and that its 
posttranslational carboxylation is essential for exerting this activity in vivo. A recent 
publication from Munroe et al. suggested that vascular calcification in humans may be more 
complex than in rodents. These authors reported data for three unrelated patients with Keutel 
syndrome (KS), which is an autosomal recessive disorder characterized by abnormal 
cartilage calcification 6. These authors showed that the three KS patients had (different) 
mutations in their MGP gene predicting frame shift or premature frame shift in the mature 
protein. KS patients may be regarded therefore as a human model for MGP-deficiency, but 
remarkably arterial calcification is not a common feature in KS. It should be noticed, 
however, that neither histological nor pathological examination of arteries had not been 
performed in the patients described, so that the effect of MGP-deficiency on human vascular 
biology remains to be investigated. 
Cardiovascular disease is one of the major life-threatening diseases in the Western society, 
but biomarkers to monitor the severity or the progression of the disease are presently not 
available. Also, the number of biochemically detectable risk factors (e.g. serum cholesterol, 
triglycerides, ApoE genotype) is surprisingly low. Based on the - limited - data available, 
serum MGP is a good candidate to become a biomarker associated with arterial calcification. 
In this chapter we report the production of a monoclonal antibody (mAb3-15) against human 
Part II: Vitamin K and Vascular Health 
106 
MGP and the development of a microtiter plate-based assay with which circulating MGP was 
demonstrated and quantified in human serum. The assay may be used to explore the 
potential value of circulating MGP as a marker in the field of cardiovascular disease. 
Furthermore, the assay was also used to investigate if certain promoter polymorphisms in the 
MGP-gene are associated with fluctuations in MGP serum concentrations. The hypothesis is 
that polymorphisms may be present in the promoter region of MGP that could result in 
interindividual variation in transcription and tissue expression of MGP. The assay may help 
us to understand the role of MGP in human vascular biology. 
 
 
METHODS 
Materials  
Synthetic peptides homologous to the sequences 3-15 and 63-75 of human MGP and the 
sequences 1-16 and 29-43 of human osteocalcin were synthesized and purified by Pepscan 
Systems (Lelystad, The Netherlands) and will be designated below as MGP3-15, MGP63-75, 
OC1-16, and OC29-43, respectively. All chemicals used were of analytical or high-performance 
liquid chromatography. 
 
Preparation of recombinant MGP  
mRNA's coding for MGP and osteocalcin (OC) were isolated from cultured human 
osteoblasts and used for preparing the corresponding cDNA's. Both cDNA's were inserted in 
the pQE-40 vector (Qiagen, Hilden, Germany) and expressed in E.coli M15 as chimeric 
proteins with murine dihydrofolate reductase (DHFR) equipped with an N-terminal 6-His tag 
for rapid purification (H.M.H. Spronk, unpublished data). Following expression, bacteria were 
lysed in buffer A (8 mol/L urea, 0.3 mol/L NaCl, and 0.01 mol/L Tris-HCl, pH 8.0). After 
centrifugation for 30 min at 10,000 x g the supernatant was passed over a Ni2+-nitrilotriacetic 
acid agarose column (Qiagen, Hilden, Germany) in buffer A, and the 6-His tagged protein 
was eluted with buffer B (8 mol/L urea, 0.5 mol/L imidazole, pH 8.0). Unfortunately, the 
preparation thus obtained was insoluble under physiological conditions, which hampered its 
use as a reference material in the MGP assay. 
 
Preparation of antibodies.  
Balb/C mice were immunized intraperitoneally with the peptide MGP3-15, which was coupled 
to keyhole limpet hemocyanin (Pierce Chemical Co). Twenty µg of antigen in Freund's 
complete adjuvant were used for the first immunisation, followed by three boosts (20 µg 
each) in Freund's incomplete adjuvant with 2-week intervals. Post-immune sera were 
screened for their affinity towards purified recombinant MGP, which was used as a chimeric 
construct with murine dihydrofolate reductase (DHFR, se below). At one week after the last 
boost, splenocytes of the best responder mouse were fused with an American Type Culture 
Collection (Manassas, Va) mouse myeloma cell line (Sp 2/01-Ag, CRL 8006) according to 
standard procedures, and growing hybridomas were screened by an enzyme-linked 
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immunosorbent assay (ELISA) in which recombinant proteins were coated to the microtiter 
plate. Positive clones were selected on the basis of specific recombinant DHFR-MGP 
recognition, whereas recombinant DHFR-osteocalcin served as a negative control. A clone 
with a strong and specific reaction with rMGP was selected for the large scale preparation of 
monoclonal antibodies (mAb3-15). In a final step the IgG was isolated from the culture medium 
by protein G affinity chromatography. 
 
MGP assay  
Urea-solubilized rMGP (1 g/L) was diluted 50-fold with coating buffer (0.1 mol/L Na-
carbonate, pH 9.6) and used for the coating of microtiter plates (50 µL/well). After incubation 
for 1 h at 37 °C remaining protein binding sites were blocked with 100 µL/well of blocking 
buffer (Hoffmann-La Roche, Basel, Switzerland, cat. no: 1 112 589) and incubated for 
another 1 h at 37 °C. After repeated washing (with washing buffer: 0.3% (w/v) tween-20 in 
PBS (0.15 mol/L NaCl, 10 mmol/L Na-phosphate, pH 7.4)) the plates were ready for use. The 
serum samples were diluted (as indicated) with PBS and 125 µL of sample were 
supplemented with 25 µL of mAb3-15 (6 mg/L in PBS containing 2% (w/v) non-fat dry milk 
protein (Nutricia, Zoetermeer, The Netherlands)) and incubated for 5 min at room 
temperature. Subsequently, 50 µL of sample were transferred to the microtiter plate and 
incubated for 1 h at 37 °C. After three washing cycles with PBS-tween-20 washing buffer 
(see above), the mAb3-15 bound to the plate was quantified using a second antibody (rabbit 
anti-mouse total IgG conjugated with horse radish peroxidase (Dako, 1 mg/L in PBS-tween)) 
and stained with 3,3',5,5'-tetramethylbenzidine (TMB from Hoffmann-La Roche). After 10 min 
the staining was stopped by adding 200 µL 1 M H2SO4, and the plate was read at 450 nm. 
The MGP content of pooled reference serum from 30 healthy individuals was arbitrarily 
defined to be 100 Units/L. 
 
Subjects  
Unless stated otherwise, fasting blood samples were taken. Serum was left at room 
temperature for 2 h before centrifugation (15 min, 2,000 x g) and storage at -80 Cº until use. 
Genomic DNA was extracted from leukocytes. For assessment of the normal range and 
reference groups, apparently healthy subjects were recruited among the Maastricht 
population. The day-to-day and within-day variations were determined in a group of 12 
healthy men (20-35 years old), from whom blood was taken by venipuncture at nine time 
points on one day, and on 4 different days at 09.00 a.m. with one week intervals. Samples 
were also obtained from 200 healthy subjects (55-65 years old) in whom the intima/media 
thickness of the carotid artery was measured by ultrasound as described by Hoeks et al. 7. In 
a collaborative study with the University of Cambridge, these samples were also used to 
determine the presence of certain promoter polymorphisms in the MGP gene. Blood 
sampling, MGP analysis and DNA extraction were performed at Maastricht, genomic analysis 
were accomplished at Cambridge 8. 
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Patient samples were obtained via the University Hospital Maastricht. The study was 
approved by the local Medical Ethics Committee, and informed consent was obtained from 
all participants according to the institutional guidelines. 
 
Statistical analysis  
The Student t-test (for groups n = 30), and the Mann Whitney U-test (for groups n < 30) were 
performed to assess whether observed differences between patient groups were statistically 
significant (p < 0.05). ANOVA and the Kruskal-Wallis test were used to detect differences in 
MGP-levels between the different types of several MGP-polymorphisms. 
 
 
RESULTS 
A. Calibration curve and test characteristics 
Calibration curves were made on 12 different days using six different dilutions of pooled 
reference serum. Each dilution was measured in duplicate, and the mean optical densities 
(OD) at 450 nm (± SD) were expressed as a function of the serum concentration (Figure 1A). 
At increasing dilutions of the serum sample, more anti-MGP was bound to the plate, with the 
buffer value as a theoretical maximum. The lower detection limit was defined as the mean 
OD + three times the standard deviation of the buffer value, and amounted 2.096 – 3 × 0.089 
= 1.829, corresponding with a MGP concentration of 8.5 U/L. The intra- and inter-assay 
variation of the test were determined using a four-fold dilution of the reference serum. The 
intra-assay variation was calculated by expressing the standard deviation as a percentage of 
the mean obtained from 21 replicates, repeated on three different days and amounted 5.4%. 
For assessment of the inter-assay variation, duplicate measurements were made on 14 
consecutive days after which the standard deviation was expressed as a percentage of the 
means to give a value of 12.6%. 
The validation of the assay was performed in a number of control experiments, which are 
partly summarized in Figure 1B. To eliminate the possibility of a false positive signal because 
of cross reaction of the second antibody with microtiter-bound proteins, the assay was 
performed in the absence of mAb3-15. No response was obtained under these conditions. To 
eliminate the possibility that human serum contains auto-antibodies against MGP which 
might interfere with the assay, serum was transferred in seven subsequent steps across 
microtiter plate wells coated with rMGP before it was used in the MGP assay. Dilution curves 
of sera with and without this pre-treatment were identical, thus denying the occurrence of 
pre-existing anti-MGP. Next, we have investigated whether human test samples might 
contain IgG that would interfere with the assay by binding directly to mouse IgG. To this aim, 
serum was analysed in various dilutions before and after adsorption onto protein G 
sepharose. Both curves were identical, thereby showing that the assay was not disturbed by 
pre-existing anti-murine IgG. 
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Figure 1  
Dose-response curves with treated and 
untreated serum. A. Reference curve for MGP 
in human reference serum. Points are means of 
duplicate measurements made on 12 different 
days, error bars represent standard deviation. 
B. Controls with pooled serum: (closed circles), 
standard assay; (open circles), serum depleted 
of potential anti-MGP by adsorption onto rMGP; 
Points represent means of duplicate 
experiments. 
Figure 2  
Reactivity of mAb3-15 antibodies with purified 
rMGP (A) and rOC (B). The amount of 
recombinant protein on the microtiter plate was 
quantitated with anti-6His antibodies (closed 
circles), the reactivity with mAb3-15 was tested in 
the same plate (open circles). In both cases 
staining was performed by incubation with a 
second antibody (rabbit anti-mouse total IgG 
conjugated with horse radish peroxidase) as 
described in Materials and Methods. 
 
B. Sample preparation 
To further evaluate the robustness of the assay, we have checked the influence of variations 
in the sample preparation procedure at the following steps: centrifugation speed (1,500 and 
10,000 x g) during serum preparation, centrifugation (10,000 x g) after adding of mAb3-15, 
freeze-thawing of the serum sample (up to 8 cycles of freeze-thawing) and incubation time 
(between 3 and 60 minutes at room temperature) of the serum sample with mAb3-15. In none 
of these cases did the sample treatment measurably affect the observed MGP concentration. 
 
C. Assay specificity 
The mAb3-15 used in the assay was tested for its ability to differentiate between two 
recombinant bone Gla-proteins: osteocalcin and MGP (both as chimeric constructs linked 
with 6His-DHFR). Microtiter plates were coated with either purified recombinant MGP (1 
µg/well) or equimolar amounts of purified recombinant osteocalcin. Coupling efficiency of 
both proteins was checked with anti-6His antibodies. As is shown in Figure 2, both plates 
contained similar amounts of recombinant protein (A: MGP; B: osteocalcin), and mAb3-15 
reacted well with MGP, but not with osteocalcin. The species specificity of mAb3-15 was 
tested further by comparing their reaction with human, rat, and murine serum. Cross reaction 
with rodent sera was below the detection limit (< 8.5 U/L) in all dilutions tested. Epitope 
specificity was tested by comparing the extent to which various synthetic peptides were 
capable of extinguishing the response with 10-fold diluted human serum. Under standard 
conditions (i.e.: when using 6.7 nmol/L of mAB3-15) almost complete quenching of the signal 
was obtained by mixing the serum with 50 nmol/L of MGP3-15, with a half-maximal effect at 5 
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nmol/L. No effect was observed with the peptides MGP63-75, OC1-16 and OC29-43 up to 
concentrations of 65 µmol/L (see also Figure 3). 
 
D. Normal range, within-day, and day-to-day variations 
The 'normal range' for MGP was established in 80 apparently healthy men between 20 and 
84 years of age. It was found that the mean value for serum MGP in this group was 96 ± 17 
U/L. Hence the normal range (defined as the mean ± 2SD) was calculated to be between 62 
and 130 U/L. No apparent age-dependence was observed for MGP in this group. Similar 
data were observed for elderly women (> 60 years of age), but a larger range was found in 
women between 20-55 years. This may be related to hormonal changes, and forms the basis 
for our decision that women < 60 years old were not included in the experiments presented in 
this paper. The time-related variability of serum MGP was established in a group of 12 
healthy subjects from whom blood was taken by venipuncture on nine time points of one day, 
and on 4 different days at 09.00 a.m. with one week intervals. The within-day variation was 
calculated for each subject separately by expressing the standard deviation as a percentage 
of the mean of the nine time points, and amounted 11%. No distinct circadian pattern was 
observed (see Figure 4). The day-to-day variation was calculated in a similar way from the 
four samples obtained with weekly intervals, and was found to be 8%. 
 
E. MGP in patients 
The potential clinical utility of the newly developed MGP assay was tested in a pilot study 
among a limited number of patients. Since bone and arterial vessel wall are the major sites of 
MGP production, we have focussed on subjects with either bone disease (osteoporosis) or 
 
 
Figure 3  
Reactivity of mAb3-15 antibodies with synthetic 
MGP-derived peptides. Serum was mixed with 
either MGP3-15 (closed circles) or MGP63-75 (open 
circles) before testing. Points represent means 
of triplicate experiments ± SD 
 
Figure 4  
Absence of circadian pattern for circulating 
human MGP. Points represent means ± SD of 
twelve different subjects; nine blood samples 
were obtained during the first 24 hours, and 5 
samples were obtained at 9 a.m. during the 
following two months. 
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vascular disease (atherosclerosis), and the data are summarized in Table 1. No correlations 
were found between serum MGP levels and either low or high bone mass, osteoporosis, or 
vascular intima thickening. On the other hand, circulating MGP was significantly elevated in 
subjects with advanced atherosclerosis. Also those with type I diabetes mellitus, a risk factor 
for atherosclerosis, circulating MGP had increased. 
 
Table 1 
Serum MGP concentrations in patients. 
Condition number serum MGP  
(% of age-and sex-matched controls) 
High femur BMD (mean + > 1SD) 40    98.5 ± 5.7 
Low femur BMD (mean - < 1SD) 38                        102.0 ± 5.2 
Senile osteoporosis 28                        101.8 ± 6.8 
Increased intima/media thickness 43                          97.3 ± 6.1 
Type 1 diabetes mellitus 23   134.5 ± 8.6* 
Severe atherosclerosis 26   145.8 ± 6.6* 
Data are given as mean ± SE. Values indicated by an asterix were significantly different 
from the controls (p<0.05). Increased intima/media thickness was the highest quartile 
from a group of 200 apparently healthy elderly subjects. Subjects with high and low BMD 
of the femur neck were obtained from a reference population (n=250) recruited among the 
Maastricht population. Patients with osteoporosis, diabetes mellitus and atherosclerosis 
were obtained via various departments of the University Hospital Maastricht. 
 
 
F. MGP-polymorphisms related to MGP serum levels 
Four polymorphisms were identified in the promoter region of the human MGP gene, two of 
which (G-7A and the T-138C) were shown to have an important impact on the in vitro 
promoter activity. The T-138C variation lies in a region of the promoter which is critical for 
transcription in vascular smooth muscle cells because it contains a potential activating 
protein-1 (AP-1) binding element. Conversion of -138T to C results in altered binding of an 
AP-1 complex to this region. To test whether the observed variations in the promoter 
sequence might affect circulating MGP-levels in vivo, restriction fragment length 
polymorphisms analysis was performed for the T-138C and G-7A polymorphism on the 
samples of 156 healthy subjects in whom serum MGP had been assayed. It was found that 
the serum levels of MGP varied as a function of the T-138C (ANOVA, p< 0.0001; Kruskal-
Wallis test, p< 0.0001) but not of the G-7A polymorphism (ANOVA, p=0.67; Kruskal-Wallis 
test, p=0.759). Thus, the CC variant at -138 was associated with higher mean serum levels 
of MGP (124.6 units/L) than subjects with TT variant (96.4 units/L). A gene dose effect is also 
evident, with the CT heterozygotes having intermediate values (101.9 units/L).  
Part II: Vitamin K and Vascular Health 
112 
DISCUSSION 
In this paper we report the development of an assay for human MGP, and with this assay (a 
so-called 'antibody-capture' ELISA) the presence of MGP-related antigen in the circulation 
was established. Recorded immunoreactive MGP turned out to be independent of sample 
preparation, and showed small within-day and day-to-day fluctuations. At this time the assay 
still has a number of weaknesses, inherent to a single-antibody assay. Substantial 
improvements may be expected from the availability of a second antibody, which will allow us 
to set up a 'sandwich' ELISA. The question remains what is the origin of serum MGP. The 
protein is known to be synthesized by the chondrocytes in cartilage, and by smooth muscle 
cells in the arterial vessel wall. In a first survey among a limited number of patients we have 
demonstrated that in severely atherosclerotic patients circulating MGP was significantly 
increased. In more elaborate clinical studies it should be investigated whether the severity of 
the disease (e.g. the extent of aortic calcification) correlates with the concentration of serum 
MGP, but at this time no such data are available. In collaboration with the University of 
Cambridge, four novel polymorphisms were identified in the promoter region of the human 
MGP gene. It was found that one of these polymorphisms (T-138C) is significantly correlated 
with serum MGP levels in human subjects. Therefore, this study strongly suggests a genetic 
basis to variations in MGP transcriptions and serum levels. It is interesting to hypothesize 
that these promoter polymorphisms may affect an individual’s susceptibility to vascular or 
valvular calcification. It is possible that the -138C variant provides protection against tissue 
calcification in vascular smooth muscle cells by resulting in higher levels of MGP 
transcription. The results of this study have important implications for understanding the 
mechanisms underlying conditions that involve vascular calcification, such as atherosclerosis 
and aortic valve stenosis, since it strongly suggests a genetic basis for regulation of tissue 
calcification.  In contrast to the data obtained in atherosclerotic subjects, MGP was found to 
be normal in all cases of bone disease tested thus far. The apparent association between 
serum MGP and vascular disease suggests that the circulating protein originates from the 
vessel wall rather than from bone.  
In bone, MGP accumulates in relatively large quantities, which is why bone is the only tissue 
from which native MGP has been isolated thus far 9. However, under physiological conditions 
MGP originating from human and bovine bone is one of the most insoluble proteins known. 
Comparison between its primary structure and the amino acid sequence derived from cDNA 
coding for MGP shows that in bone-derived MGP the last 7 C-terminal amino acids are 
missing 10, and it may be imagined that proteolytic cleavage of its C-terminus forms a 
mechanism for insolubilizing MGP by which it is retained in bone tissue. On the other hand it 
cannot be excluded that in bone MGP is complexed to the organic or inorganic matrix, or that 
it is folded in a way preventing its escape into the circulation. Because of its poor solubility it 
is difficult to envisage how significant amounts of MGP could be filtering from bone into the 
circulation.  
From in situ hybridization we know that also in the arterial vessel wall MGP mRNA 
transcription takes place, but with the aid of immunohistochemical techniques only low levels 
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of MGP protein were found in the healthy vessel wall 11. Thus, unlike bone and cartilage, 
healthy vessels do not retain considerable stores of MGP. The reported strong upregulation 
of MGP mRNA synthesis and high amounts of immunoreactive MGP at sites of 
atherosclerotic lesions 11-13 suggests a feed-back mechanism for local synthesis of MGP-
related antigen, the Gla-content and calcification-inhibitory activity of which remains 
unknown. This is consistent with the hypothesis that at least part of the vascular MGP 
reaches the circulation and may account for the positive signal obtained in healthy subjects, 
and for the elevated serum values observed in atherosclerotic patients. Our hypothesis does 
not explain the mechanism by which circulating MGP remains in solution. One possibility is 
that after cellular secretion vascular MGP is processed differently than that in bone. From its 
primary structure it can be deduced that among the last 7 amino acids predicted by the cDNA 
sequence coding for the 84 residues of human MGP, five are positively charged. These 7 C-
terminal amino acids are missing in MGP isolated from bone, but may be present in serum 
MGP. Hence the isolation and C-terminal sequence determination of serum MGP may 
provide evidence for its origin. An alternative explanation for the apparent solubility of serum 
MGP is that it may be bound to a soluble carrier protein or that it is associated with the 
lipoprotein fraction. 
Assuming that the Gla-residues in MGP are essential either for its cellular secretion or for its 
calcification-inhibitory activity, poor vitamin K status could be an independent risk factor for 
tissue calcification. The latter hypothesis is consistent with data from Jie et al., who 
demonstrated in a population-based study (EPOZ) an inverse correlation between dietary 
vitamin K intake and the occurrence of calcified aortic lesions in elderly subjects 14. The fact 
that major fractions of both osteocalcin and MGP isolated from human bone 15,16, as well as 
circulating osteocalcin seem to occur in an undercarboxylated form 17,18, suggests that 
human vitamin K requirement should not be inferred from the hepatic synthesis of fully 
carboxylated coagulation factors, but from the ability of non-hepatic tissues to maintain full 
carboxylation of locally produced proteins such as osteocalcin and MGP. All presently 
available data suggest that the extra-hepatic Gla-proteins are more susceptible to a reduced 
dietary intake of vitamin K than are the classical coagulation factors, and that present RDA 
values have to be redefined to ensure complete carboxylation of the extrahepatic Gla-
proteins 19. Unfortunately, the assay described in this paper does not allow for the 
discrimination between carboxylated and undercarboxylated MGP, which hampers full 
evaluation of its diagnostic value. More elaborate clinical studies are required to evaluate 
whether MGP total antigen may become a marker for the diagnosis or patient follow-up 
during the treatment of atherosclerosis.  
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SUMMARY AND GENERAL CONCLUSIONS 
Vitamin K is a group name for a number of related compounds, which have in common a 
methylated naphthoquinone ring structure, but which vary in the aliphatic side chain attached 
at the 3-position. The two most important forms of vitamin K are vitamin K1 (phylloquinone) 
and the group of K2 vitamins (menaquinones). Green vegetables such as broccoli and 
spinach, as well as some plant oils are the major source of phylloquinone in the human diet 1-
4. Menaquinones are primarily found in meat (menaquinone-4, MK-4) and fermented foods 
like cheese and curds (MK-6 through MK-9) 4. The only known function of vitamin K in 
mammals is that it serves as a cofactor for the endoplasmic enzyme gamma-
glutamylcarboxylase. The vitamin K-dependent step is a posttranslational carboxylation 
reaction by which a number of well-defined peptide-bound glutamate residues are converted 
into gamma-carboxyglutamate (Gla) 5-7. Gla-residues form calcium-binding groups in 
proteins, and are essential for the correct functionality of these proteins. During episodes of 
vitamin K-deficiency the carboxylation reaction cannot proceed and undercarboxylated 
species of Gla-proteins are released in the circulation. A general literature overview on 
vitamin K is given in chapter 1.  
The classical role of vitamin K is its requirement for normal blood coagulation: six different 
Gla-proteins are involved in the regulation of this complex process: prothrombin, factors VII, 
IX, and X, and the proteins C and S 8. More recently, it was discovered that other Gla-
proteins function as regulator of bone formation (osteocalcin) 9,10, inhibitor of cartilage and 
vascular calcification (MGP) 11 and regulator of cell growth and apoptosis (Gas6) 12. Gla-
proteins seem to be important for bone and vascular health, and these two functions form the 
topic of this thesis. In the first part we describe the effects of vitamin K supplementation on 
bone health. Several authors have demonstrated that low serum vitamin K 13-15 and high 
circulating undercarboxylated osteocalcin concentrations 16-18 as well as low dietary intakes 
of vitamin K 19 are associated with low bone mineral density (BMD) and an increased risk for 
osteoporotic hip fractures. The two vitamin K intervention studies described in this thesis are 
the first clinical trials reported thus far in which the effects of vitamin K1 supplementation on 
BMD in different risk groups are monitored. In chapter 2 we have investigated the potential 
synergistic effect of vitamin K1 and a mineral + vitamin D3 supplement on bone loss in 
postmenopausal women during a 3-year treatment period. Participants received a daily 
supplement containing either a mixture of calcium, zinc, magnesium and vitamin D3 or the 
same supplement with additional vitamin K1; a third group received a placebo only. It turned 
out that the supplement containing minerals and vitamin D3 transiently decreased the rate of 
bone loss. Addition of vitamin K1 to this supplement, however, resulted in a long-term 
beneficial effect at the site of the femoral neck, leading to a 35% reduction of bone loss (as 
compared to placebo). It is to be expected that a more complete carboxylation of the bone 
Gla-protein osteocalcin contributes to the observed effects, but since the function of this 
protein on a molecular level has remained unclear thus far, the mechanism by which vitamin 
K promotes bone health remains a matter of speculation. It is at least encouraging that – 
although a complete halt of bone loss was not achieved in this study – the rate of bone loss 
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was substantially decreased by a simple food supplement. If this result may be extrapolated 
to longer treatment periods, the proposed formulation may result in a significant reduction of 
osteoporotic fractures. Our data have been applied by the nutrition industry, and the optimal 
formulation used in our study is presently marketed in several countries.  
A second group at risk for rapid bone loss is formed by female endurance athletes. The high 
intensity and work load of training may lead to a disturbed hormonal metabolism, low 
endogenous oestrogen production, amenorrhoea, and loss of bone mass at young age 20,21. 
Although these problems are well recognized among sport physicians, the number of 
prospective studies to quantify the bone loss and to monitor effect of treatment in this group 
is low. In chapter 3 we report on a 2-year follow-up study among the largest cohort of female 
endurance athletes described thus far, in which we have quantified the rate of bone loss, and 
investigated the effects of oestrogen and vitamin K supplementation. Participants were 
recruited from Belgium, Germany and the Netherlands, and belonged to the national top in 
their sports. The rate of bone loss in female endurance athletes was unexpectedly high and a 
significant higher rate of femoral neck bone loss was found in the amenorrheic athletes 
compared to the eumenorrheic athletes. Oestrogen supplementation may retard, but did not 
prevent the bone loss. In contrast to the study in postmenopausal women, no beneficial 
effect of vitamin K was found in athletes. The most plausible reason for this apparent 
discrepancy is that bone loss is a multifactorial process in which also minerals and vitamin D 
play an important role. As a consequence an optimal effect of vitamin K will only be found if 
also the other components are supplemented. Another reason for the discrepancy between 
the data in postmenopausal women and female endurance athletes may be the accumulation 
of risk factors for bone loss in the latter group and the resulting extremely high rate of bone 
loss. It is at least feasible that under these conditions food supplements are inadequate tools 
to reverse this process, and that only medication such as bisphosphonates may prevent 
further damage. 
 
In the second part of this thesis the function of vitamin K in vascular tissue was investigated. 
When hypothesizing about mechanisms underlying a possible relationship between vitamin K 
and vascular health, the most obvious protein involved is the vitamin K-dependent matrix 
Gla-protein (MGP), which is synthesized by the vascular smooth muscle cells in the arterial 
vessel wall. In experimental animals, MGP was found to be a potent inhibitor of soft tissue 
calcification 11, and its five Gla residues are essential for this activity 22. Accumulating 
evidence suggests that in a substantial part of the population the vitamin K status of the 
arterial vessel wall is inadequate to support full MGP carboxylation 23, which may contribute 
to cardiovascular calcification. The hypothesis that subclinical vitamin K-deficiency forms a 
risk factor for cardiovascular disease is the basis for the second part of this thesis. 
Consequences of such deficiency at the site of the arteries may be vascular hardening and 
calcification, increasing stiffness, and loss of elastic properties. Several studies were 
performed to establish the potential importance of vitamin K for vascular health. In the well-
known Framingham Offspring cohort we have investigated the association between vitamin K 
intake and intermediary markers for cardiovascular disease. In chapter 4 we describe the 
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associations between reported dietary vitamin K intake, lifestyle, and serum lipid 
concentrations in this cohort. It turned out that participants with a reported high vitamin K1 
intake had a healthy dietary pattern and a healthy overall lifestyle. Furthermore, higher 
reported vitamin K1 intakes were associated with a lipoprotein profile indicative of decreased 
risk for developing cardiovascular disease (high HDL-cholesterol, low LDL-cholesterol, and 
low ratio of total cholesterol to HDL-cholesterol). In contrast to vitamin K1, the reported 
dietary vitamin K2 intakes were associated with an overall less healthy lifestyle pattern, 
including higher BMI, higher intakes of total fat, saturated fat, cholesterol and meat, and 
lower intakes of dietary fruit and fibre. Surprisingly, reported vitamin K2 intakes in the current 
study were also associated with a favourable lipid profile. The magnitude of the effect of K2 is 
remarkable, because vitamin K2 forms about 10% of the total vitamin K content in the human 
diet. The fact that both in healthy and unhealthy lifestyles vitamin K intake was positively 
correlated with a favourable serum lipid profile, is consistent with the hypothesis that low 
vitamin K intake is an independent risk factor in the development of cardiovascular disease. 
A subsequent step in investigating the importance of high vitamin K intake for vascular health 
was to measure the effect of vitamin K supplements on vessel wall characteristics. The term 
vessel wall characteristics is used to describe the elastic properties and the intima-media 
thickness of the vessel wall. Changes in the elastic properties of the main arteries have 
major implications for the development of vascular disease. Arteries, especially the larger 
ones such as the common carotid artery, become stiffer during ageing and arterial stiffness 
has been shown to be associated with cardiovascular disease 24,25. Before investigating the 
effects of vitamin K supplementation on vessel wall characteristics, it was decided to monitor 
first in a prospective way the effects of ageing on vessel wall characteristics in healthy 
postmenopausal women (chapter 5). In this study we have measured with a 3-year interval 
the distensibility coefficient (DC) and the compliance coefficient (CC), both variables are 
generally used to describe the elastic properties of the vessel wall. With the same 
(ultrasound-based) technique, also the intima-media thickness (IMT) of the artery wall was 
measured 26-28. The results showed a significant decrease in DC and CC of the common 
carotid artery as a function of time. In parallel with the decreased elasticity, we observed a 
significant increase of the arterial diameter and IMT of the common carotid artery. An 
increase in arterial diameter is the adaptation of the vessel wall to stiffening and the resulting 
increased blood pressure, whereas an increase of the IMT is generally regarded as one of 
the first steps in atherosclerosis 29,30. The same cohort as described in chapter 2 was used to 
study effects of vitamins D+K supplementation on the vessel wall characteristics in 
postmenopausal women (chapter 6). Participants received either placebo, minerals + 
vitamin D, or minerals + vitamins D + K. For recording the vessel wall characteristics the 
outcome variables mentioned in chapter 5 were used. The supplement containing minerals 
and vitamin D did not influence any of the outcome variables. However, the supplement with 
additional vitamin K had a long-term beneficial effect on the elastic properties of the carotid 
artery, namely, DC, CC and also the blood pressure remained constant over the entire 3-
year period. In contrast to the effects on vascular elasticity, no effect of vitamin K was found 
on the IMT. To our knowledge, this is the first intervention study showing a beneficial effect of 
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vitamins K1 + D supplementation on the vessel wall characteristics. These data are 
consistent with a common subclinical vitamin K-deficiency, sub-optimal MGP carboxylation, 
and inadequate protection against cardiovascular calcification in non-supplemented subjects. 
Clinical trials in which the effect of vitamin K supplements on the progression of calcification 
is measured by more sophisticated techniques (such as computed tomography) are needed 
to provide conclusive evidence for the importance of vitamin K in the prevention of 
cardiovascular disease.  
On the basis of our present knowledge, MGP seems to be the most likely Gla-protein via 
which vitamin K exerts its beneficial effect on the vessel wall. MGP does not exclusively 
accumulate in tissue, but in low concentrations it also occurs in the circulation. If the 
concentration and Gla-content of MGP in serum would reflect vascular MGP synthesis and 
Gla-content, circulating MGP might be used as a marker either for cardiovascular risk 
assessment, or for the diagnosis of cardiovascular disease. In this respect we differentiate 
between assays for total MGP, which are based on antibodies recognizing any form of MGP, 
and conformation-specific assays, which are based on antibodies against either fully 
carboxylated or undercarboxylated MGP. In chapter 7 we describe the development of such 
assay for total MGP. It is shown that in patients with atherosclerosis and diabetes mellitus 
the serum MGP concentration is significantly increased compared to age-matched healthy 
controls. The assay was also used to demonstrate that certain promotor poymorphisms in 
the MGP gene are associated with a high or low MGP expression and parallel fluctuations in 
MGP serum concentrations. Although the results clearly show an association between serum 
MGP and cardiovascular disease, more work needs to be done before the diagnostic utility of 
this assay will be clear. 
 
In conclusion, we have demonstrated that vitamin K1 retards bone loss in postmenopausal 
women, but only if it is co-administered with minerals and vitamin D. We would recommend 
such products, therefore, for subjects at risk for bone loss (e.g. women after 50 years of 
age). If the effect continues during longer periods of supplementation, the threshold for 
osteoporotic fractures may shift to higher ages by 8-10 years, which must be regarded as a 
major benefit to public health and which may substantially contribute to the reduction of 
health care costs. The question of whether vitamin K alone is effective in counteracting high 
bone loss needs to be addressed since this could not be demonstrated in this thesis. Other 
questions remaining to be answered are: 1) are the effects of vitamins K1 and K2 of 
comparable magnitude, 2) what is the optimal dose for achieving maximal effect, 3) what is 
the optimal formulation of the supplement (e.g. other vitamins and minerals), and 4) is this 
formulation also of potential benefit for other groups at risk for high bone loss, such as 
endurance athletes, ballet dancers, astronauts during weightlessness, and patients with 
anorexia nervosa. 
A second observation of potential importance was that vitamin K1 strongly retards age-
related loss of arterial elasticity. Because the vascular measurements formed the second 
arm of the study on bone density, it cannot be excluded that also in the vessel wall minerals 
and vitamins D and K have a synergistic effect. However, based on our present knowledge 
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this seems unlikely. Rather we would postulate that the observed effect is solely due to an 
improved vascular vitamin K status, resulting in a more complete MGP carboxylation and 
enhanced calcification inhibitory effect of this protein. Since at the dosage used no loss of 
elasticity was observed during the entire 3-year study, the minimal dose required for 
maintenance of elasticity remains to be established, and also the question of whether the 
effect may continue at much longer (lifelong?) intake of vitamin K. Without doubt this part of 
our work has the potency of a breakthrough in the primary and secondary prevention of 
cardiovascular disease.  
The data on the utility of serum MGP as a marker for cardiovascular disease are promising 
but need further exploration. The assay described is a typical home-made lab test, and has 
been improved considerably since our first publication. In parallel with this assay for total 
circulating MGP antigen, assays for carboxylated and undercarboxylated fractions thereof 
are badly needed. Monoclonal antibodies on which such assays are necessarily based, are 
being developed at this time. Data presented in this thesis demonstrate the feasibility of the 
diagnostic approach, and form the start of an independent diagnostics line in our group. 
Apart from their potential importance in cardiovascular diagnostics, it may be expected that 
new, conformation-based assays will form a tool for the assessment of a subject’s vascular 
vitamin K status (Glu-MGP / Gla-MGP ratio). This ratio may than be used as a guidance for 
the further development of functional foods and food supplements with health benefit claims 
in the cardiovascular field.  
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SAMENVATTING EN ALGEMENE CONCLUSIES 
Vitamine K is de verzamelnaam voor een aantal vergelijkbare stoffen die allemaal dezelfde 
gemethyleerde naphthoquinon ringstructuur bezitten, maar die verschillen in de alifatische 
zijketen, gebonden aan de 3-positie. De twee belangrijkste vormen van vitamine K zijn 
vitamine K1 (fyllochinon) en vitamine K2 (menachinonen). De belangrijkste voedselbronnen 
van fyllochinon zijn groene groenten zoals broccoli en spinazie, en plantaardige oliën 1-4. 
Menachinonen komen voornamelijk voor in vlees (menachinon-4, MK-4) en gefermenteerde 
producten zoals kaas en kwark (MK-6 t/m MK-9) 4. Vitamine K functioneert als een cofactor 
voor het endoplasmatisch enzym gamma-glutamylcarboxylase. De carboxylering van 
specifieke glutaminezuur (Glu) residuen tot gamma-carboxy glutaminezuur (Gla) is een van 
de posttranslationele modificaties die worden uitgevoerd door het vitamine K-afhankelijke 
enzym gamma-glutamyl carboxylase 5-7. De omzetting van Glu naar Gla is nodig voor de 
calcium bindende eigenschappen van Gla-eiwitten. Tijdens perioden van vitamine K–
deficiëntie, kan de carboxyleringsreactie niet plaatsvinden en zullen er Gla-eiwitten in een 
niet-actieve, ondergecarboxyleerde vorm gesynthetiseerd worden. Een algemeen literatuur 
overzicht over vitamine K wordt weergegeven in hoofdstuk 1 van dit proefschrift.  
Vitamine K speelt een belangrijke rol in de bloedstolling: zes verschillende Gla-eiwitten zijn 
betrokken bij de regulatie van dit complexe proces: protrombine, factor VII, IX, and X, en 
protein C en S 8. Meer recent zijn nieuwe Gla-eiwitten ontdekt die niet betrokken zijn bij het 
bloedstollingproces. Dit zijn onder andere osteocalcine (regulator van botvorming) 9,10, 
matrix-gla proteine (MGP) (remmer van kraabeen en vaatwand verkalking) 11 en Gas6 
(regulator van celgroei en remmer van apoptose) 12. Gla-eiwitten spelen dus ook een 
belangrijke rol in het bot en de vaatwand en deze functies vormen de basis van het in dit 
proefschrift beschreven onderzoek. In het eerste gedeelte beschrijven we de effecten van 
vitamine K-supplementatie op de botdichtheid. Lage serum vitamine K-concentraties 13-15, 
hoge niet-gecarboxyleerde osteocalcine concentraties 16-18 en lage innames van vitamine K 
19, zijn geassocieerd zijn met een lage botdichtheid en een verhoogd risico op 
osteoporotische heupfracturen. De twee interventiestudies beschreven in dit proefschrift, zijn 
de eerste studies waarin de effecten van vitamine K-supplementatie op botdichtheid 
onderzocht worden. In hoofdstuk 2 hebben we het mogelijke synergistische effect 
onderzocht van een supplement bestaande uit mineralen en de vitamines D en K1 op het 
botverlies in postmenopausale vrouwen gedurende een periode van drie jaar. De 
proefpersonen ontvingen dagelijks een placebo of een supplement bestaande uit een 
mengsel van calcium, zink, magnesium en vitamine D3 of hetzelfde supplement met extra 
vitamine K1. Het bleek dat het supplement met mineralen en vitamine D3 alleen een 
kortdurend effect had op de remming van het botverlies. De toevoeging van vitamine K1 aan 
het supplement resulteerde echter in een langdurende bescherming tegen botverlies, waarbij 
het botverlies met 35% gereduceerd was ten opzichte van placebo. De verwachting is dat 
een meer complete carboxylering van het Gla-eiwit osteocalcine bijdraagt aan het 
geobserveerde effect, maar omdat de functie van het eiwit op moleculair niveau nog niet 
bekend is, blijft het achterliggende mechanisme via welke vitamine K het botverlies remt nog 
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onduidelijk. Het is op zijn minst opmerkelijk dat het botverlies gereduceerd werd door een 
eenvoudig voedingssupplement, hoewel een complete remming van het botverlies niet 
bereikt is in deze studie. Indien men deze resultaten extrapoleert naar langdurige 
behandelingsperioden, kan het gebruik van het onderzochte supplement resulteren in een 
significante reductie van het aantal osteoporotische fracturen. Onze resultaten worden 
gebruikt door de voedingsindustrie en het optimale supplement wordt op dit moment in 
verschillende landen op de markt gebracht.  
Een tweede risicogroep voor het ontwikkelen van botverlies zijn de vrouwelijke atleten. De 
hoge intensiteit en belasting van training kan leiden tot een verstoring van de 
hormoonhuishouding, een lage endogene oestrogeen productie, amenorroe (het wegblijven 
van de menstruatie) en het verlies van botmassa op jonge leeftijd 20,21. Hoewel deze 
problemen wel bekend zijn bij de sportartsen, zijn er maar weinig prospectieve studies die 
het botverlies in vrouwelijke atleten gekwantificeerd hebben en effecten van behandeling 
onderzocht hebben. In hoofdstuk 3 beschrijven we een follow-up studie van 2 jaar omtrent 
een cohort van 115 vrouwelijk atleten, waarin de snelheid van botverlies gekwantificeerd is 
en de effecten van oestrogeen- en vitamine K-behandeling (zonder toevoeging van 
mineralen en vitamine D) onderzocht zijn. De proefpersonen werden gerekruteerd uit België, 
Duitsland en Nederland en behoorden tot de nationale top in de atletiek. De snelheid van 
botverlies van de femur hals was ongekend hoog in de vrouwelijke atleten en een significant 
hoger botverlies werd geobserveerd bij de atleten met amenorroe in vergelijking met de 
atleten met een regelmatige menstruatie. Oestrogeen-supplementatie verminderde wel het 
botverlies, maar zorgde niet voor een complete remming. In tegenstelling tot de studie in 
postmenopausale vrouwen, werden er geen gunstige effecten van vitamine K gevonden op 
de snelheid van het botverlies bij de vrouwelijke atleten. De meest voor de hand liggende 
verklaring voor deze schijnbare tegenstelling is dat botverlies een multifactorieel proces is 
waarin mineralen en vitamine D ook een belangrijke rol spelen. Als gevolg hiervan, zal een 
optimaal effect alleen gevonden worden indien deze componenten tegelijk met vitamine K 
ook gesupplementeerd worden. Een andere reden voor de discrepantie tussen de resultaten 
van de postmenopausale vrouwen en atleten is de accumulatie van risicofactoren voor 
botverlies in de atleten en het extreem hoge botverlies in deze groep. Onder deze 
omstandigheden is het waarschijnlijk vrijwel onmogelijk om het botverlies terug te dringen 
door eenvoudige voedingssupplementen en is op z’n minst medicatie (zoals bisfosfonaten) 
nodig om het proces stoppen.  
 
 
In het tweede gedeelte van dit proefschrift wordt de rol van vitamine K in de vaatwand 
onderzocht. Het vitamine K-afhankelijke eiwit matrix-gla proteine (MGP) wordt 
gesynthetiseerd door de gladde spiercellen in de vaatwand. In experimentele 
proefdierstudies is aangetoond dat MGP een remmmer is van arteriële verkalking 11, en dat 
de vijf Gla-residuen binnen het eiwit essentieel zijn voor de activiteit van MGP 22. Recente 
studies laten zien dat in een groot deel van de populatie de vitamine K status van de 
vaatwand onvoldoende is om volledige MGP carboxylering te bewerkstellingen 23, waardoor 
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het risico op arteriële verkalking verhoogd is. Mogelijk dat een suboptimale vitamine K-
status, verharding, verhoogde stijfheid en verlies van elastische eigenschappen van de 
vaatwand tot gevolg kan hebben; dit leidt op den duur weer tot een verhoogd risico op het 
ontstaan van hart-en vaatziekten. Verschillende studies zijn uitgevoerd om deze hypothese 
verder te onderzoeken. In het bekende Framingham Offspring Cohort is de associatie tussen 
de vitamine K-inname via de voeding en intermediaire markers van hart-en vaatziekten 
bestudeerd. In hoofdstuk 4 beschrijven we de associatie tussen vitamine K-inname, 
levensstijl en serum lipide concentraties in dit cohort. Uit de resultaten bleek dat personen 
met een hoge gerapporteerde vitamine K1-inname een gezond voedingspatroon hadden en 
een algemeen gezonde levensstijl. Verder waren hoge vitamine K1-innames geassocieerd 
met een gunstig lipoproteine profiel (hoog HDL-cholesterol, laag LDL-cholesterol, en een 
lage ratio van totaal cholesterol / HDL-cholesterol). In tegenstelling tot vitamine K1, was de 
vitamine K2-inname geassocieerd met een ongezonde levensstijl, namelijk een hoge body 
mass index (BMI), hoge inname van totaal vet, verzadigd vet, cholesterol, vlees en lage 
inname van fruit en vezel. De vitamine K2-innames waren echter ook geassocieerd met een 
gunstig lipideprofiel, terwijl vitamine K2 maar ongeveer 10% van het totale vitamine K gehalte 
in de voeding omvat. Het feit dat de vitamine K-inname correleerde met een gunstig 
lipideprofiel in associatie met zowel een gezonde als een ongezonde levensstijl is consistent 
met de hypothese dat een lage vitamine K inname een onafhankelijke risicofactor is voor het 
ontstaan van hart-en vaatziekten.  
Een volgende stap in het bestuderen van de rol van vitamine K in de vaatwand was het 
meten van het effect van vitamine K-supplementen op vaatwandeigenschappen. De term 
vaatwandeigenschappen wordt gebruikt om de elastische eigenschappen van de vaatwand 
en de vaatwanddikte te beschrijven. Een verandering in de elastische eigenschappen van 
arteriën heeft implicaties voor het ontstaan van hart- en vaatziekten. Arteriën zoals de 
halsslagader, worden stijver met het ouder worden, en arteriële stijfheid is geassocieerd met 
hart-en vaatziekten 24,25. Alvorens de effecten van vitamine K-supplementatie op de 
vaatwandeigenschappen werden onderzocht, werden eerst de effecten van veroudering op 
de vaatwand bestudeerd in gezonde postmenopausale vrouwen (hoofdstuk 5). Aan het 
begin en aan het einde van de 3 jaar-durende studie, werden met behulp van ultrasound de 
distensibiliteits coefficient (DC), compliantie-coefficient (CC) evenals de vaatwanddikte 
gemeten 26-28. Deze variabelen worden gebruikt om de elastische eigenschappen van de 
vaatwand te beschrijven. De resultaten van deze studie toonden een significante daling in 
DC en CC als functie van de tijd. Parallel met de gedaalde elasticiteit werd een significante 
stijging van de arteriële diameter en de vaatwanddikte geobserveerd. Een stijging van de 
arteriële diameter kan gezien worden als een adaptatie proces als gevolg van de verstijving 
van de vaatwand en de gestegen bloeddruk, terwijl een gestegen vaatwanddikte algemeen 
beschouwd wordt als een van de eerste stappen van het atherosclerose proces 29,30. Het in 
hoofdstuk 2 beschreven cohort is ook gebruikt om de effecten van vitamine D+K-
supplementatie te bestuderen op de vaatwandeigenschappen (hoofdstuk 6). Het 
supplement bestaande uit alleen mineralen en vitamine D had geen invloed op de 
vaatwandeigenschappen, terwijl het supplement bestaande uit mineralen, vitamine D+K een 
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gunstig effect bleek te hebben op de elastische eigenschappen van de halsslagader. 
Gedurende de hele periode van drie jaar bleven de DC,CC en ook de bloeddruk constant; de 
vaatwanddikte was echter wel significant gestegen en niet verschillend ten opzichte van de 
placebo. Dit is de eerste interventiestudie die een gunstig effect van vitamine D+K1 laat zien 
op vaatwandeigenschappen. Deze resultaten zijn consistent met de hypothese dat er in de 
vaatwand onvoldoende vitamine K aanwezig is voor een adequate carboxylering van MGP, 
dat op zijn beurt een onvoldoende bescherming tegen arteriële verkalking als gevolg heeft. 
Klinische trials, waarin de effecten van vitamine K-supplementatie op arteriële verkalking 
(gemeten door geadvanceerde technieken zoals CT) worden onderzocht, zijn nodig om 
bewijs te leveren dat vitamine K een belangrijke rol speelt in de preventie van hart-en 
vaatziekten. 
Op basis van de huidige kennis, lijkt vitamine K zijn gunstige effect op de vaatwand uit te 
oefenen via MGP. MGP accumuleert niet alleen in weefsels, maar in lage concentraties komt 
het ook voor in de circulatie. Als de concentratie en het Gla-gehalte van MGP de vasculaire 
MGP-synthese zou reflecteren, dan kan het serum MGP gebruikt worden als een marker 
voor het risico op en de diagnose van hart-en vaatziekten. Hierbij dient onderscheid te 
worden gemaakt tussen tests voor totaal MGP, die gebaseerd zijn op antilichamen die elke 
vorm van MGP herkennen en conformatie-specifieke tests, die gebaseerd zijn op 
antilichamen die tegen ofwel alleen gecarboxyleerd dan wel niet-gecarboxyleerd MGP 
gericht zijn. In hoofdstuk 7 beschrijven we de ontwikkeling van een assay voor totaal MGP. 
De resultaten laten zien dat bij patiënten met atherosclerose en diabetes mellitus de serum 
MGP concentratie significant hoger is dan bij gezonde controle patiënten. De test werd ook 
gebruikt om te demonstreren dat bepaalde promoter polymorfismen in het MGP gen 
geassocieerd zijn met een hoge of een lage MGP expressie en parallelle fluctuaties in MGP 
serum concentraties. Hoewel de resultaten duidelijk een associatie laten zien tussen serum 
MGP en hart-en vaatziekten, dient nog meer onderzoek te gebeuren voordat de 
diagnostische bruikbaarheid van deze test zichtbaar wordt.  
 
Concluderend, in dit proefschrift hebben we aangetoond dat vitamine K1 het botverlies remt 
in postmenopausale vrouwen, maar alleen als het samen gesupplementeerd wordt met 
mineralen en vitamine D. Dergelijke supplementen zijn dus aan te bevelen voor vrouwen die 
een verhoogd risico hebben op botverlies (vrouwen > 50 jaar). Als het effect aanblijft tijdens 
langdurig gebruik, dan is het treshhold niveau voor osteoporotische fracturen met 8-10 jaar 
verlengd. Dit heeft een belangrijke impact op de algehele gezondheid en draagt substantieel 
bij aan reductie van de kosten van gezondheid. De vraag of vitamine K alleen effectief is in 
het tegengaan van hoog botverlies dient beantwoord te worden in vervolgstudies, aangezien 
dit niet aangetoond kon worden in dit proefschrift. Andere vragen die nog beantwoord dienen 
te worden, zijn: 
 1) zijn de effecten van vitamine K1 and K2 vergelijkbaar 2) wat is de optimale dosis voor het 
bereiken van een maximaal effect 3) wat is de optimale samenstelling van het supplement 
(bijvoorbeeld welke andere vitaminen en mineralen), en 4) is dit supplement ook gunstig voor 
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andere risicogroepen voor botverlies, zoals astronauten, ballet danseressen and patiënten 
met anorexia nervosa. 
De tweede belangrijke observatie in dit proefschrift is dat vitamine K1 het verlies aan arteriële 
elasticiteit bij veroudering tegengaat. Het kan niet uitgesloten worden dat ook in de vaatwand 
mineralen en vitaminen D+K een synergistisch effect hebben. Gebaseerd op de huidige 
kennis lijkt dit echter onwaarschijnlijk. De hypothese is dat het geobserveerde effect vrijwel 
geheel te wijten is aan de verbeterde vasculaire vitamine K status, resulterend in een meer 
complete MGP-carboxylering en daarmee een versterkt remmend effect van arteriële 
verkalking door MGP. De minimale dosis die nodig is voor het behoud van elasticiteit dient 
vastgesteld te worden en ook de vraag of het effect aanblijft tijdens langdurig gebruik (> 3 
jaar) van vitamine K supplementen is nog onbeantwoord. Zonder twijfel heeft dit onderzoek 
de potentie om te leiden tot een doorbraak in de primaire en secundaire preventie van hart-
en vaatziekten. 
De resultaten over de bruikbaarheid van serum MGP als een marker voor hart- en 
vaatziekten zijn veelbelovend, maar dienen verder onderzocht te worden. De beschreven 
assay is een typische home-made laboratorium test en dient verder ontwikkeld te worden na 
de eerste publicatie. Naast de test voor totaal circulerend MGP antigen, zijn assays voor 
gecarboxyleerd en ondergecarboxyleerd MGP antigen dringend nodig. Monoclonale 
antilichamen waar zulke assays op gebaseerd zijn, worden momenteel ontwikkeld. Data die 
gepresenteerd worden in dit proefschrift, demonstreren de mogelijkheid van een 
diagnostische benadering en vormen de start van een onafhankelijke diagnostische lijn 
binnen onze onderzoeksgroep. Naast het belang voor de cardiovasculaire diagnostiek, kan 
verwacht worden dat nieuwe conformatie-specifieke assays een instrument vormen voor de 
vaststelling van de vitamine K status van een persoon (Glu-MGP / Gla-MGP ratio). Deze 
ratio kan dan gebruikt worden als richtlijn voor de verdere ontwikkeling van functional foods 
en voedingssupplementen met gezondheid claims op het gebied van hart-en vaatziekten.  
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analyseren van de resultaten en het schrijven van artikelen en daar ben ik je dan ook zeer 
dankbaar voor. 
Beste Berry, het sociale middelpunt van de vitamine K-groep. Iedere ochtend bij aankomst 
op het lab was jouw kamer het sociale trefpunt en de aanwezigheid van het koffie-apparaat 
was hier voor mij in ieder geval niet de reden voor. Door jouw openheid, spontaniteit en je 
oprechte interesse in mensen vonden hier de ware gesprekken plaats en leerde ik je kennen 
als een sociaal bewogen persoon met veel mensenkennis. Je goede wetenschappelijke 
adviezen, hulp op PC-gebied en de gastvrijheid bij jou en Anneke thuis heb ik altijd zeer 
gewaardeerd, bedankt Berry! 
Beste Henri, mijn kamergenoot en goede vriend! Mijn dank voor jouw hulp tijdens mijn 
gehele AIO-periode is oneindig groot. Mijn vele PC-problemen werden door jou altijd weer 
binnen een mum van tijd opgelost en verder heb je heel veel moeite en tijd gestopt  in het tot 
stand komen van dit proefschrift. Zonder jouw aanwezigheid was dit boekje niet alleen 
minder fraai geworden, maar had ik ook veel minder plezier gehad. Samen hebben we veel 
gelachen, muziek gedraaid, gesprekken gevoerd, veelvuldig de gedachtenwereld van de 
vrouw geanalyseerd en vooral met heel veel plezier samengewerkt. Ik heb er dan ook nooit 
over getwijfeld dat jij mijn paranimf zou worden aangezien jij al die jaren mijn werkmaatje 
was. Ik hoop dat als onze wegen zich op werkgebied gaan scheiden, onze vriendschap zal 
blijven voortduren. 
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Beste Leon, niet alleen een collega maar ook een goede vriend! Ik bewonder je om je 
eeuwige optimisme, je altijd goede humeur en je enorme ambitie en gedrevenheid. Zelfs in 
deze drukke tijd waarin je bent gaan bouwen en promoveren, heb ik je nog nooit een dag 
chagrijnig gezien. Als collega ben je altijd bereid geweest me te helpen met een en ander, 
me op de hoogte te houden van de laatste literatuur en me wegwijs te maken in de vele 
praktische aspecten van het promotietraject. Ik ben heel blij dat je mijn paranimf wilt zijn en ik 
hoop van harte dat de vele gezellige avondjes samen met Romy en de kinderen nog heel 
vaak zullen voorkomen. Bedankt voor alles Leon! 
Beste Marjo, veel dank ben ik jou verschuldigd voor de fijne, zorgzame begeleiding die je mij 
als beginnend AIO gaf op het gebied van klinische trials. Je was degene die me aan de hand 
nam en me hielp met de vele praktische aspecten van het onderzoek. Mede dankzij jou 
liepen de twee trials op rolletjes en werden de vele labbepalingen met grote precisie 
uitgevoerd. Later kreeg je het zelf druk met de EISAI-trial en heb ik geprobeerd jou hierin 
behulpzaam te zijn. Bij deze heel veel succes gewenst met de resultatenverwerking van het 
onderzoek en hopelijk dat het een mooie aansluiting vormt op de resultaten van dit 
proefschrift. 
Beste Kirsten, de benjamin van de groep. Inmiddels ben je al weer een tijdje bij ons en heb ik 
je leren kennen als een gezellige, hardwerkende meid die met gemak het mannelijk geweld 
in onze groep trotseert. Je hebt inmiddels je eigen plekje gecreëerd en je bent met recht een 
aanwinst voor de groep. Hopelijk dat je nog lang binnen het vitamine K-onderzoek wilt 
blijven. 
Beste Pauline, de moeder van de groep. Ook al werk je maar een dag per week bij ons, ik 
heb het gevoel dat je altijd hier bent. Dit dankzij je geweldige sociale eigenschappen, je 
aanstekelijke lach en vooral je wijze raad.  
Mijn oud-collega’s Paul en Roger wil ik ook persoonlijk bedanken. Paul, ons goed contact is 
door je nieuwe werkplek enigszins verwaterd, maar de interesse in elkaar en de leuke 
herinneringen aan onze tijd samen op het lab en vooral daarbuiten zullen altijd blijven! 
Roger, als er iemand het senior AIO-schap met recht heeft vervuld, was jij het wel. Je 
gezelligheid en organiserend vermogen waren groot en het gemis toen je wegging des te 
meer. De andere oud-collega’s: Birgit, Jacintha, Marieke, Marion, Alexandra, Ilja en Marscha 
wil ik ook bedanken voor de leuke en goede samenwerking. 
De oud-collega AIO’s: Joyce, Irene, Jacco, Dave en Harold wil ik bedanken voor de gezellige 
stap-avondjes en het bondgenootschap tijdens de vele CARIM-cursussen (vooral in 
Houthalen natuurlijk!). 
Mariet en Trees, bedankt voor de interesse en secretariële ondersteuning en alle overige 
collega’s van Biochemie bedankt! 
Professor Jan Rosing wil ik bedanken voor het vertrouwen dat hij de afgelopen jaren in mij 
heeft gesteld, voor het kritisch doornemen van mijn artikelen en voor de tijd die hij altijd voor 
me vrijmaakte. De leden van de beoordelingscommissie, Prof. Dr. Ir. van den Brandt, Prof. 
Dr. Knottnerus, Prof. Kitslaar, Dr. Landewe en Prof. Dr. Ir. Saris wil ik bedanken voor de 
beoordeling van dit proefschrift. 
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Prof. Dr. P. Geusens, Dr. F. Brouns en Prof. Dr. K. Hamulyak bedankt voor het kritisch lezen 
van mijn manuscripten en de nuttige adviezen. 
Jean Willigers en Christine Willekes ben ik veel dank verschuldigd voor de wijze waarop zij 
mij de ultrasound techniek geleerd hebben en voor het oplossen van de technische 
problemen die gepaard gingen met het meten van de vele honderden proefpersonen. 
Lia, Sandra en Florence van de afdeling Nucleaire Geneeskunde ben ik ontzettend dankbaar 
voor de enorme hoeveelheid werk die zij voor mijn onderzoek verricht hebben.  Ik heb 
waardering voor de manier waarop jullie ieder jaar weer honderden DEXA-metingen verricht 
hebben. Dr. Liem wil ik ook bedanken voor de vele tijd die hij voor ons vrijmaakte om alle 
DEXA-metingen tot in de details te bestuderen. Prof. Heidendal, bedankt voor de 
mogelijkheid om van jullie apparatuur gebruik te maken.  
De afdeling Klinische Chemie: bedankt voor de leuke medewerking bij het uitvoeren van de 
calcium- en creatinine-bepalingen in jullie lab! 
I wish to thank Novartis Consumer Health (especially Monique Gerichhausen) and Roche 
Vitamins Ltd (especially Dr. Stoecklin) for their financial support of this study and their 
interest in our research.   
Dr. S. Booth, Dear Sarah, many thanks for the wonderful stay I had in your lab during several 
months.  You always made me feel welcome and took care for me to have a pleasant time. 
This I will never forget! It was a learning full experience for me to work with the data of a 
large population-based cohort and I thank you for the opportunity you gave me. Also, I would 
like to thank Ligia, Nicola, Aina, Molly, Jim and Nancy for their hospitality and for the 
pleasure we had together.  
Dr. E. Stolk, Prof. A. Goris en Dr. F. Hartgens wil ik bedanken voor hun betrokkenheid bij het 
onderzoek onder de vrouwelijke atleten, mede dankzij jullie hulp is deze trial tot stand 
gekomen, Prof. P. Platen möchte ich gerne danken für ihre hilfe mit unseren studie.  
Dr. C. Shanahan, Dr. D. Proudfoot, Dr. A. Far and Dr. H. Colhoun, thank you all for the nice 
collaboration, leading to several publications in the field of MGP. 
De vele proefpersonen die bereid zijn geweest jarenlang deel te nemen aan het vitamine K-
onderzoek ben ik zeer dankbaar. Zonder hun medewerking was dit proefschrift nooit tot 
stand gekomen. 
 
Misschien niet direct betrokken bij het tot stand komen van dit proefschrift, maar wel heel 
belangrijk in mijn privé-leven: alle lieve vrienden, bedankt voor jullie belangstelling en 
gezelligheid! Een aantal wil ik even persoonlijk noemen:  
Lieve Jen, inmiddels kennen we elkaar zo’n 5 jaar nu, maar het lijkt wel of je mijn hele leven 
al mijn vriendinnetje bent. Bedankt voor je altijd luisterend oor en voor de vele gezellige 
momenten samen!  
Danielle, Jozet en Esther, studievriendinnetjes van het eerste uur! Samen gestudeerd en 
altijd bij elkaar, maar ook na onze studie bleef de vriendschap hecht en ik hoop dat dit nog 
lang zo zal blijven.  
Steere en Mutze: Gunnar, Anouk, Nicole, Roel, Marcia, Lars en Jos, bedankt voor de 
geweldige uitspattingen iedere keer weer. Onze uitstapjes naar Verbibbe, Crans, de Moezel,  
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Parijs en de vele stapavondjes zorgde telkens weer voor de broodnodige ontspanning tussen 
het promoveren door. Een speciaal woord van dank voor Roel: je stortte je helemaal in de 
‘vitamine K-wereld’ om deze prachtige omslag voor me te ontwerpen. Ik vind het knap hoe je 
het voor elkaar hebt gekregen, in een tijd waarin jezelf zo druk bezig was met afstuderen, 
bedankt Roel! 
 
Tenslotte mijn lieve familie, 
Mijn schoonouders die me altijd het gevoel hebben gegeven een eigen dochter te zijn, bij 
jullie (en de rest van de schoonfamilie) had ik vanaf het eerste moment het gevoel dat ik in 
een warm nest was terechtgekomen. Bedankt voor jullie liefde, geweldige steun en hulp.  
Mijn twee zussen, Lianne en Luciënne, onze jeugd samen kenmerkte zich door zoveel 
gezelligheid die ik nu ook weer terug zie bij jullie eigen prachtige gezinnen. Ik wil jullie, 
samen met Luc en Laury, bedanken voor de steun, de gezelligheid en de interesse in mijn 
onderzoek. Ik hoop dat we samen met Mitch, Kay, Eva (en ?) nog heel lang een gelukkige 
familie zullen vormen.  
Pap en Mam, dankzij jullie ben ik geworden tot wat ik nu ben. Jullie vormen het fundament 
van mijn leven en mijn dank naar jullie toe is oneindig groot, mede voor de 
vanzelfsprekendheid waarmee jullie altijd weer klaar staan en de onvoorwaardelijke steun bij 
alles wat ik doe. Jullie liefde, interesse en warmte is altijd aanwezig. 
 
En op de achtergrond van dit alles schuilt een sterke beer die continu in mijn leven aanwezig 
is, dan wel in levende lijve of in mijn gedachten: mijn allerliefste Cyril. Jij bent diegene die me 
telkens weer omarmt, me steunt, laat huilen, maar vooral zoveel laat lachen. Met je eeuwig 
zonnige karakter en vrolijkheid sleepte je me altijd door moeilijke momenten heen. Mijn dank 
naar jou toe is moeilijk te verwoorden op een manier zoals jij die verdient. William 
Shakespeare kon dat net iets beter: ‘’What I have done is yours, what I have to do is yours, 
being part in all I have devoted yours”.  
  
 
 
